## Contents

1 Introduction  iv1  
1.1 Statement of intent  iv1  

2 Diagnosis  iv2  
2.1 Diagnosis in children  iv2  
2.2 Other investigations  iv8  
2.3 Summary  iv9  
2.4 Diagnosis in adults  iv11  
2.5 Further investigations that may be useful in patients with an intermediate probability of asthma  iv16  
2.6 Monitoring asthma  iv18  

3 Non-pharmacological management  iv24  
3.1 Primary prophylaxis  iv24  
3.2 Secondary non-pharmacological prophylaxis  iv27  
3.3 Other environmental factors  iv28  
3.4 Dietary manipulation  iv29  
3.5 Complementary and alternative medicine  iv31  
3.6 Other complementary or alternative approaches  iv32  

4 Pharmacological management  iv33  
4.1 Step 1: mild intermittent asthma  iv34  
4.2 Step 2: introduction of regular preventer therapy  iv34  
4.3 Step 3: initial add-on therapy  iv37  
4.4 Step 4: poor control on moderate dose of inhaled steroid + add-on therapy: addition of fourth drug  iv39  
4.5 Step 5: continuous or frequent use of oral steroids  iv40  
4.6 Stepping down  iv45  
4.7 Specific management issues  iv45  

5 Inhaler devices  iv48  
5.1 Technique and training  iv48  
5.2 $\beta_2$ agonist delivery  iv48  
5.3 Inhaled steroids for stable asthma  iv49  
5.4 CFC propellant pmdi vs HFA propellant pMDI  iv49  
5.5 Prescribing devices  iv50  
5.6 Use and care of spacers  iv50  

6 Management of acute asthma  iv51  
6.1 Lessons from studies of asthma deaths and near fatal asthma  iv51  
6.2 Acute asthma in adults  iv53  
6.3 Treatment of acute asthma in adults  iv56  
6.4 Further investigation and monitoring  iv59  
6.5 Asthma management protocols and proformas  iv60  
6.6 Hospital discharge and follow up  iv60  
6.7 Acute asthma in children aged over 2 years  iv61  
6.8 Treatment of acute asthma in children aged over 2 years  iv62  
6.9 Assessment of acute asthma in children aged less than 2 years  iv65  
6.10 Treatment of acute asthma in children aged less than 2 years  iv65  

7 Special situations  iv67  
7.1 Difficult asthma  iv67  
7.2 Factors contributing to difficult asthma  iv67  
7.3 Asthma in pregnancy  iv70  
7.4 Management of acute asthma in pregnancy  iv71  
7.5 Drug therapy in pregnancy  iv71  
7.6 Management during labour  iv73  
7.7 Drug therapy in breast feeding mothers  iv73  
7.8 Occupational asthma  iv74  
7.9 Management of occupational asthma  iv76  

8 Organisation and delivery of care, and audit  iv77  
8.1 Routine primary care  iv77  
8.2 Acute exacerbations  iv79  
8.3 Audit  iv80  

9 Patient education and self management  iv82  
9.1 Self management education and personalised asthma action plans  iv82  
9.2 Compliance and concordance  iv83  
9.3 Implementation in practice  iv85  
9.4 Practical advice  iv85  

10 Development of the guideline  iv87  
10.1 Introduction  iv87  
10.2 Executive and steering groups  iv87  
10.3 Evidence review groups  iv88  
10.4 Dissemination group  iv91  
10.5 Systematic literature review  iv91  
10.6 Consultation and peer review  iv91  

Abbreviations  iv93  
Annexes  iv95  
References  iv107
KEY TO EVIDENCE STATEMENTS AND GRADES OF RECOMMENDATIONS

LEVELS OF EVIDENCE

1++ High quality meta-analyses, systematic reviews of RCTs, or RCTs with a very low risk of bias
1+ Well conducted meta-analyses, systematic reviews, or RCTs with a low risk of bias
1– Meta-analyses, systematic reviews, or RCTs with a high risk of bias
2++ High quality systematic reviews of case control or cohort studies
    High quality case control or cohort studies with a very low risk of confounding or bias and a high probability that the relationship is causal
2+ Well conducted case control or cohort studies with a low risk of confounding or bias and a moderate probability that the relationship is causal
2– Case control or cohort studies with a high risk of confounding or bias and a significant risk that the relationship is not causal
3 Non-analytic studies, eg case reports, case series
4 Expert opinion

GRADES OF RECOMMENDATION

Note: The grade of recommendation relates to the strength of the evidence on which the recommendation is based. It does not reflect the clinical importance of the recommendation.

A At least one meta-analysis, systematic review, or RCT rated as 1++, and directly applicable to the target population; or
    A body of evidence consisting principally of studies rated as 1+, directly applicable to the target population, and demonstrating overall consistency of results
B A body of evidence including studies rated as 2++, directly applicable to the target population and demonstrating overall consistency of results; or
    Extrapolated evidence from studies rated as 1++ or 1+
C A body of evidence including studies rated as 2+, directly applicable to the target population and demonstrating overall consistency of results; or
    Extrapolated evidence from studies rated as 2++
D Evidence level 3 or 4; or
    Extrapolated evidence from studies rated as 2+

GOOD PRACTICE POINTS

☑ Recommended best practice based on the clinical experience of the guideline development group.

❖ Audit point
1 Introduction

In 1999 the British Thoracic Society (BTS) and the Scottish Intercollegiate Guidelines Network (SIGN) agreed to jointly produce a comprehensive new asthma guideline, both having previously published guidance on asthma. The original BTS guideline dated back to 1990 and the SIGN guidelines to 1996. Both organisations recognised the need to develop the new guideline using explicitly evidence based methodology. The joint process was further strengthened by collaboration with Asthma UK, the Royal College of Physicians of London, the Royal College of Paediatrics and Child Health, the General Practice Airways Group, and the British Association of Accident and Emergency Medicine (now the College of Emergency Medicine). The outcome of these efforts was the British Guideline on the Management of Asthma published in 2003.1

The 2003 guideline was developed using SIGN methodology,2 adapted for UK-wide use. Electronic literature searches extended to 1995, although some sections required searches back as far as 1966. The pharmacological management section utilised the North of England Asthma guideline to address some of the key questions on adult management.3 The North of England guideline literature search covered a period from 1984 to December 1997, and SIGN augmented this with a search from 1997 onwards.

Since 2003 sections within the guideline have been updated annually and posted on both the BTS (www.brit-thoracic.org.uk) and SIGN (www.sign.ac.uk) websites. In 2004 the sections on pharmacological management, acute asthma and patient self management and compliance were revised. In 2005 sections on pharmacological management, inhaler devices, outcomes and audit and asthma in pregnancy were updated, and occupational asthma was rewritten with help from the British Occupational Health Research Foundation.

In 2006 the pharmacological management section was again updated. While the web-based alterations appeared successful, it was felt an appropriate time to consider producing a new paper-based version in which to consolidate the various yearly updates. In addition, since 2006, the guideline has had input from colleagues from Australia and New Zealand.

The new 2008 guideline has considered literature published up to March 2007. It contains a completely rewritten section on diagnosis for both adults and children; a section on special situations which includes occupational asthma, asthma in pregnancy and the new topic of difficult asthma; updated sections on pharmacological and non-pharmacological management; and amalgamated sections on patient education and compliance, and on organisation of care and audit. The timescale of the literature search for each section is given in Annex 1.

It is hoped that this 2008 asthma guideline continues to serve as a basis for high quality management of both acute and chronic asthma and a stimulus for research into areas of management for which there is little evidence. Sections of the guideline will continue to be updated on the BTS and SIGN websites on an annual basis.

1.1 STATEMENT OF INTENT

This guideline is not intended to be construed or to serve as a standard of care. Standards of care are determined on the basis of all clinical data available for an individual case and are subject to change as scientific knowledge and technology advance and patterns of care evolve. Adherence to guideline recommendations will not ensure a successful outcome in every case, nor should they be construed as including all proper methods of care or excluding other acceptable methods of care aimed at the same results. The ultimate judgement must be made by the appropriate healthcare professional(s) responsible for clinical decisions regarding a particular clinical procedure or treatment plan. This judgement should only be arrived at following discussion of the options with the patient, covering the diagnostic and treatment choices available. It is advised, however, that significant departures from the national guideline or any local guidelines derived from it should be fully documented in the patient’s case notes at the time the relevant decision is taken.
2 Diagnosis

The diagnosis of asthma is a clinical one; there is no standardised definition of the type, severity or frequency of symptoms, nor of the findings on investigation. The absence of a gold standard definition means that it is not possible to make clear evidence based recommendations on how to make a diagnosis of asthma.

Central to all definitions is the presence of symptoms (more than one of wheeze, breathlessness, chest tightness, cough) and of variable airflow obstruction. More recent descriptions of asthma in children and in adults have included airway hyper-responsiveness and airway inflammation as components of the disease. How these features relate to each other, how they are best measured and how they contribute to the clinical manifestations of asthma, remains unclear.

Although there are many shared features in the diagnosis of asthma in children and in adults there are also important differences. The differential diagnosis, the natural history of wheezing illnesses, the ability to perform certain investigations and their diagnostic value, are all influenced by age.

2.1 DIAGNOSIS IN CHILDREN

Asthma in children causes recurrent respiratory symptoms of:
- wheezing
- cough
- difficulty breathing
- chest tightness.

Wheezing is one of a number of respiratory noises that occur in children. Parents often use “wheezing” as a non-specific label to describe any abnormal respiratory noise. It is important to distinguish wheezing – a continuous, high-pitched musical sound coming from the chest – from other respiratory noises, such as stridor or rattly breathing.4

There are many different causes of wheeze in childhood and different clinical patterns of wheezing can be recognised in children. In general, these patterns (“phenotypes”) have been assigned retrospectively. They cannot reliably be distinguished when an individual child first presents with wheezing. In an individual child the pattern of symptoms may change as they grow older.

The commonest clinical pattern, especially in pre-school children and infants, is episodes of wheezing, cough and difficulty breathing associated with viral upper respiratory infections (colds), with no persisting symptoms. Most of these children will stop having recurrent chest symptoms by school age.

A minority of those who wheeze with viral infections in early life will go on to develop wheezing with other triggers so that they develop symptoms between acute episodes (interval symptoms) similar to older children with classical atopic asthma.5,9

Children who have persisting or interval symptoms are most likely to benefit from therapeutic interventions.

2.1.1 MAKING A DIAGNOSIS IN CHILDREN

Initial clinical assessment

The diagnosis of asthma in children is based on recognising a characteristic pattern of episodic respiratory symptoms and signs (see Table 1) in the absence of an alternative explanation for them (see Tables 2 and 3).
Table 1: Clinical features that increase the probability of asthma

More than one of the following symptoms: wheeze, cough, difficulty breathing, chest tightness, particularly if these symptoms:

◊ are frequent and recurrent\(^ {10-13}\)
◊ are worse at night and in the early morning\(^ {11,12,14}\)
◊ occur in response to, or are worse after, exercise or other triggers, such as exposure to pets, cold or damp air, or with emotions or laughter
◊ occur apart from colds\(^ {10}\)
• Personal history of atopic disorder\(^ {10,13,15}\)
• Family history of atopic disorder and/or asthma\(^ {10,16}\)
• Widespread wheeze heard on auscultation
• History of improvement in symptoms or lung function in response to adequate therapy

Table 2: Clinical features that lower the probability of asthma

• Symptoms with colds only, with no interval symptoms\(^ {10}\)
• Isolated cough in the absence of wheeze or difficulty breathing\(^ {17}\)
• History of moist cough\(^ {18}\)
• Prominent dizziness, light-headedness, peripheral tingling
• Repeatedly normal physical examination of chest when symptomatic
• Normal peak expiratory flow (PEF) or spirometry when symptomatic
• No response to a trial of asthma therapy\(^ {19}\)
• Clinical features pointing to alternative diagnosis (see Table 3)

Several factors are associated with a high (or low) risk of developing persisting wheezing or asthma through childhood.\(^ {15,20}\) The presence of these factors increases the probability that a child with respiratory symptoms will have asthma.

These factors include:

**Age at presentation**

The natural history of wheeze is dependent on age at first presentation. In general, the earlier the onset of wheeze, the better the prognosis. Cohort studies show a “break point” at around two years; most children who present before this age become asymptomatic by mid-childhood.\(^ {6,8,9,21}\) Co-existent atopy is a risk factor for persistence of wheeze independent of age of presentation.

**Sex**

Male sex is a risk factor for asthma in pre-pubertal children. Female sex is a risk factor for the persistence of asthma in the transition from childhood to adulthood.\(^ {22,23}\) Boys with asthma are more likely to “grow out” of their asthma during adolescence than girls.\(^ {10,21,22,24-37}\)

**Severity and frequency of previous wheezing episodes**

Frequent or severe episodes of wheezing in childhood are associated with recurrent wheeze that persists into adolescence.\(^ {5,8,13,16,21,26,36,39}\)
Coexistence of atopic disease

A history of other atopic conditions such as eczema and rhinitis increases the probability of asthma. Positive tests for atopy in a wheezing child also increase the likelihood of asthma. A raised specific IgE to wheat, egg white, or inhalant allergens such as house dust mite and cat dander, predicts later childhood asthma.40,41

Other markers of allergic disease at presentation, such as positive skin prick tests and a raised blood eosinophil count, are related to the severity of current asthma and persistence through childhood.

Family history of atopy

A family history of atopy is the most clearly defined risk factor for atopy and asthma in children. The strongest association is with maternal atopy, which is an important risk factor for the childhood onset of asthma and for recurrent wheezing that persists throughout childhood.6,34,37,42,43

Abnormal lung function

Persistent reductions in baseline airway function and increased airway responsiveness during childhood are associated with having asthma in adult life.23

Table 3: Clinical clues to alternative diagnoses in wheezy children (features not commonly found in children with asthma)

<table>
<thead>
<tr>
<th>Perinatal and family history</th>
<th>Possible diagnosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Symptoms present from birth or perinatal lung problem</td>
<td>Cystic fibrosis; chronic lung disease of prematurity; ciliary dyskinesia; developmental anomaly</td>
</tr>
<tr>
<td>Family history of unusual chest disease</td>
<td>Cystic fibrosis; neuromuscular disorder</td>
</tr>
<tr>
<td>Severe upper respiratory tract disease</td>
<td>Defect of host defence; ciliary dyskinesia</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Symptoms and signs</th>
<th>Possible diagnosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Persistent moist cough18</td>
<td>Cystic fibrosis; bronchiectasis; protracted bronchitis; recurrent aspiration; host defence disorder; ciliary dyskinesia</td>
</tr>
<tr>
<td>Excessive vomiting</td>
<td>Gastro-oesophageal reflux (± aspiration)</td>
</tr>
<tr>
<td>Dysphagia</td>
<td>Swallowing problems (± aspiration)</td>
</tr>
<tr>
<td>Breathlessness with light-headedness and peripheral tingling</td>
<td>Hyperventilation/panic attacks</td>
</tr>
<tr>
<td>Inspiratory stridor</td>
<td>Tracheal or laryngeal disorder</td>
</tr>
<tr>
<td>Abnormal voice or cry</td>
<td>Laryngeal problem</td>
</tr>
<tr>
<td>Focal signs in chest</td>
<td>Developmental anomaly; post-infective syndrome; bronchiectasis; tuberculosis</td>
</tr>
<tr>
<td>Finger clubbing</td>
<td>Cystic fibrosis; bronchiectasis</td>
</tr>
<tr>
<td>Failure to thrive</td>
<td>Cystic fibrosis; host defence disorder; gastro-oesophageal reflux</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Investigations</th>
<th>Possible diagnosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Focal or persistent radiological changes</td>
<td>Developmental anomaly; cystic fibrosis; post-infective disorder; recurrent aspiration; inhaled foreign body; bronchiectasis; tuberculosis</td>
</tr>
</tbody>
</table>
Case detection studies have used symptom questionnaires to screen for asthma in school-age children. A small number of questions - about current symptoms, their relation to exercise and their occurrence at night has been sufficient to detect asthma relatively efficiently. The addition of spirometry or bronchial hyper-responsiveness testing to these questionnaires adds little to making a diagnosis of asthma in children.

Focus the initial assessment in children suspected of having asthma on:
- presence of key features in the history and examination
- careful consideration of alternative diagnoses.

Record the basis on which a diagnosis of asthma is suspected.

2.1.2 ASSESSING THE PROBABILITY OF A DIAGNOSIS OF ASTHMA

Based on the initial clinical assessment it should be possible to determine the probability of a diagnosis of asthma.

With a thorough history and examination, an individual child can usually be classed into one of three groups (see Figure 1):
- high probability – diagnosis of asthma likely
- low probability – diagnosis other than asthma likely
- intermediate probability – diagnosis uncertain.

2.1.3 HIGH PROBABILITY OF ASTHMA

In children with a high probability of asthma based on the initial assessment, move straight to a diagnostic trial of treatment. The initial choice of treatment will be based on an assessment of the degree of asthma severity (see section 4).

The clinical response to treatment should be reassessed within 2-3 months. In this group, reserve more detailed investigations for those whose response to treatment is poor or those with severe disease.

In children with a high probability of asthma:
- start a trial of treatment
- review and assess response
- reserve further testing for those with a poor response.

2.1.4 LOW PROBABILITY OF ASTHMA

Where symptoms, signs or initial investigations suggest that a diagnosis of asthma is unlikely, (see Table 2), or they point to an alternative diagnosis (see Table 3), consider further investigations. This may require referral for specialist assessment (see Table 4).

Reconsider a diagnosis of asthma in those who do not respond to specific treatments.

In children with a low probability of asthma, consider more detailed investigation and specialist referral.
2.1.5 INTERMEDIATE PROBABILITY OF ASTHMA

In some children, and particularly those below the age of four to five, there is insufficient evidence at the first consultation to make a firm diagnosis of asthma, but no features to suggest an alternative diagnosis. There are several possible approaches to reaching a diagnosis in this group. Which approach is taken will be influenced by the frequency and severity of the symptoms.

These approaches include:

**Watchful waiting with review**

In children with mild, intermittent wheeze and other respiratory symptoms which occur only with viral upper respiratory infections (colds), it is often reasonable to give no specific treatment and to plan a review of the child after an interval agreed with the parents/carers.

**Trial of treatment with review**

The choice of treatment (for example, inhaled bronchodilators or corticosteroids) depends on the severity and frequency of symptoms. Although a trial of therapy with inhaled or oral corticosteroids is widely used to help make a diagnosis of asthma, there is little objective evidence to support this approach in children with recurrent wheeze.

It can be difficult to assess the response to treatment as an improvement in symptoms or lung function may be due to spontaneous remission. If it is unclear whether a child has improved, careful observation during a trial of withdrawing the treatment may clarify whether a response to asthma therapy has occurred.

**Spirometry and reversibility testing**

In children, as in adults, tests of airflow obstruction, airway responsiveness and airway inflammation may provide support for a diagnosis of asthma. However, normal results on testing, especially if performed when the child is asymptomatic, do not exclude a diagnosis of asthma. Abnormal results may be seen in children with other respiratory diseases. Measuring lung function in young children is difficult and requires techniques which are not widely available.

Above five years of age, conventional lung function testing is possible in most children in most settings. This includes measures of airway obstruction (spirometry and peak flow), reversibility with bronchodilators, and airway hyper-responsiveness.

The relationship between asthma symptoms and lung function tests including bronchodilator reversibility is complex. Asthma severity classified by symptoms and use of medicines correlates poorly with single measurements of forced expiratory volume in one second (FEV₁) and other spirometric indices; FEV₁ is often normal in children with persistent asthma. Serial measures of peak flow variability and FEV₁ show poor concordance with disease activity and do not reliably rule the diagnosis of asthma in or out. Measures of gas trapping (residual volume and the ratio of residual volume to total lung capacity, RV/TLC) may be superior to measurements of expiratory flow at detecting airways obstruction especially in asymptomatic children.

A significant increase in FEV₁ (>12% from baseline) or PEF after bronchodilator indicates reversible airflow obstruction and supports the diagnosis of asthma. It is also predictive of a good response to inhaled corticosteroids. However, an absent response to bronchodilators does not exclude asthma.

Between 2-5 years of age, many children can perform several newer lung function tests that do not rely on their cooperation or the ability to perform a forced expiratory manoeuvre. In general, these tests have not been evaluated as diagnostic tests for asthma. There is often substantial overlap between the values in children with and without asthma. Of the tests available, specific airways resistance (sRaw), impulse oscillometry (IOS), and measurements of residual volume (RV) appear the most promising. While some of these tests have been useful in research, their role in clinical practice is uncertain. Most have only been used in specialist centres and are not widely available elsewhere. It is often not practical to measure variable airway obstruction in children below the age of five.
2.1.6 CHILDREN WITH AN INTERMEDIATE PROBABILITY OF ASTHMA AND EVIDENCE OF AIRWAY OBSTRUCTION

Asthma is the by far the commonest cause of airways obstruction on spirometry in children. Obstruction due to other disorders, or due to multiple causes, is much less common in children than in adults. Spirometry and other lung function tests, including tests of PEF variability, lung volumes and airway responsiveness, are poor at discriminating between children with asthma and those with obstruction due to other conditions.

☑ In children with an intermediate probability of asthma who can perform spirometry and have evidence of airways obstruction, assess the change in FEV₁ or PEF in response to an inhaled bronchodilator (reversibility) and/or the response to a trial of treatment for a specified period:

- if there is significant reversibility, or if a treatment trial is beneficial, a diagnosis of asthma is probable. Continue to treat as asthma, but aim to find the minimum effective dose of therapy. At a later point, consider a trial of reduction or withdrawal of treatment.
- if there is no significant reversibility, and a treatment trial is not beneficial, consider tests for alternative conditions (see Table 3).

2.1.7 CHILDREN WITH AN INTERMEDIATE PROBABILITY OF ASTHMA WITHOUT EVIDENCE OF AIRWAY OBSTRUCTION

In this group, further investigations, including assessment of atopic status and bronchodilator responsiveness and if possible tests of airway responsiveness, should be considered (see section 2.2.1). This is particularly so if there has been a poor response to a trial of treatment or if symptoms are severe. In these circumstances, referral for specialist assessment is indicated.

C In children with an intermediate probability of asthma who can perform spirometry and have no evidence of airways obstruction:

- consider testing for atopic status, bronchodilator reversibility and, if possible, bronchial hyper-responsiveness using methacholine, exercise or mannitol.
- consider specialist referral.

2.1.8 CHILDREN WITH AN INTERMEDIATE PROBABILITY OF ASTHMA WHO CANNOT PERFORM SPIROMETRY

Most children under five years and some older children cannot perform spirometry. In these children, offer a trial of treatment for a specific period. If there is clear evidence of clinical improvement, the treatment should be continued and they should be regarded as having asthma (it may be appropriate to consider a trial of withdrawal of treatment at a later stage). If the treatment trial is not beneficial, then consider tests for alternative conditions and referral for specialist assessment.

☑ In children with an intermediate probability of asthma who cannot perform spirometry, offer a trial of treatment for a specified period:

- if treatment is beneficial, treat as asthma and arrange a review
- if treatment is not beneficial, stop asthma treatment and consider tests for alternative conditions and specialist referral.
2.2 OTHER INVESTIGATIONS

2.2.1 TESTS OF AIRWAY HYPER-RESPONSIVENESS

The role of tests of airway responsiveness (airway hyper-reactivity) in the diagnosis of childhood asthma is unclear.\(^{45,55}\) For example, a methacholine challenge test has a much lower sensitivity than symptoms in diagnosing asthma in children and only marginally increases the diagnostic accuracy after the symptom history is taken into account.\(^{45}\) However, a negative methacholine test in children, which has a high negative predictive value, makes a diagnosis of asthma improbable.\(^{55}\) Similarly, a negative response to an exercise challenge test is helpful in excluding asthma in children with exercise related breathlessness.\(^{36}\)

2.2.2 TEST OF EOSINOPHILIC AIRWAY INFLAMMATION

Eosinophilic inflammation in children can be assessed non-invasively using induced sputum differential eosinophil count or exhaled nitric oxide concentrations (FENO).

Sputum induction is feasible in school age children.\(^{57,58}\) Higher sputum eosinophil counts are associated with more marked airways obstruction and reversibility, greater asthma severity and atopy.\(^{59}\) In children with newly diagnosed mild asthma, sputum eosinophilia is present and declines with inhaled steroid treatment.\(^{58}\) Sputum induction is possible in approximately 75% of children tested, but it is technically demanding and time consuming and at present remains a research tool.

It is feasible to measure FENO in unsedated children from the age of 3–4 years.\(^{60}\) A raised FENO is neither a sensitive nor a specific marker of asthma with overlap with children who do not have asthma.\(^{61}\) FENO is closely linked with atopic status, age and height.\(^{62,63}\) In some studies, FENO correlated better with atopic dermatitis and allergic rhinitis than with asthma. It is not closely linked with underlying lung function. FENO could not differentiate between groups once atopy was taken into account.\(^{64}\) Home measurements of FENO have a highly variable relationship with other measures of disease activity and vary widely from day to day.\(^{65}\)

At present, there is insufficient evidence to support a role for markers of eosinophilic inflammation in the diagnosis of asthma in children. They may have a role in assessing severity of disease or response to treatment.

2.2.3 TESTS OF ATOPY

Positive skin tests,\(^{66}\) blood eosinophilia \(\geq 4\%\),\(^{11}\) or a raised specific IgE to cat, dog or mite,\(^{67,68}\) increase the probability of asthma in a child with wheeze, particularly in children over five years of age.\(^{66}\) It is important to recognise that non-atopic wheezing is as frequent as atopic wheezing in school-age children.\(^{69}\)

2.2.4 CHEST X-RAY

A study in primary care in children age 0–6 years concluded that a chest X-ray (CXR), in the absence of a clinical indication, need not be part of the initial diagnostic work up.\(^{70}\)

[ ] Reserve chest X-rays for children with severe disease or clinical clues suggesting other conditions.
2.3 SUMMARY

Focus the initial assessment of children suspected of having asthma on:

- presence of key features in the history and clinical examination
- careful consideration of alternative diagnoses.

Record the basis on which the diagnosis of asthma is suspected.

Using a structured questionnaire may produce a more standardised approach to the recording of presenting clinical features and the basis for a diagnosis of asthma.

1. In children with a high probability of asthma:
   - move straight to a trial of treatment
   - reserve further testing for those with a poor response.

2. In children with a low probability of asthma:
   - consider more detailed investigation and specialist referral.

3. In children with an intermediate probability of asthma who can perform spirometry and have evidence of airways obstruction, offer a reversibility test and/or a trial of treatment for a specified period:
   - if there is reversibility, or if treatment is beneficial, treat as asthma
   - if there is insignificant reversibility, and/or treatment trial is not beneficial, consider tests for alternative conditions.

4. In children with an intermediate probability of asthma who can perform spirometry, and have no evidence of airways obstruction, consider testing for atopic status, bronchodilator reversibility and, if possible, bronchial hyper-responsiveness using methacholine or exercise.

5. In children with an intermediate probability of asthma who cannot perform spirometry, consider testing for atopic status and offering a trial of treatment for a specified period:
   - if treatment is beneficial, treat as asthma
   - if treatment is not beneficial, stop asthma treatment, and consider tests for alternative conditions and specialist referral.

Table 4: Indications for specialist referral in children

- Diagnosis unclear or in doubt
- Symptoms present from birth or perinatal lung problem
- Excessive vomiting or possetting
- Severe upper respiratory tract infection
- Persistent wet or productive cough
- Family history of unusual chest disease
- Failure to thrive
- Nasal polyps
- Unexpected clinical findings eg focal signs, abnormal voice or cry, dysphagia, inspiratory stridor
- Failure to respond to conventional treatment (particularly inhaled corticosteroids above 400 mcg/day or frequent use of steroid tablets)
- Parental anxiety or need for reassurance
**Figure 1: Presentation with suspected asthma in children**

Clinical assessment

- **HIGH PROBABILITY:** diagnosis of asthma likely
- **INTERMEDIATE PROBABILITY:** diagnosis uncertain or poor response to asthma treatment
- **LOW PROBABILITY:** other diagnosis likely

**HIGH PROBABILITY:**
- Trial of asthma treatment
- +VE

**INTERMEDIATE PROBABILITY:**
- Consider tests of lung function* and atopy
- -VE

**LOW PROBABILITY:**
- Investigate/treat other condition

Response?
- Yes
  - Continue treatment and find minimum effective dose
- No
  - Assess compliance and inhaler technique. Consider further investigation and/or referral

Response?
- Yes
  - Further investigation. Consider referral
- No
  - Continue treatment

---

* Lung function tests include spirometry before and after bronchodilator (test of airway reversibility) and possible exercise or methacholine challenge (tests of airway responsiveness). Most children over the age of 5 years can perform lung function tests.
2.4 DIAGNOSIS IN ADULTS

The diagnosis of asthma is based on the recognition of a characteristic pattern of symptoms and signs and the absence of an alternative explanation for them (see Table 5). The key is to take a careful clinical history. In many cases this will allow a reasonably certain diagnosis of asthma, or an alternative diagnosis, to be made. If asthma does appear likely, the history should also explore possible causes, particularly occupational.

In view of the potential requirement for treatment over many years, it is important even in relatively clear cut cases, to try to obtain objective support for the diagnosis. Whether or not this should happen before starting treatment depends on the certainty of the initial diagnosis and the severity of presenting symptoms. Repeated assessment and measurement may be necessary before confirmatory evidence is acquired.

Confirmation hinges on demonstration of airflow obstruction varying over short periods of time. Spirometry, which is now becoming more widely available, is preferable to measurement of peak expiratory flow because it allows clearer identification of airflow obstruction, and the results are less dependent on effort. It should be the preferred test where available (although some training is required to obtain reliable recordings and to interpret the results). Of note, a normal spirogram (or PEF) obtained when the patient is not symptomatic does not exclude the diagnosis of asthma.

Results from spirometry are also useful where the initial history and examination leave genuine uncertainty about the diagnosis. In such cases, the differential diagnosis and approach to investigation is different in patients with and without airflow obstruction (see Figure 2 and Table 6). In patients with a normal or near-normal spirogram when symptomatic, potential differential diagnoses are mainly non-pulmonary; these conditions do not respond to inhaled corticosteroids and bronchodilators. In contrast, in patients with an obstructive spirogram the question is less whether they will need inhaled treatment but rather exactly what form and how intensive this should be.

Other tests of airflow obstruction, airway responsiveness and airway inflammation can also provide support for the diagnosis of asthma, but to what extent the results of the tests alter the probability of a diagnosis of asthma has not been clearly established, nor is it clear when these tests are best performed.
Table 5: Clinical features in adults that influence the probability that episodic respiratory symptoms are due to asthma

<table>
<thead>
<tr>
<th>Features that increase the probability of asthma</th>
</tr>
</thead>
<tbody>
<tr>
<td>▪ More than one of the following symptoms: wheeze, breathlessness, chest tightness and cough, particularly if:</td>
</tr>
<tr>
<td>◊ symptoms worse at night and in the early morning</td>
</tr>
<tr>
<td>◊ symptoms in response to exercise, allergen exposure and cold air</td>
</tr>
<tr>
<td>◊ symptoms after taking aspirin or beta blockers</td>
</tr>
<tr>
<td>▪ History of atopic disorder</td>
</tr>
<tr>
<td>▪ Family history of asthma and/or atopic disorder</td>
</tr>
<tr>
<td>▪ Widespread wheeze heard on auscultation of the chest</td>
</tr>
<tr>
<td>▪ Otherwise unexplained low FEV1 or PEF (historical or serial readings)</td>
</tr>
<tr>
<td>▪ Otherwise unexplained peripheral blood eosinophilia</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Features that lower the probability of asthma</th>
</tr>
</thead>
<tbody>
<tr>
<td>▪ Prominent dizziness, light-headedness, peripheral tingling</td>
</tr>
<tr>
<td>▪ Chronic productive cough in the absence of wheeze or breathlessness</td>
</tr>
<tr>
<td>▪ Repeatedly normal physical examination of chest when symptomatic</td>
</tr>
<tr>
<td>▪ Voice disturbance</td>
</tr>
<tr>
<td>▪ Symptoms with colds only</td>
</tr>
<tr>
<td>▪ Significant smoking history (ie &gt;20 pack-years)</td>
</tr>
<tr>
<td>▪ Cardiac disease</td>
</tr>
<tr>
<td>▪ Normal PEF or spirometry when symptomatic*</td>
</tr>
</tbody>
</table>

* A normal spirogram/spirometry when not symptomatic does not exclude the diagnosis of asthma. Repeated measurements of lung function are often more informative than a single assessment.

 ☑ Base initial diagnosis on a careful assessment of symptoms and a measure of airflow obstruction:
  ▪ in patients with a high probability of asthma move straight to a trial of treatment. Reserve further testing for those whose response to a trial of treatment is poor.
  ▪ in patients with a low probability of asthma, whose symptoms are thought to be due to an alternative diagnosis, investigate and manage accordingly. Reconsider the diagnosis of asthma in those who do not respond.
  ▪ the preferred approach in patients with an intermediate probability of having asthma is to carry out further investigations, including an explicit trial of treatments for a specified period, before confirming a diagnosis and establishing maintenance treatment.

 D Spirometry is the preferred initial test to assess the presence and severity of airflow obstruction.
2.4.1 FURTHER INVESTIGATION OF PATIENTS WITH AN INTERMEDIATE PROBABILITY OF ASTHMA

Patients with airways obstruction

Tests of peak expiratory flow variability, lung volumes, gas transfer, airway hyper-responsiveness and airway inflammation are of limited value in discriminating patients with established airflow obstruction due to asthma from those whose airflow obstruction is due to other conditions. Patients may have more than one cause of airflow obstruction, which complicates the interpretation of any test. In particular, asthma and chronic obstructive pulmonary disease (COPD) commonly coexist.

Offer patients with airways obstruction and intermediate probability of asthma a reversibility test and/or a trial of treatment for a specified period:

- if there is significant reversibility, or if a treatment trial is clearly beneficial treat as asthma
- if there is insignificant reversibility and a treatment trial is not beneficial, consider tests for alternative conditions.*

Patients without airways obstruction

In patients with a normal or near-normal spirogram it is more useful to look for evidence of airway hyper-responsiveness and/or airway inflammation. These tests are sensitive so normal results provide the strongest evidence against a diagnosis of asthma.

In patients without evidence of airways obstruction and with an intermediate probability of asthma, arrange further investigations* before commencing treatment.

* see section 2.5 for more detailed information on further tests
**Figure 2: Presentation with suspected asthma in adults**

Presentation with suspected asthma

Clinical assessment including spirometry (or PEF if spirometry not available)

HIGH PROBABILITY: diagnosis of asthma likely

INTERMEDIATE PROBABILITY: diagnosis uncertain

LOW PROBABILITY: other diagnosis likely

- **FEV₁ / FVC < 0.7**
  - Trial of treatment*
  - Response?°
    - Yes: Continue treatment
    - No: Assess compliance and inhaler technique. Consider further investigation and/or referral

- **FEV₁ / FVC > 0.7**
  - Investigate/treat other condition
  - Response?
    - No: No
    - Yes: Yes

* See section 2.5.1
° See Table 6
Table 6: Differential diagnosis of asthma in adults, according to the presence or absence of airflow obstruction (FEV₁/FVC < 0.7).

<table>
<thead>
<tr>
<th>Without airflow obstruction</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Chronic cough syndromes</td>
</tr>
<tr>
<td>• Hyperventilation syndrome</td>
</tr>
<tr>
<td>• Vocal cord dysfunction</td>
</tr>
<tr>
<td>• Rhinitis</td>
</tr>
<tr>
<td>• Gastro-oesophageal reflux</td>
</tr>
<tr>
<td>• Heart failure</td>
</tr>
<tr>
<td>• Pulmonary fibrosis</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>With airflow obstruction</th>
</tr>
</thead>
<tbody>
<tr>
<td>• COPD</td>
</tr>
<tr>
<td>• Bronchiectasis*</td>
</tr>
<tr>
<td>• Inhaled foreign body*</td>
</tr>
<tr>
<td>• Obliterative bronchiolitis</td>
</tr>
<tr>
<td>• Large airway stenosis</td>
</tr>
<tr>
<td>• Lung cancer*</td>
</tr>
<tr>
<td>• Sarcoidosis*</td>
</tr>
</tbody>
</table>

*may also be associated with non-obstructive spirometry

Consider performing chest X-ray in any patient presenting atypically or with additional symptoms or signs. Additional investigations such as full lung function tests, blood eosinophil count, serum IgE and allergen skin prick tests may be of value in selected patients.

Criteria for referral to a specialist are outlined in box 1.

Box 1: Criteria for specialist referral in adults

- Diagnosis unclear
- Unexpected clinical findings (ie crackles, clubbing, cyanosis, cardiac disease)
- Unexplained restrictive spirometry
- Suspected occupational asthma
- Persistent non-variable breathlessness
- Monophonic wheeze or stridor
- Prominent systemic features (myalgia, fever, weight loss)
- Chronic sputum production
- CXR shadowing
- Marked blood eosinophilia (>1 x 10⁹/l)
- Poor response to asthma treatment
- Severe asthma exacerbation
2.5 FURTHER INVESTIGATIONS THAT MAY BE USEFUL IN PATIENTS WITH AN INTERMEDIATE PROBABILITY OF ASTHMA

Three studies have looked at tests to discriminate patients with asthma from those with conditions that are commonly confused with asthma.\textsuperscript{71,77,79} These studies provide a basis for evaluating the diagnostic value of different tests. Table 7 summarises the sensitivity and specificity of different findings on investigation. As not all studies included patients with untreated asthma, these values may underestimate the value of the investigations in clinical practice, where many patients will be investigated before treatment is started. The diagnostic value of testing may also be greater when more than one test is done or if there are previous lung function results available in the patient’s notes. The choice of test will depend on a number of factors including severity of symptoms and local availability of tests.

An alternative and promising approach to the classification of airways disease is to use tests which best identify patients who are going to respond to corticosteroid therapy.\textsuperscript{78,80} A raised sputum eosinophil count and an increased exhaled nitric oxide concentration (\textit{FE\textsubscript{ENO}}) are more closely related to corticosteroid response than other tests in a variety of clinical settings.\textsuperscript{78,81,83} There is also evidence that markers of eosinophilic airway inflammation are of value in monitoring the response to corticosteroid treatment.\textsuperscript{84-86} More experience with these techniques and more information on the long term response to corticosteroid in patients who do not have a raised sputum eosinophil count or \textit{FE\textsubscript{ENO}} is needed before this approach can be recommended.

Table 7: Estimates of sensitivity and specificity of test results in adults with suspected asthma and normal or near-normal spirometric values.\textsuperscript{71,77,79}

<table>
<thead>
<tr>
<th>Test</th>
<th>Normal range</th>
<th>Validity</th>
<th>Sensitivity</th>
<th>Specificity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methacholine PC\textsubscript{20}</td>
<td>&gt; 8 mg/ml</td>
<td>High</td>
<td>Medium</td>
<td></td>
</tr>
<tr>
<td>Indirect challenges*</td>
<td>varies</td>
<td>Medium\textsuperscript{#}</td>
<td>High</td>
<td></td>
</tr>
<tr>
<td>\textit{FE\textsubscript{ENO}}</td>
<td>&lt; 25 ppb</td>
<td>High\textsuperscript{#}</td>
<td>Medium</td>
<td></td>
</tr>
<tr>
<td>Sputum eosinophil count</td>
<td>&lt; 2%</td>
<td>High\textsuperscript{#}</td>
<td>Medium</td>
<td></td>
</tr>
<tr>
<td>PEF A%H</td>
<td>&lt; 8\textsuperscript{<strong>} &lt; 20%\textsuperscript{</strong>*}</td>
<td>Low</td>
<td>Medium</td>
<td></td>
</tr>
</tbody>
</table>

\textit{PC\textsubscript{20}} = the provocative concentration of methacholine required to cause a 20% fall in \textit{FEV\textsubscript{1}}. \textit{FE\textsubscript{ENO}} = exhaled nitric oxide concentration. PEF A%H = peak expiratory flow amplitude percent highest.

*ie exercise challenge, \textit{inhaled mannitol} \# in untreated patients. **with twice daily readings ***with four or more readings

2.5.1 TREATMENT TRIALS AND REVERSIBILITY TESTING

Treatment trials with bronchodilators or inhaled corticosteroids in patients with diagnostic uncertainty should use one or more objective methods of assessment. Using spirometric values or PEF as the prime outcome of interest is of limited value in patients with normal or near-normal pre-treatment lung function since there is little room for measurable improvement. One study has shown that the sensitivity of a positive response to inhaled corticosteroid, defined as a > 15% improvement in PEF, is 24\%.\textsuperscript{79} A variety of tools to assess asthma control is available to assess the response to a trial of treatment (see Table 8).

Using \textit{FEV\textsubscript{1}}, or PEF as the primary method to assess reversibility or the response to treatment trials may be more helpful in patients with established airflow obstruction.

In adults, most clinicians would try a 6-8 week treatment trial of 200 mcg inhaled beclomethasone (or equivalent) twice daily. In patients with significant airflow obstruction there may be a degree of inhaled corticosteroid resistance \textsuperscript{87} and a treatment trial with oral prednisolone 30 mg daily for two weeks is preferred.
A >400 ml improvement in FEV₁ to either β₂ agonists or corticosteroid treatment trials strongly suggests underlying asthma. Smaller improvements in FEV₁ are less discriminatory and a decision on continuation of treatment should be based on objective assessment of symptoms using validated tools (see Table 8). Trials of treatment withdrawal may be helpful where there is doubt.

C Assess FEV₁ (or PEF) and/or symptoms:
- before and after 400 mcg inhaled salbutamol in patients with diagnostic uncertainty and airflow obstruction present at the time of assessment
- in other patients, or if there is an incomplete response to inhaled salbutamol, after either inhaled corticosteroids (200 mcg twice daily beclometasone equivalent for 6-8 weeks) or oral prednisolone (30 mg once daily for 14 days).

2.5.2 PEAK EXPIRATORY FLOW MONITORING

PEF should be recorded as the best of three forced expiratory blows from total lung capacity with a maximum pause of two seconds before blowing. The patient can be standing or sitting. Further blows should be done if the largest two PEF are not within 40 l/min. PEF is best used to provide an estimate of variability of airflow from multiple measurements made over at least two weeks. Increased variability may be evident from twice daily readings. More frequent readings will result in a better estimate but the improved precision is likely to be achieved at the expense of reduced patient compliance.

PEF variability is best calculated as the difference between the highest and lowest PEF expressed as a percentage of either the mean or highest PEF.

The upper limit of the normal range for the amplitude % highest is around 20% using four or more PEF readings per day but may be lower using twice daily readings. Epidemiological studies have shown sensitivities of between 19 and 33% for identifying physician-diagnosed asthma.

PEF variability can be increased in patients with conditions commonly confused with asthma so the specificity of abnormal PEF variability is likely to be less in clinical practice than it is in population studies.

PEF records from frequent readings taken at work and away from work are useful when considering a diagnosis of occupational asthma (see section 7.8). A computer generated analysis of occupational records which provides an index of the work effect is available.

Peak flow records should be interpreted with caution and with regard to the clinical context. They are more useful in the monitoring of patients with established asthma than in making the initial diagnosis.

2.5.3 ASSESSMENT OF AIRWAY RESPONSIVENESS

Tests of airway responsiveness have been useful in research but are not yet widely available in everyday clinical practice. The most widely used method of measuring airway responsiveness relies on measuring response in terms of change in FEV₁ (changing after inhalation of increasing concentrations of histamine or methacholine. The agent can be delivered by breath-activated dosimeter, via a nebuliser using tidal breathing, or via a hand held atomiser. The response is usually quantified as the concentration (or dose) required to cause a 20% fall in FEV₁ (PC₂₀ or PD₂₀) calculated by linear interpolation of the log concentration or dose-response curve.

Community studies in adults have consistently shown that airway responsiveness has a unimodal distribution with between 90 and 95% of the normal population having a histamine or methacholine PC₂₀ of >8 mg/ml (equivalent to a PD₂₀ of >4 micromoles). This value has a sensitivity of between 60-100% in detecting physician-diagnosed asthma.
In patients with normal or near-normal spirometric values, assessment of airway responsiveness is significantly better than other tests in discriminating patients with asthma from patients with conditions commonly confused with asthma (see Table 6).\textsuperscript{71,77} In contrast, tests of airway responsiveness are of little value in patients with established airflow obstruction as the specificity is low.\textsuperscript{73,76}

Other potentially helpful constrictor challenges include indirect challenges such as inhaled mannitol and exercise.\textsuperscript{101} A positive response to these indirect stimuli (ie a $>$ 15% fall in FEV\textsubscript{1}) is a specific indicator of asthma but the tests are less sensitive than tests using methacholine and histamine, particularly in patients tested while on treatment.\textsuperscript{101,102}

2.5.4 TESTS OF EOSINOPHILIC AIRWAY INFLAMMATION

Eosinophilic airway inflammation can be assessed non-invasively using the induced sputum differential eosinophil count or the exhaled nitric oxide concentration (FE\textsubscript{NO}).\textsuperscript{103,104} A raised sputum eosinophil count ($>$ 2\%) or FE\textsubscript{NO} ($>$ 25 ppb at 50 ml/sec) is seen in 70-80\% of patients with untreated asthma.\textsuperscript{74,103} Neither finding is specific to asthma: 30-40\% of patients with chronic cough\textsuperscript{82,105,106} and a similar proportion of patients with COPD\textsuperscript{81} have abnormal results. There is growing evidence that measures of eosinophilic airway inflammation are more closely linked to a positive response to corticosteroids than other measures even in patients with diagnoses other than asthma.\textsuperscript{81,83,105}

Experience with induced sputum and FE\textsubscript{NO} is limited to a few centres and more research needs to be done before any recommendations can be made.

\begin{mdframed}
\textbf{C} In patients in whom there is diagnostic uncertainty and no evidence of airflow obstruction on initial assessment, test airway responsiveness wherever possible.
\end{mdframed}

2.6 MONITORING ASTHMA

In the majority of patients with asthma symptom-based monitoring is adequate. Patients achieving control of symptoms with treatment have a low risk for exacerbations.\textsuperscript{107}

Table 8 summarises the methodology, measurement characteristics and interpretation of some of the validated tools used to assess symptoms and other aspects of asthma. Some measures provide information about future risk (ie sputum eosinophil count, airway responsiveness and FE\textsubscript{NO}) rather than immediate clinical control. Risk reduction, eg minimising future adverse outcomes such as exacerbations and accelerated decline in lung function, is also a goal of asthma management.

A management strategy that controls eosinophilic airway inflammation\textsuperscript{84,86} or airway hyper-responsiveness\textsuperscript{108} results in better control of exacerbations than one which controls immediate clinical manifestations. The benefits of this more intensive approach are greater in patients with severe asthma, when exacerbations can occur frequently and unpredictably. More research is needed to assess the relative roles of the different measures and to address the feasibility and cost of incorporating them into monitoring protocols before they can be recommended more widely.
2.6.1 MONITORING IN PRIMARY CARE

Asthma is best monitored in primary care by routine clinical review on at least an annual basis (see section 8.1.2).

The factors that should be monitored and recorded include:

- symptomatic asthma control: best assessed using directive questions such as the RCP ‘3 questions’, or the Asthma Control Questionnaire or Asthma Control Test (see Table 8), since broad non-specific questions may underestimate symptoms.
- lung function, assessed by spirometry or by PEF. Reduced lung function compared to previously recorded values may indicate current bronchoconstriction or a long term decline in lung function and should prompt detailed assessment.
- exacerbations, oral corticosteroid use and time off work or school since last assessment.
- inhaler technique (see section 5).
- compliance (see section 9.2) which can be assessed by reviewing prescription refill frequency.
- bronchodilator reliance which can be assessed by reviewing prescription refill frequency.
- possession of and use of self management plan/personal action plan (see section 9.1).
Table 8: Summary of tools that can be used to assess asthma.

<table>
<thead>
<tr>
<th>Measurement</th>
<th>Methodology</th>
<th>Measurement characteristics</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Spirometry\textsuperscript{110, 111}</td>
<td>Widely available.</td>
<td>Normal ranges widely available and robust.</td>
<td>Good for short and longer term reversibility testing in subjects with pre-existing airflow obstruction.</td>
</tr>
<tr>
<td></td>
<td>Enables clear demonstration of airflow obstruction.</td>
<td>Short term (20 minute) 95% range for repeat measure of FEV\textsubscript{1} &lt; 160 ml; FVC &lt; 330 ml, independent of baseline value.</td>
<td>&gt;400 ml increase in FEV\textsubscript{1}, highly suggestive of asthma.</td>
</tr>
<tr>
<td></td>
<td>FEV\textsubscript{1} largely independent of effort and highly repeatable.</td>
<td></td>
<td>Less helpful in subjects with normal pre-treatment values because of ceiling effect.</td>
</tr>
<tr>
<td></td>
<td>Less applicable in acute severe asthma.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Only assesses one aspect of the disease state.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Peak expiratory flow (PEF)\textsuperscript{88, 91, 92, 112}</td>
<td>Widely available and simple.</td>
<td>Normal ranges of PEF are wide, and currently available normative tables are outdated and do not encompass ethnic diversity.</td>
<td>Useful for short and longer term reversibility testing in subjects with pre-existing airflow obstruction.</td>
</tr>
<tr>
<td></td>
<td>Applicable in a wide variety of circumstances including acute severe asthma.</td>
<td>Change in PEF more meaningful than absolute value.</td>
<td>Less helpful in subjects with normal pre-treatment values because of ceiling effect.</td>
</tr>
<tr>
<td></td>
<td>PEF variability can be determined from home readings in most subjects.</td>
<td>&gt;60 l/min increase in PEF suggested as best criteria for defining reversibility.</td>
<td>Little information on the use of PEF variability as an index of treatment response.</td>
</tr>
<tr>
<td></td>
<td>PEF effort dependent and not as repeatable as FEV\textsubscript{1}.</td>
<td>Normal range of PEF variability defined as amplitude % highest &lt;8% or &lt;20% depending on number of readings and degree of patient coaching.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Only assesses one aspect of the disease state.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Measurement</td>
<td>Methodology</td>
<td>Measurement characteristics</td>
<td>Comments</td>
</tr>
<tr>
<td>-------------------------------------------------</td>
<td>-----------------------------------------------------------------------------</td>
<td>----------------------------</td>
<td>--------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Royal College of Physicians (RCP) 3 Questions</td>
<td>Yes/no or graded response to the following three questions:</td>
<td>No to all questions consistent with controlled asthma.</td>
<td>Not well validated. Simplicity is attractive for use in day to day clinical practice.</td>
</tr>
<tr>
<td></td>
<td>1. Have you had difficulty sleeping because of your asthma symptoms (including cough)?</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>2. Have you had your usual asthma symptoms during the day (cough, wheeze, chest tightness or breathlessness)?</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>3. Has your asthma interfered with your usual activities (eg housework, work/school etc)?</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Asthma Control Questionnaire</td>
<td>Response to 7 questions, 5 relating to symptoms, 1 rescue treatment use and 1 FEV&lt;sub&gt;1&lt;/sub&gt;.</td>
<td>Well controlled ≤ 0.75, inadequately controlled ≥ 1.5. 95% range for repeat measure +/- 0.36. Minimal important difference 0.5.</td>
<td>Well validated composite scoring system with a strong bias to symptoms. Could be used to assess response to longer term treatment trials. Shortened five-point questionnaire is probably best for those with normal or near normal FEV&lt;sub&gt;1&lt;/sub&gt;.</td>
</tr>
<tr>
<td></td>
<td>Response usually assessed over the preceding week.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Shortened, five question symptom only questionnaire is just as valid.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Asthma Control Test (ACT)</td>
<td>Response to 5 questions, 3 related to symptoms, 1 medication use and 1 overall control. 5 point response score</td>
<td>Well controlled &lt; 19. Within subject intraclass correlation coefficient 0.77. 95% range for repeat measure and minimally clinically important difference not defined.</td>
<td>Could be used to assess response to longer term treatment trials, particularly in those with normal or near-normal spirometric values. 95% range for repeat measure and minimally clinically important difference need to be defined.</td>
</tr>
<tr>
<td>Measurement</td>
<td>Methodology</td>
<td>Measurement characteristics</td>
<td>Comments</td>
</tr>
<tr>
<td>----------------------------------------------------------</td>
<td>-----------------------------------------------------------------------------</td>
<td>-----------------------------------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Mini Asthma Quality of Life Questionnaire (AQLQ)(^{114, 118})</td>
<td>Response to 15 questions in 4 domains (symptoms, activity limitations, emotional function and environmental stimuli). Response usually assessed over the preceding week. Closely related to larger 32-item asthma quality of life questionnaire.</td>
<td>95% range for repeat measure +/- 0.36. Minimal important difference 0.5.</td>
<td>Well validated quality of life questionnaire. Could be used to assess response to longer term treatment trials.</td>
</tr>
<tr>
<td>Airway responsiveness(^{98, 108})</td>
<td>Only available in selected secondary care facilities.</td>
<td>Normal methacholine PC(_{20}) &gt; 8 mg/ml. 95% range for repeat measure +/- 1.5-2 doubling doses.</td>
<td>Has not been widely used to monitor disease and assess treatment responses. Some evidence that using airway responsiveness as an additional measure for monitoring asthma results in a reduction in asthma exacerbations and improved airway pathology.</td>
</tr>
</tbody>
</table>


<table>
<thead>
<tr>
<th>Measurement</th>
<th>Methodology</th>
<th>Measurement characteristics</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exhaled nitric oxide (FENO)</td>
<td>Not widely available. Monitor still expensive, although expect the technology to become cheaper and more widespread. Measurements can be obtained in almost all adults and children over 5 years. Immediate results are available. Reasonably close relationship between FENO and eosinophilic airway inflammation, which is independent of gender, age, atopy and inhaled corticosteroid use. Relationship is lost in smokers. Not closely related to other measures of asthma morbidity.</td>
<td>Normal range &lt;25 ppb at exhaled flow of 50 ml/sec. 95% range for repeat measure 4 ppb. &gt;50 ppb highly predictive of eosinophilic airway inflammation. &lt;25 ppb highly predictive of its absence.</td>
<td>Raised FENO (&gt;50 ppb) very predictive of a positive response to corticosteroids. Use of FENO to guide corticosteroid treatment has been shown to result in a non-significant 25% reduction in exacerbations with 40% less corticosteroid. Low FENO (&lt;25 ppb) may be of particular value in identifying patients who can step down corticosteroid treatment safely. Protocols for diagnosis and monitoring have not been well defined and experience with the technique is limited.</td>
</tr>
<tr>
<td>Sputum eosinophil differential count</td>
<td>Only available in specialist centres although technology is widely available and inexpensive. Information available in 80-90% of patients although immediate results are not available. Sputum eosinophil count not closely related to other measures of asthma morbidity.</td>
<td>Normal range &lt;2%; 95% range for repeat measure +/- 2-3 fold.</td>
<td>Close relationship between raised sputum eosinophil count and corticosteroid responsiveness. Use of sputum eosinophil count to guide corticosteroid therapy has been consistently shown to result in better outcome for the same exposure to corticosteroids. Benefits are greater in patients with more severe disease.</td>
</tr>
</tbody>
</table>
3 Non-pharmacological management

There is a common perception amongst patients and carers that there are numerous environmental, dietary and other triggers of asthma and that avoiding these triggers will improve asthma and reduce the requirement for pharmacotherapy. Failure to address a patient, parent or carer’s concern about environmental triggers may compromise concordance with recommended pharmacotherapy. Evidence that non-pharmacological management is effective can be difficult to obtain and more well controlled intervention studies are required.

This section distinguishes:

1. primary prophylaxis - interventions introduced before the onset of disease and designed to reduce its incidence.
2. secondary prophylaxis - interventions introduced after the onset of disease to reduce its impact.

3.1 PRIMARY PROPHYLAXIS

The evidence for primary interventional strategies is based predominantly on observational studies, though some have been tested using experimental methods. Many are multifaceted and it can be difficult to disentangle the effects of one exposure or intervention from another.

3.1.1 AEROALLERGEN AVOIDANCE

Exposure to high levels of house dust mite allergen in early life is associated with an increased likelihood of sensitisation to house dust mite by three to seven years of age. Sensitisation to house dust mite is an important risk factor for the development of asthma and a few studies have suggested that high early house dust mite exposure increases the risks of subsequent asthma. A UK study showed that low levels of house dust mite and cat allergen exposures in early life increased the risk of IgE sensitisation and asthma at five years, with some attenuation at high levels of exposure, but there were significant interactions with heredity and birth order.

Outcomes from intervention studies attempting to reduce exposure to house dust mites are inconsistent. A multifaceted Canadian intervention study showed a reduced prevalence of doctor-diagnosed asthma but no impact on other allergic diseases, positive skin prick tests or bronchial hyper-responsiveness; others have shown no effect on either allergic sensitisation or symptoms of allergic diseases. In one UK study, early results from environmental manipulation commenced in early pregnancy and focused mainly on house dust mite avoidance, showed reductions in some respiratory symptoms in the first year of life. Subsequent results showed a paradoxical effect with increased allergy but better lung function in the intervention group.

The considerable variation in the methodology used in these studies precludes the merging of data or generation of meta-analyses.

Intensive house dust mite avoidance may reduce exposure to a range of other factors including endotoxin. Epidemiological studies suggest that close contact with a cat or a dog in early life may reduce the subsequent prevalence of allergy and asthma. This has raised the question of whether high pet allergen exposure causes high-dose immune tolerance or increases exposure to endotoxin and other microbial products as a component of the “hygiene hypothesis”.

In the absence of consistent evidence of benefit from domestic aeroallergen avoidance it is not possible to recommend it as a strategy for preventing childhood asthma.
3.1.2 FOOD ALLERGEN AVOIDANCE

Sensitisation to foods, particularly eggs, frequently precedes the development of aeroallergy and subsequent asthma. Food allergen avoidance in pregnancy and postnatally has not been shown to prevent the later development of asthma. Allergen avoidance during pregnancy may adversely affect maternal, and perhaps fetal, nutrition. High-dose food allergen exposure during pregnancy may reduce subsequent sensitisation rates by inducing tolerance.

B In the absence of any evidence of benefit and given the potential for adverse effects, maternal food allergen avoidance during pregnancy and lactation is not recommended as a strategy for preventing childhood asthma.

3.1.3 BREAST FEEDING

A systematic review of observational studies on the allergy preventive effects of breast feeding indicates that it is effective for all infants irrespective of allergic heredity. The preventive effect is more pronounced in high-risk infants provided they are breast fed for at least four months. However, not all studies have demonstrated benefit and in a large birth cohort there was no protective effect against atopy and asthma and maybe even an increase in risk.

Observational studies have the potential to be confounded by, for example, higher rates of breast feeding in atopic families, and taking this into account, the weight of evidence is in favour of breast feeding as a preventive strategy.

C Breast feeding should be encouraged for its many benefits, and as it may also have a potential protective effect in relation to early asthma.

3.1.4 MODIFIED INFANT MILK FORMULAE

Trials of modified milk formulae have not included sufficiently long follow up to establish whether there is any impact on asthma. A Cochrane review identified inconsistencies in findings and methodological concerns amongst studies, which mean that hydrolysed formulae cannot currently be recommended as part of an asthma prevention strategy. A review of the use of soy formulae found no significant effect on asthma or any other allergic disease.

In the absence of any evidence of benefit from the use of modified infant milk formulae it is not possible to recommend it as a strategy for preventing childhood asthma.

3.1.5 WEANING

There are conflicting data on the association between early introduction of allergenic foods into the infant diet and the subsequent development of allergy and atopic eczema. No evidence was identified in relation to asthma. In one study late introduction of egg was associated with a non-significant increase in pre-school wheezing.

In the absence of evidence on outcomes in relation to asthma no recommendations on modified weaning can be made.
3.1.6 NUTRITIONAL SUPPLEMENTATION - FISH OILS

Fish oils have a high level of omega-3 polyunsaturated fatty acids (n-3PUFAs). Western diets have a low intake of n-3 PUFAs with a corresponding increase in intake of n-6 PUFAs. This change has been associated with increasing rates of allergic disease and asthma.143 Two randomised controlled studies have investigated early life fish oil dietary supplementation in relation to asthma outcomes in children at high risk of atopic disease (at least one parent or sibling had atopy with or without asthma). In a study, powered only to detect differences in cord blood, maternal dietary fish oil supplementation during pregnancy was associated with reduced cytokine release from allergen stimulated cord blood mononuclear cells. However, effects on clinical outcomes at one year, in relation to atopic eczema, wheeze and cough, were marginal.145 In a second study, fish oil supplementation commencing in early infancy with or without additional house dust mite avoidance, was associated with a significant reduction in wheeze at 18 months of age. By five years of age fish oil supplementation was not associated with effects on asthma or other atopic diseases.146

In the absence of any evidence of benefit from the use of fish oil supplementation in pregnancy it is not possible to recommend it as a strategy for preventing childhood asthma.

3.1.7 OTHER NUTRIENTS

A number of observational studies have suggested an increased risk of subsequent asthma following reduced (maternal) intakes of selenium (based on umbilical cord levels),147 or vitamin E based on maternal pregnancy intake.148 No intervention studies in relation to selenium or vitamin E have yet been conducted and overall there is insufficient evidence to make any recommendations on maternal dietary supplementation as an asthma prevention strategy.143 Observational studies suggest that intervention trials are warranted.

3.1.8 MICROBIAL EXPOSURE

The “hygiene hypothesis” suggested that early exposure to microbial products would switch off allergic responses thereby preventing allergic diseases such as asthma. The hypothesis is supported by some epidemiological studies comparing large populations who have or have not had such exposure.149,150

The concept is sometimes described as “the microbial exposure hypothesis”. A double blind placebo controlled trial of the probiotic lactobacillus GG given to mothers resulted in a reduced incidence of atopic eczema in their children but had no effect on IgE antibody or allergic skin test responses. The small sample size and short follow up in this study limit its interpretation.151 Other trials of a range of probiotics and prebiotics are now in progress. There remains insufficient understanding of the ecology of gut flora in infancy in relation to outcomes. Bifido-bacteria may be more important than lactobacilli in reducing susceptibility to allergic disease.152

There is insufficient evidence to indicate that the use of dietary probiotics in pregnancy reduces the incidence of childhood asthma.

This is a key area for further work with longer follow up to establish outcomes in relation to asthma.

3.1.9 AVOIDANCE OF TOBACCO SMOKE AND OTHER AIR POLLUTANTS

No evidence has been found to support a link between exposure to environmental tobacco smoke (ETS) or other air pollutants and the induction of allergy.

There is an increased risk of infant wheezing associated with maternal smoking during pregnancy which adversely affects infant lung function.153-156 Evidence suggests that early life ETS exposure is associated with later persistent asthma157,158 with a strong interaction with genetic polymorphisms which affect antioxidant activity.159

Parents and parents-to-be should be advised of the many adverse effects which smoking has on their children including increased wheezing in infancy and increased risk of persistent asthma.
The limited data on antenatal or early life exposure to other pollutants suggest similar effects to those for ETS, namely increased infant wheezing, enhanced by additional ETS exposure and antioxidant gene variations.160-162 There is one small study suggesting that vitamin C supplementation will modify the combined effects of genetic polymorphisms and pollution on lung function in children with asthma.163 Further research is required before recommendations for practice can be made.

3.1.10 IMMUNOTHERAPY

Three observational studies with contemporaneous untreated controls in over 8,000 patients have shown that allergen immunotherapy in individuals with a single allergy reduces the numbers subsequently developing new allergic sensitisation over a three to four year follow up.164-166 One trial compared pollen allergen immunotherapy in children with allergic rhinitis with contemporaneous untreated controls and showed a lower rate of onset of asthma during three years of treatment.167 This effect was sustained for two years after stopping the therapy.168 More studies are required to establish whether immunotherapy might have a role in primary prophylaxis.

3.1.11 IMMUNISATION

In keeping with the “microbial exposure hypothesis” some studies have suggested an association between tuberculin responsiveness and subsequent reduced prevalence of allergy, implying a protective effect of BCG. At present, it is not possible to disentangle whether poor tuberculin responsiveness represents an underlying defect which increases the risk of allergy and asthma or whether the immunisation itself has a protective effect.169

Investigation of the effects of any other childhood immunisation suggests that at worst there is no influence on subsequent allergic disease and maybe some protective effect against the development of asthma.170

C All childhood immunisations should proceed normally as there is no evidence of an adverse effect on the incidence of asthma.

3.2 SECONDARY NON-PHARMACOLOGICAL PROPHYLAXIS

3.2.1 HOUSE DUST MITE AVOIDANCE

Increased allergen exposure in sensitised individuals is associated with an increase in asthma symptoms, bronchial hyper-responsiveness and deterioration in lung function.127,171,172 However, evidence that reducing allergen exposure can reduce morbidity and/or mortality in asthma is tenuous. In uncontrolled studies, children and adults have derived benefit from removal to a low allergen environment such as occurs at high altitude, although the benefits seen are not necessarily attributable to allergen avoidance alone.173

Cochrane reviews on house dust mite control measures in a normal domestic environment have concluded that chemical and physical methods aimed at reducing exposure to house dust mite allergens cannot be recommended.174 Subsequent studies involving large numbers of patients tend to support this conclusion.175,176 Heterogeneity between studies with regard to the intervention and monitoring of outcomes makes interpretation of the systematic review difficult.

Studies of mattress barrier systems have suggested that benefits in relation to treatment requirements for asthma and lung function can occur.177,178 Larger and more carefully conducted controlled studies employing combinations of house dust mite reduction strategies are required. At present house dust mite control measures do not appear to be a cost-effective method of achieving benefit, although it is recognised that many families are very committed to attempts to reduce exposure to triggers.
Measures to decrease house dust mites have been shown to reduce numbers of house dust mites, but have not been shown to have an effect on asthma severity.

Families with evidence of house dust mite allergy and who wish to try mite avoidance might consider the following:
- complete barrier bed-covering systems
- removal of carpets
- removal of soft toys from bed
- high temperature washing of bed linen
- acaricides to soft furnishings
- good ventilation with or without dehumidification.

3.2.2 OTHER ALLERGENS

Animal allergens, particularly from cat and dog, are potent provokers of asthma symptoms. The reported effects of removal of pets from homes are paradoxical, with either no benefit for asthma or a potential for continued high exposure to induce a degree of tolerance. In homes where there is no cat but still detectable cat allergen, there may be a benefit from introducing additional avoidance measures such as air filters and high efficiency vacuum cleaners for cat allergic patients.

Although fungal exposure has been strongly associated with hospitalisation and increased mortality in asthma, no controlled trials have addressed the efficacy of reduction of fungal exposure in relation to control of asthma. Cockroach allergy is not a common problem in the UK and studies of attempts to avoid this allergen elsewhere have produced conflicting results.

Studies of individual aeroallergen avoidance strategies show that single interventions have limited or no benefit. A multi faceted approach is more likely to be effective if it addresses all the indoor asthma triggers. Such approaches may even be cost effective. A strategy with a potential impact on mites, mould allergens and indoor pollutants is the use of a mechanical ventilation system to reduce humidity and increase indoor air exchange. The only trial that has assessed this in a controlled fashion failed to demonstrate any significant effects, but the numbers involved were small. A systematic review of this topic concluded that more research is required.

3.3 OTHER ENVIRONMENTAL FACTORS

3.3.1 SMOKING

Direct or passive exposure to cigarette smoke adversely affects quality of life, lung function, need for rescue medications for acute episodes of asthma and long term control with inhaled steroids.

There are very few trials which have assessed smoking cessation in relation to asthma control. Two studies have demonstrated decreases in childhood asthma severity when parents were able to stop smoking. One study in adults with asthma suggested that smoking cessation improved asthma-specific quality of life, symptoms and drug requirements. Intervention to reduce smoking has had disappointing outcomes. It is likely that more intensive intervention will be required to achieve meaningful outcomes.

Uptake of smoking in teenagers increases the risks of persisting asthma. One study showed a doubling of risk for the development of asthma over six years in 14 year old children who started to smoke (see section 4.2.4 for effect of smoking on treatment).

Parents with asthma should be advised about the dangers of smoking to themselves and their children with asthma and offered appropriate support to stop smoking.
3.3.2 AIR POLLUTION

Challenge studies demonstrate that various pollutants can enhance the response of patients with asthma to allergen inhalation.\textsuperscript{198,199} Time-series studies suggest that air pollution may provoke acute asthma attacks or aggravate existing chronic asthma although the effects are very much less than those with infection or allergen exposure.\textsuperscript{200,201} While it might seem likely that moving from a highly polluted environment might help, in the UK, asthma is more prevalent in 12-14 year olds in non-metropolitan rather than metropolitan areas.\textsuperscript{202} Much less attention has been focused on indoor pollutants in relation to asthma and more work is required.\textsuperscript{203,204}

3.3.3 IMMUNOTHERAPY

\textbf{Subcutaneous immunotherapy}

Trials of allergen specific immunotherapy by subcutaneous injection of increasing doses of allergen extracts have consistently demonstrated beneficial effects compared with placebo in the management of allergic asthma. Allergens included house dust mite, grass pollen, tree pollen, cat and dog allergens and moulds. Cochrane reviews have concluded that immunotherapy reduces asthma symptoms, the use of asthma medications and improves bronchial hyper-reactivity. The most recent review included 36 trials with house dust mite, 20 with pollen, 10 with animal allergens, two with cladosporium mould, one with latex and six with multiple allergens.\textsuperscript{205}

Evidence comparing the roles of immunotherapy and pharmacotherapy in the management of asthma is lacking. One study directly compared allergen immunotherapy with inhaled steroids and found that symptoms and lung function improved more rapidly in the group on inhaled steroids.\textsuperscript{206} Further comparative studies are required.

Immunotherapy for allergic rhinitis has been shown to have a carry over effect after therapy has stopped.\textsuperscript{207}

\begin{itemize}
  \item Immunotherapy can be considered in patients with asthma where a clinically significant allergen cannot be avoided. The potential for severe allergic reactions to the therapy must be fully discussed with patients.
\end{itemize}

\textbf{Sublingual immunotherapy}

There has been increasing interest in the use of sublingual immunotherapy, which is associated with far fewer adverse reactions than subcutaneous immunotherapy. A systematic review suggested there were some benefits for asthma control but the magnitude of the effect was small.\textsuperscript{208} Further randomised controlled trials are required.

\begin{itemize}
  \item Sublingual immunotherapy cannot currently be recommended for the treatment of asthma in routine practice.
\end{itemize}

3.4 DIETARY MANIPULATION

3.4.1 ELECTROLYTES

Increasing dietary sodium has been implicated in the geographical variations in asthma mortality\textsuperscript{209} and high sodium intake is associated with increased bronchial hyper-responsiveness.\textsuperscript{210,211} A systematic review of intervention studies reducing salt intake identified only minimal effects and concluded that dietary salt reduction could not be recommended in the management of asthma.\textsuperscript{212} Low magnesium intakes have been associated with a higher prevalence of asthma with increasing intake resulting in reduced bronchial hyper-responsiveness and higher lung function.\textsuperscript{213} Magnesium plays a beneficial role in the treatment of asthma through bronchial smooth muscle relaxation, leading to the use of intravenous or inhaled preparations of magnesium sulphate for acute exacerbations of asthma.\textsuperscript{214} Studies of oral supplementation are limited and more trials are required.\textsuperscript{215-217}
3.4.2 FISH OILS/LIPIDS

In vitro studies suggest that supplementing the diet with omega n-3 fatty acids, which are most commonly found in fish oils, might reduce the inflammation associated with asthma.\textsuperscript{218,219} Results from observational studies are inconsistent and a Cochrane review of nine randomised controlled trials concluded that there was insufficient evidence to recommend fish oil supplementation for the treatment of asthma.\textsuperscript{220}

3.4.3 ANTIOXIDANTS

Observational studies have reported that low vitamin C, vitamin E and selenium intakes are associated with a higher prevalence of asthma.\textsuperscript{143} Intervention studies suggest that neither supplementation with vitamin C, vitamin E or selenium is associated with clinical benefits in people with asthma.\textsuperscript{221-223} Observational studies in both adults and children have also consistently shown that a high intake of fresh fruit and vegetable is associated with less asthma and better pulmonary function.\textsuperscript{224-230} No intervention studies evaluating the intake of fruit or vegetables and their effects on asthma have been reported.

3.4.4 WEIGHT REDUCTION IN OBESE PATIENTS WITH ASTHMA

Several studies have reported an association between increasing body mass index and symptoms of asthma.\textsuperscript{231-234} One randomised parallel group study has shown improved asthma control following weight reduction in obese patients with asthma.\textsuperscript{235}

**C** Weight reduction is recommended in obese patients with asthma to promote general health and to improve asthma control.

3.4.5 PROBIOTICS

Studies have suggested that an imbalance in gut flora is associated with a higher risk of development of allergy.\textsuperscript{236} Trials have investigated the use of probiotics in the treatment of established allergic disease with variable results.\textsuperscript{237,238} Only one study focused on asthma, finding a decrease in eosinophilia but no effect on clinical parameters.\textsuperscript{239}

In the absence of evidence of benefit, it is not possible to recommend the use of probiotics in the management of asthma.

3.4.6 IMMUNISATIONS

A number of large studies have concluded that high vaccination coverage has no significant impact on any allergic outcome or asthma. There is a suggestion that the higher the vaccine coverage the greater the possibility that there is a degree of protection against the development of allergy in the first years of life.\textsuperscript{240,243}

There is some discussion about whether BCG immunisation may confer protection against allergy and asthma. Research has focused on primary prophylaxis, though there are some studies investigating the use of BCG, with or without allergen, as a means to switch off allergic immune responses. There are some observations suggesting that benefit might occur,\textsuperscript{244} but results of trials have been disappointing.\textsuperscript{245,246} This is an area that requires further investigation.

There has been concern that influenza vaccination might aggravate respiratory symptoms, though any such effect would be outweighed by the benefits of the vaccination.\textsuperscript{247} Studies in children have suggested that immunisation with the vaccine does not exacerbate asthma\textsuperscript{248} but has a small beneficial effect on quality of life in children with asthma.\textsuperscript{249} The immune response to the immunisation may be adversely affected by high-dose inhaled corticosteroid therapy and this requires further investigation.\textsuperscript{250} A Cochrane review of pneumococcal vaccine found very limited evidence to support its use specifically in individuals with asthma.\textsuperscript{251}

**B** Immunisations should be administered independent of any considerations related to asthma. Responses to vaccines may be attenuated by high-dose inhaled steroids.
3.5 COMPLEMENTARY AND ALTERNATIVE MEDICINE

Successive reviews have concluded that the evidence to support any recommendations on complementary or alternative medicine is lacking.\textsuperscript{252} It is recognised that a lack of evidence does not necessarily mean that treatment is ineffective and high quality research, conducted in the same rigorous and objective fashion as that for conventional therapy, is required.

3.5.1 ACUPUNCTURE

A Cochrane review of 21 trials highlighted many methodological problems with the studies reviewed. Only seven of the trials in 174 patients employed randomisation to active (recognised in traditional Chinese medicine to be of benefit in asthma) or sham acupuncture points (with no recognised activity) for the treatment of persistent or chronic asthma. Blinding was a major problem in the assessment of the results and there were considerable inconsistencies in methodology. The review concluded that there was no evidence for a clinically valuable benefit for acupuncture and no significant benefits in relation to lung function.\textsuperscript{253} A later systematic review and meta-analysis of 11 randomised controlled trials found no evidence of an effect in reducing asthma severity but a suggestion that where broncho-constriction was induced to establish efficacy of acupuncture there was a beneficial effect. Concern was expressed about potential preferential publication in favour of positive outcome studies.\textsuperscript{254} Two other trials of acupuncture in relation to induced asthma were also negative.\textsuperscript{255,256}

3.5.2 AIR IONISERS

Ionisers have been widely promoted as being of benefit for patients with asthma. A Cochrane review of five studies using negative ion generators and one with a positive ion generator found no evidence of benefit in reducing symptoms in patients with asthma.\textsuperscript{257} One study demonstrated an increase in night-time cough to a level which approached statistical significance.\textsuperscript{258}

A Air ionisers are not recommended for the treatment of asthma.

3.5.3 BREATHING EXERCISES INCLUDING YOGA AND THE BUTEYKO BREATHING TECHNIQUE

The principle of yoga and Buteyko breathing technique is to control hyperventilation by lowering respiratory frequency. A Cochrane review of breathing exercises found no change in routine measures of lung function.\textsuperscript{259} One study showed a small reduction in airway responsiveness to histamine utilising pranayama, a form of yoga breathing exercise.\textsuperscript{260}

The Buteyko breathing technique specifically focuses on control of hyperventilation and any ensuing hypocapnia. Four clinical trials suggest benefits in terms of reduced symptoms and bronchodilator usage but no effect on lung function.\textsuperscript{261-264}

B Buteyko breathing technique may be considered to help patients to control the symptoms of asthma.

3.5.4 HERBAL AND TRADITIONAL CHINESE MEDICINE

A Cochrane review identified 17 trials, nine of which reported some improvement in lung function but it was not clear that the results would be generalisable.\textsuperscript{265} A more recent double blind placebo controlled trial of a Chinese herb decoction (Ding Chuan Tang) showed improvement in airway hyper-responsiveness in children with stable asthma.\textsuperscript{266} It is difficult to disentangle the effects of multiple ingredients; Ding Chuan Tang for example contains nine components. In a second study, 100 children with asthma found that a five-herb mixture gave some benefits in relation to lung function and symptoms compared with placebo.\textsuperscript{267}

The conclusions of these trials of Chinese herbal therapy are not generalisable due to variations in the herbal mixtures and study designs. There are likely to be pharmacologically active ingredients in the mixtures and further investigations are warranted. There is a need for large appropriately powered placebo controlled studies.
3.5.5 HOMEOPATHY

A Cochrane review identified only three methodologically sound randomised controlled trials, two of which reported some positive effects. A criticism of the studies was that they did not employ individualised homeopathy, which is the essence of this approach to treatment. A more recent trial of individualised homeopathy in childhood asthma, which was placebo controlled and appropriately powered, failed to show any evidence of benefit over conventional treatment in primary care.

3.5.6 HYPNOSIS AND RELAXATION THERAPIES

A systematic review of relaxation therapies, including hypnotherapy, identified five controlled trials, two of which showed some benefits. Overall the methodology of the studies was poor and the review concluded that there was a lack of evidence of efficacy but that muscle relaxation could conceivably benefit lung function in patients with asthma.

3.6 OTHER COMPLEMENTARY OR ALTERNATIVE APPROACHES

3.6.1 MANUAL THERAPY INCLUDING MASSAGE AND SPINAL MANIPULATION

A Cochrane review identified four relevant RCTs. The two trials of chiropractic suggest that there is no place for this modality of treatment in the management of asthma. No conclusions can be drawn on massage therapy.

3.6.2 PHYSICAL EXERCISE TRAINING

A Cochrane review has shown no effect of physical training on PEF, FEV₁, FVC or VEmax. However, oxygen consumption, maximum heart rate, and work capacity all increased significantly. Most studies discussed the potential problems of exercise induced asthma, but none made any observations on this phenomenon. As physical training improves indices of cardiopulmonary efficiency, it should be seen as part of a general approach to improving lifestyle and rehabilitation in asthma, with appropriate precautions advised about exercise induced asthma (see section 4.7.2).

3.6.3 FAMILY THERAPY

A Cochrane review identified two trials, in 55 children, showing that family therapy may be a useful adjunct to medication in children with asthma. Small study size limits the recommendations.

In difficult childhood asthma, there may be a role for family therapy as an adjunct to pharmacotherapy.
4 Pharmacological management

The aim of asthma management is control of the disease. Control of asthma is defined as:

- no daytime symptoms
- no night time awakening due to asthma
- no need for rescue medication
- no exacerbations
- no limitations on activity including exercise
- normal lung function (in practical terms FEV₁ and/or PEF > 80% predicted or best)

with minimal side effects.

In clinical practice patients may have different goals and may wish to balance the aims of asthma management against the potential side effects or inconvenience of taking medication necessary to achieve perfect control.

- Lung function measurements cannot be reliably used to guide asthma management in children under five years of age.

A stepwise approach aims to abolish symptoms as soon as possible and to optimise peak flow by starting treatment at the level most likely to achieve this. Patients should start treatment at the step most appropriate to the initial severity of their asthma. The aim is to achieve early control and to maintain control by stepping up treatment as necessary and stepping down when control is good (see figures 4, 5 and 6 for summaries of stepwise management in adults and children).

- Before initiating a new drug therapy practitioners should check compliance with existing therapies (see section 9.2), inhaler technique (see section 5) and eliminate trigger factors (see section 3).

All doses of inhaled steroids in this section refer to beclometasone (BDP) given via CFC-MDIs (metered dose inhaler). Although now almost phased out, this is the device used in most of the evidence base that supports current asthma management. Adjustment to dose will have to be made for other devices and other corticosteroid molecules.

In this and the following section, each recommendation has been graded and the supporting evidence assessed for adults (> 12 years old), children 5-12 years, and children under 5 years. The evidence is less clear in children under two and the threshold for seeking an expert opinion should be lowest in these children.

- Recommendation does not apply to this age group.
4.1 STEP 1: MILD INTERMITTENT ASTHMA

The following medicines act as short-acting bronchodilators:
- inhaled short-acting β₂ agonists
- inhaled ipratropium bromide
- β₂ agonist tablets or syrup
- theophyllines

Short-acting inhaled β₂ agonists work more quickly and/or with fewer side effects than the alternatives.

Prescribe an inhaled short-acting β₂ agonist as short term reliever therapy for all patients with symptomatic asthma.

4.1.1 FREQUENCY OF DOSING OF INHALED SHORT-ACTING β₂ AGONISTS

Using short acting β₂ agonists as required is at least as good as regular (four times daily) administration. Unless individual patients are shown to benefit from regular use of inhaled short-acting β₂ agonists then as required use is recommended.

Good asthma control is associated with little or no need for short-acting β₂ agonist. Using two or more canisters of β₂ agonists per month or >10-12 puffs per day is a marker of poorly controlled asthma that puts individuals at risk of fatal or near-fatal asthma.

Patients with a high usage of inhaled short-acting β₂ agonists should have their asthma management reviewed.

4.2 STEP 2: INTRODUCTION OF REGULAR PREVENTER THERAPY

For steps 2, 3, and 4, treatments have been judged on their ability to improve symptoms, improve lung function, and prevent exacerbations, with an acceptable safety profile. Improvement of quality of life, while important, is the subject of too few studies to be used to make recommendations at present.

4.2.1 INHALED STEROIDS

Inhaled steroids are the most effective preventer drug for adults and older children for achieving overall treatment goals. There is an increasing body of evidence demonstrating that, at recommended doses, they are also safe and effective in infants and younger children with asthma.

Many children with recurrent episodes of viral-induced wheezing in infancy do not go on to have chronic atopic asthma. The majority do not require treatment with regular inhaled steroids (see section 2.1).

Inhaled steroids are the recommended preventer drug for adults and children for achieving overall treatment goals.

Inhaled steroids should be considered for adults, children aged 5-12 and children under the age of five with any of the following features: using inhaled β₂ agonists three times a week or more; symptomatic three times a week or more; or waking one night a week. In addition, inhaled steroids should be considered in adults and children aged 5-12 who have had an exacerbation of asthma requiring oral corticosteroids in the last two years.
Inhaled steroids should be considered for patients with any of the following asthma-related features:

- Exacerbations of asthma in the last two years
- Using inhaled β₂ agonists three times a week or more
- Symptomatic three times a week or more
- Waking one night a week.

Starting dose of inhaled steroids

In mild to moderate asthma, starting at very high doses of inhaled steroids and stepping down confers no benefit.\(^2\) Start patients at a dose of inhaled steroids appropriate to the severity of disease.

In adults, a reasonable starting dose will usually be 400 mcg per day and in children 200 mcg per day. In children under five years, higher doses may be required if there are problems in obtaining consistent drug delivery.

Titrate the dose of inhaled steroid to the lowest dose at which effective control of asthma is maintained.

Frequency of dosing of inhaled steroids

Most current inhaled steroids are slightly more effective when taken twice rather than once daily, but may be used once daily in some patients with milder disease.\(^2\) There is little evidence of benefit for dosage frequency more than twice daily.\(^2\)

Give inhaled steroids initially twice daily, except ciclesonide which is given once daily.

Once a day inhaled steroids at the same total daily dose can be considered if good control is established.

4.2.2 SAFETY OF INHALED STEROIDS

The safety of inhaled steroids is of crucial importance and a balance between benefits and risks for each individual needs to be assessed. Account should be taken of other topical steroid therapy when assessing systemic risk. It has been suggested that steroid warning cards should be issued to patients on higher dose inhaled steroids, but the benefits and possible disadvantages, particularly with regard to compliance, of such a policy remain to be defined.

Adults

There is little evidence that doses below 800 mcg per day cause any short term detrimental effects apart from the local side effects of dysphonia and oral candidiasis. However, the possibility of long term effects on bone has been raised. One systematic review reported no effect on bone density at doses up to 1,000 mcg per day.\(^2\) The significance of small biochemical changes in adrenocortical function is unknown.

Titrating the dose of inhaled steroid to the lowest dose at which effective control of asthma is maintained.

Children

Administration of inhaled steroids at or above 400 mcg a day of BDP or equivalent may be associated with systemic side effects.\(^2\) These may include growth failure and adrenal suppression. Isolated growth failure is not a reliable indicator of adrenal suppression and monitoring growth cannot be used as a screening test of adrenal function.\(^2\)
Clinical adrenal insufficiency has been identified in a small number of children who have become acutely unwell at the time of intercurrent illness. Most of these children had been treated with high doses of inhaled corticosteroids. The dose or duration of inhaled steroid treatment required to place a child at risk of clinical adrenal insufficiency is unknown but is likely to occur at $\geq 800$ mcg per day of BDP or equivalent. The low dose ACTH test is considered to provide a physiological stimulation of adrenal responsiveness but it is not known how useful such a sensitive test is at predicting clinically relevant adrenal insufficiency. In addition, it is unknown how frequently tests of adrenal function would need to be repeated if a child remained on high-dose inhaled corticosteroid. At higher doses, add-on agents, for example, long-acting $\beta_2$ agonists, should be actively considered.

- Monitor height of children on high doses of inhaled steroids on a regular basis.
- The lowest dose of inhaled steroids compatible with maintaining disease control should be used.

For children treated with $\geq 800$ mcg per day of BDP or equivalent:

- Specific written advice about steroid replacement in the event of a severe intercurrent illness should be part of the management plan.
- The child should be under the care of a specialist paediatrician for the duration of the treatment.

Consider the possibility of adrenal insufficiency in any child maintained on inhaled steroids presenting with shock or a decreased level of consciousness; serum biochemistry and blood glucose levels should be checked urgently. Consider whether intramuscular (IM) hydrocortisone is required.

4.2.3 COMPARISON OF INHALED STEROIDS

Many studies comparing different inhaled steroids are of inadequate design and have been omitted from further assessment. In view of the clear differences between normal volunteers and asthma patients in the absorption of inhaled steroids, data from normal volunteers have not been taken into account. Only studies in which more than one dose of at least one of the inhaled steroids or both safety and efficacy had been studied together in the same trial were evaluated. Non-blinded studies also had to be considered because of the problems of obtaining competitors’ delivery devices. Most comparisons used BDP-CFC (chloorofluorocarbons) as the reference. A series of Cochrane reviews comparing different inhaled steroids using a different methodology have come to the same conclusion.

BDP and budesonide are approximately equivalent in clinical practice, although there may be variations with different delivery devices. There is limited evidence from two open studies of less than ideal design that budesonide via the turbohaler is more clinically effective. However, at present a 1:1 ratio should be assumed when changing between BDP and budesonide.

Fluticasone provides equal clinical activity to BDP and budesonide at half the dosage. The evidence that it causes fewer side effects at doses with equal clinical effect is limited.

Mometasone is a new inhaled steroid that appears to provide equal clinical activity to BDP and budesonide at half the dosage. The relative safety of mometasone is not fully established.

Ciclesonide is a new inhaled steroid. Evidence from clinical trials suggests that it has less systemic activity and fewer local oropharyngeal side effects than conventional inhaled steroids. The clinical benefit of this is not clear as the exact efficacy to safety ratio compared to other inhaled steroids has not been fully established.

Non-CFC beclometasone is available in more than one preparation, and the potency relative to CFC beclometasone is not consistent between these (see section 5.4).
4.2.4 SMOKING

Current and previous smoking reduces the effect of inhaled steroids; which may be overcome with increased doses.187,302

Patients should be advised that smoking reduces the effectiveness of therapy.

Clinicians should be aware that higher doses of inhaled steroids may be needed in patients who are smokers or ex-smokers.

### OTHER PREVENTER THERAPIES

Inhaled steroids are the first choice preventer drug. Long-acting inhaled β₂ agonists should not be used without inhaled corticosteroids.301 Alternative, less effective preventer therapies in patients taking short-acting β₂ agonists alone are:

- **Chromones**
  - Sodium cromoglicate is of some benefit in adults273, 304 and is effective in children aged 5-12305
  - Nedocromil sodium is also of benefit in adults and children >5 306,307
  - There is no clear evidence of benefit with sodium cromoglicate in children aged <5308
- **Leukotriene receptor antagonists** have some beneficial clinical effect279,309,310
- **Theophyllines** have some beneficial effect273,278
- **Antihistamines** and ketotifen are ineffective.311

### STEP 3: INITIAL ADD-ON THERAPY

A proportion of patients with asthma may not be adequately controlled at step 2. Before initiating a new drug therapy practitioners should recheck compliance, inhaler technique and eliminate trigger factors. The duration of a trial of add-on therapy will depend on the desired outcome. For instance, preventing nocturnal awakening may require a relatively short trial of treatment (days or weeks), whereas preventing exacerbations of asthma or decreasing steroid tablet use may require a longer trial of therapy (weeks or months). If there is no response to treatment the drug should be discontinued.

#### CRITERIA FOR INTRODUCTION OF ADD-ON THERAPY

No exact dose of inhaled steroid can be deemed the correct dose at which to add another therapy. The addition of other treatment options to inhaled steroids has been investigated at doses from 200-1000 mcg in adults and up to 400 mcg in children.312-315 Many patients will benefit more from add-on therapy than from increasing inhaled steroids above doses as low as 200 mcg/day. At doses of inhaled steroid above 800 mcg/day side effects become more frequent. An absolute threshold for introduction of add-on therapy in all patients cannot be defined.

#### ADD-ON THERAPY

Options for add-on therapy are summarised in Figure 3.

In adult patients taking inhaled steroids at doses of 200-800 mcg/day and in children taking inhaled steroids at a dose of 400 mcg/day the following interventions are of value:

- first choice would be the addition of an inhaled long-acting β₂ agonist (LABA), which improves lung function and symptoms, and decreases exacerbations.312,316,317

The first choice as add-on therapy to inhaled steroids in adults (5-12 years) is an inhaled long-acting β₂ agonist, which should be considered before going above a dose of 400 mcg BDP or equivalent per day and certainly before going above 800 mcg BDP.

See Figure 6 for options in children under five years old.
If, as occasionally happens, there is no response to inhaled long-acting β₂ agonist, stop the LABA and increase the dose of inhaled steroid to 800 mcg/day (adults) or 400 mcg/day (children) if not already on this dose. If there is a response to LABA, but control remains suboptimal, continue with the LABA and increase the dose of inhaled steroid to 800 mcg/day (adults) or 400 mcg/day (children 5-12 years). If asthma control remains suboptimal after the addition of an inhaled long-acting β₂ agonist then the dose of inhaled steroids should be increased to 800 mcg/day in adults or 400 mcg/day in children (5-12 years), if not already on these doses.

- Leukotriene receptor antagonists may provide improvement in lung function, a decrease in exacerbations, and an improvement in symptoms. ¹³⁻¹⁵, ¹⁶⁻¹⁸
- Theophyllines may improve lung function and symptoms, but side effects occur more commonly. ¹¹⁻¹³
- Slow-release β₂ agonist tablets may also improve lung function and symptoms, but side effects occur more commonly. ¹¹⁻¹²

If control remains inadequate after stopping a LABA and increasing the dose of inhaled steroid, consider sequential trials of add-on therapy, ie leukotriene receptor antagonists, theophyllines, slow-release β₂ agonist tablets (this in adults only).

Addition of short-acting anticholinergics is generally of no value. ¹¹⁻¹³ Addition of nedocromil is of marginal benefit. ¹⁰⁻¹¹

In patients on inhaled steroids whose asthma is stable, no intervention has been consistently shown to decrease inhaled steroid requirement in a clinically significant manner compared to placebo.

The Medicines and Healthcare products Regulatory Agency (MHRA) has completed a full review of the balance of risks and benefits associated with long-acting β₂ agonists in the management of asthma and chronic obstructive pulmonary disease. ¹²⁻¹⁴ They have concluded that long-acting β₂ agonists can continue to be used in the management of asthma provided they are used with inhaled corticosteroids. This issue has been reviewed by the guideline development group, which came to the same conclusion.

Long-acting inhaled β₂ agonists should only be started in patients who are already on inhaled corticosteroids.
4.3.3 COMBINATION INHALERS

There is no difference in efficacy in giving inhaled steroid and long-acting β₂ agonist in combination or in separate inhalers.\textsuperscript{318}

Once a patient is on stable therapy, combination inhalers have the advantage of guaranteeing that the long-acting β₂ agonist is not taken without inhaled steroid.

In adult patients at step 3 who are poorly controlled, the use of budesonide/formoterol in a single inhaler as rescue medication instead of a short-acting β₂ agonist, in addition to its regular use as a controller treatment, has been shown to be an effective treatment option.\textsuperscript{323-327} This management technique has not been investigated with other combination inhalers. Before instituting this management careful patient education is required.

4.4 STEP 4: POOR CONTROL ON MODERATE DOSE OF INHALED STEROID + ADD-ON THERAPY: ADDITION OF FOURTH DRUG

In a small proportion of patients asthma is not adequately controlled on a combination of short-acting β₂ agonist as required, inhaled steroid (800 mcg daily), and an additional drug, usually a long-acting β₂ agonist. There are very few clinical trials in this specific patient group to guide management. The following recommendations are largely based on extrapolation from trials of add-on therapy to inhaled steroids alone.
If control remains inadequate on 800 mcg daily (adults) and 400 mcg daily (children) of an inhaled steroid plus a long-acting β₂ agonist, consider the following interventions:

- increasing inhaled steroids to 2000 mcg/day (adults) or 800 mcg/day (children 5-12 years) *
- leukotriene receptor antagonists
- theophyllines
- slow release β₂ agonist tablets, though caution needs to be used in patients already on long-acting β₂ agonists.

* at high doses of inhaled steroid via MDI, a spacer should be used.

There are no controlled trials indicating which of these is the best option, although the potential for side effects is greater with theophyllines and β₂ agonist tablets.

- If a trial of an add-on treatment is ineffective, stop the drug (or in the case of increased dose of inhaled steroid, reduce to the original dose).
- Before proceeding to step 5, consider referring patients with inadequately controlled asthma, especially children, to specialist care.

4.5 STEP 5: CONTINUOUS OR FREQUENT USE OF ORAL STEROIDS

- For the small number of patients not controlled at step 4, use daily steroid tablets in the lowest dose providing adequate control.

4.5.1 PREVENTION AND TREATMENT OF STEROID TABLET-INDUCED SIDE EFFECTS

Patients on long term steroid tablets (eg longer than three months) or requiring frequent courses of steroid tablets (eg three to four per year) will be at risk of systemic side effects.59

- blood pressure should be monitored
- diabetes mellitus and hyperlipidaemia may occur
- bone mineral density should be monitored. When a significant reduction occurs, treatment with a long-acting bisphosphonate should be offered (see British Osteoporosis Society guidelines, www.nos.org.uk)328
- growth should be monitored in children
- cataracts may be screened for in children through community optometric services.
4.5.2 STEROID TABLET-SPARING MEDICATION

The aim of treatment is to control the asthma using the lowest possible dose or, if possible, to stop long term steroid tablets completely.

Inhaled steroids are the most effective drug for decreasing requirement for long term steroid tablets.\textsuperscript{280,281}

There is limited evidence for the ability of long-acting $\beta_2$ agonists, theophyllines, or leukotriene receptor antagonists to decrease requirement for steroid tablets, but they may improve symptoms and pulmonary function.\textsuperscript{129}

<table>
<thead>
<tr>
<th>A</th>
<th>D</th>
<th>D</th>
</tr>
</thead>
<tbody>
<tr>
<td>In adults, the recommended method of eliminating or reducing the dose of steroid tablets is inhaled steroids, at doses of up to 2,000 mcg/day, if required.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>D</th>
<th>D</th>
<th>D</th>
</tr>
</thead>
<tbody>
<tr>
<td>There is a role for a trial of treatment with long-acting $\beta_2$ agonists, leukotriene receptor antagonists, and theophyllines for about six weeks. They should be stopped if no improvement in steroid dose, symptoms or lung function is detected.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Immunosuppressants (methotrexate, ciclosporin and oral gold) decrease long term steroid tablet requirements, but all have significant side effects. There is no evidence of persisting beneficial effect after stopping them; and there is marked variability in response.\textsuperscript{330}

<table>
<thead>
<tr>
<th>D</th>
</tr>
</thead>
<tbody>
<tr>
<td>Immunosuppressants (methotrexate, ciclosporin and oral gold) may be given as a three month trial, once other drug treatments have proved unsuccessful. Their risks and benefits should be discussed with the patient and their treatment effects carefully monitored. Treatment should be in a centre with experience of using these medicines.</td>
</tr>
</tbody>
</table>

Colchicine and intravenous immunoglobulin have not been shown to have any beneficial effect in adults.\textsuperscript{330}

<table>
<thead>
<tr>
<th>D</th>
</tr>
</thead>
<tbody>
<tr>
<td>Continuous subcutaneous terbutaline infusion has been reported to be beneficial in severe asthma but efficacy and safety have not been assessed in RCTs.\textsuperscript{331,332} Anti-TNF alpha therapy has been investigated in severe asthma but these studies are too small and too short term to allow recommendation of anti-TNF therapy outside the context of a controlled clinical trial.</td>
</tr>
</tbody>
</table>

4.5.3 STEROID FORMULATIONS

Prednisolone is the most widely used steroid tablet for maintenance therapy in chronic asthma. There is no evidence that other formulations offer any advantage.

4.5.4 FREQUENCY OF DOSING OF STEROID TABLETS

Although popular in paediatric practice, there are no studies to show whether alternate day steroids produce fewer side effects than daily steroids.
Inhaled short-acting $\beta_2$ agonist as required

Add inhaled steroid 200-800 mcg/day*
400 mcg is an appropriate starting dose for many patients
Start at dose of inhaled steroid appropriate to severity of disease.

STEP 1
Mild intermittent asthma

STEP 2
Regular preventer therapy

1. Add inhaled long-acting $\beta_2$ agonist (LABA)
2. Assess control of asthma:
   - good response to LABA - continue LABA
   - benefit from LABA but control still inadequate
     - continue LABA and increase inhaled steroid dose to 800 mcg/day* (if not already on this dose)
   - no response to LABA
     - stop LABA and increase inhaled steroid to 800 mcg/day. If control still inadequate, institute trial of other therapies, leukotriene receptor antagonist or SR theophylline

Consider trials of:
- increasing inhaled steroid up to 2000 mcg/day*
- addition of a fourth drug e.g. leukotriene receptor antagonist, SR theophylline, $\beta_2$ agonist tablet

STEP 3
Initial add-on therapy

Use daily steroid tablet in lowest dose providing adequate control
Maintain high dose inhaled steroid at 2000 mcg/day*
Consider other treatments to minimise the use of steroid tablets
Refer patient for specialist care

STEP 4
Continuous or frequent use of oral steroids

STEP 5
Persistent poor control

* BDP or equivalent

Patients should start treatment at the step most appropriate to the initial severity of their asthma. Check concordance and reconsider diagnosis if response to treatment is unexpectedly poor.

Figure 4: Summary of stepwise management in adults
Patients should start treatment at the step most appropriate to the initial severity of their asthma. Check concordance and reconsider diagnosis if response to treatment is unexpectedly poor.

**STEP 1**
Mild intermittent asthma

Inhaled short-acting β₂ agonist as required
Add inhaled steroid 200-400 mcg/day* (other preventer drug if inhaled steroid cannot be used) 200 mcg is an appropriate starting dose for many patients
Start at dose of inhaled steroid appropriate to severity of disease.

**STEP 2**
Regular preventer therapy

**STEP 3**
Initial add-on therapy

1. Add inhaled long-acting β₂ agonist (LABA)
2. Assess control of asthma:
   - good response to LABA - continue LABA
   - benefit from LABA but control still inadequate - continue LABA and increase inhaled steroid dose to 400 mcg/day* (if not already on this dose)
   - no response to LABA - stop LABA and increase inhaled steroid to 400 mcg/day. If control still inadequate, institute trial of other therapies, leukotriene receptor antagonist or SR theophylline

**STEP 4**
Persistent poor control

Increase inhaled steroid up to 800 mcg/day*

**STEP 5**
Continuous or frequent use of oral steroids

Use daily steroid tablet in lowest dose providing adequate control
Maintain high dose inhaled steroid at 800 mcg/day*
Refer to respiratory paediatrician

* BDP or equivalent

**SYMPTOMS vs TREATMENT**

Figure 5: Summary of stepwise management in children aged 5-12. Years
Patients should start treatment at the step most appropriate to the initial severity of their asthma. Check concordance and reconsider diagnosis if response to treatment is unexpectedly poor.

**STEP 1**
Mild intermittent asthma

Inhaled short-acting β₂ agonist as required

Add inhaled steroid 200-400 mcg/day*†
or leukotriene receptor antagonist if inhaled steroid cannot be used.

Start at dose of inhaled steroid appropriate to severity of disease.

**STEP 2**
Regular preventer therapy

In those children taking inhaled steroids 200-400 mcg/day consider addition of leukotriene receptor antagonist.

In those children taking a leukotriene receptor antagonist alone reconsider addition of an inhaled steroid 200-400 mcg/day.

In children under 2 years consider proceeding to step 4.

**STEP 3**
Initial add-on therapy

**STEP 4**
Persistent poor control

Refer to respiratory paediatrician.

* BDP or equivalent
† Higher nominal doses may be required if drug delivery is difficult

**SYMPTOMS VS TREATMENT**

Figure 6: Summary of stepwise management in children less than 5 years
4.6 STEPPING DOWN

Stepping down therapy once asthma is controlled is recommended, but often not implemented leaving some patients over-treated. There are few studies that have investigated the most appropriate way to step down treatment. A study in adults on at least 900 mcg per day of inhaled steroids has shown that for patients who are stable it is reasonable to attempt to halve the dose of inhaled steroids every three months.334

- Regular review of patients as treatment is stepped down is important. When deciding which drug to step down first and at what rate, the severity of asthma, the side effects of the treatment, time on current dose, the beneficial effect achieved, and the patient’s preference should all be taken into account.

- Patients should be maintained at the lowest possible dose of inhaled steroid. Reduction in inhaled steroid dose should be slow as patients deteriorate at different rates. Reductions should be considered every three months, decreasing the dose by approximately 25-50% each time.

4.7 SPECIFIC MANAGEMENT ISSUES

4.7.1 EXACERBATIONS OF ASTHMA

Although recommended for both adults and children in previous guidelines and as part of asthma action plans, doubling the dose at the time of an exacerbation is of unproven value.335 In adult patients on a low dose (200 mcg) of inhaled steroids, a fivefold increase in dose at the time of exacerbation leads to a decrease in the severity of exacerbations.335,336 This study should not be extrapolated to patients already taking higher doses of inhaled steroids and further evidence in this area is required.

4.7.2 EXERCISE INDUCED ASTHMA

When given chronically the following medicines give protection against exercise induced asthma:

- inhaled steroids280, 281,337
- short-acting $\beta_2$ agonists 273
- long-acting $\beta_2$ agonists338
- theophyllines259,339
- leukotriene receptor antagonists340
- chromones341
- $\beta_2$ agonist tablets.342

The following medicines do not give protection against exercise induced asthma at normal doses:

- anticholinergics343
- ketotifen344
- antihistamine.345

Long-acting $\beta_2$ agonists and leukotriene antagonists provide more prolonged protection than short-acting $\beta_2$ agonists, but a degree of tolerance develops with LABA particularly with respect to duration of action. No tolerance has been demonstrated with leukotriene receptor antagonists.338,340

- For most patients, exercise induced asthma is an expression of poorly controlled asthma and regular treatment including inhaled steroids should be reviewed.
If exercise is a specific problem in patients taking inhaled steroids who are otherwise well controlled, consider the following therapies:

- **Leukotriene receptor antagonists**
- **Long-acting β₂ agonists**
- **Chromones**
- **Oral β₂ agonists**
- **Theophyllines**

Immediately prior to exercise, inhaled short-acting β₂ agonists are the drug of choice.²²³

### 4.7.3 Rhinitis

Patients with asthma often have rhinitis. The most effective therapy is intranasal steroids.³⁴⁶ Treatment of allergic rhinitis with intranasal steroids has not been shown in double blind placebo-controlled trials to improve asthma control.

### 4.7.4 Allergic Bronchopulmonary Aspergillosis

In adult patients with allergic bronchopulmonary aspergillosis (ABPA), itraconazole may decrease steroid tablet dose and improve asthma control.³⁴⁷,³⁴⁸

In adult patients with ABPA, a four month trial of itraconazole should be considered. Careful monitoring for side effects, particularly hepatic, is recommended.

### 4.7.5 Aspirin-Intolerant Asthma

There are theoretical reasons to suggest that leukotriene receptor antagonists might be of particular value in the treatment of aspirin-intolerant asthma. However, there is little evidence to justify managing patients with aspirin-intolerant asthma in a different manner to other patients with asthma, apart from the rigorous avoidance of non-steroidal anti-inflammatory medications.³⁴⁹

### 4.7.6 Gastro-Oesophageal Reflux

A Cochrane review of twelve double blind controlled trials found that treatment of gastro-oesophageal reflux had no benefit on asthma symptoms or lung function when both conditions were present. Reduction in dry cough was observed although this was probably not due to improved asthma control.³⁵⁰,³⁵¹

### 4.7.7 β-Blockers

β-blockers, including eye drops, are contraindicated in patients with asthma.

### 4.7.8 Anti-IgE Monoclonal Antibody

Omalizumab is a humanised monoclonal antibody which binds to circulating IgE, markedly reducing levels of free serum IgE.³⁵⁰,³⁵¹ In adults and children over 12, it is licensed in the UK with the following indication; patients on high-dose inhaled steroids and long-acting β₂ agonists who have impaired lung function are symptomatic with frequent exacerbations, and have allergy as an important cause of their asthma. Omalizumab is given as a subcutaneous injection every two to four weeks depending on dose. The total IgE must be less than 700 iu/litre for it to be effective.
In the single study in the licensed group, there was a 19% reduction in exacerbations of asthma requiring oral steroids which was non-significant. When corrected for imbalance in the exacerbation history at baseline, there was a 26% reduction in severe exacerbations (0.91 on placebo vs 0.68 on omalizumab over a 28 week period, p = 0.042). This was associated with a 2.8% increase in FEV₁, a non-significant 0.5 puffs/day decrease in β₂ agonist use and 13% more patients having a significant improvement in health related quality of life. At IgE levels below 76 iu/l the beneficial effect is reduced.

Local skin reactions may occur. Anaphylaxis, presenting as bronchospasm, hypotension, syncope, urticaria, and/or angioedema of the throat or tongue has been reported to occur after administration of omalizumab. Anaphylaxis has occurred as early as the first dose, but has also occurred after one year. Due to risk of anaphylaxis, omalizumab should only be administered to patients in a healthcare setting under direct medical supervision.

- Omalizumab treatment should only be initiated in specialist centres with experience of evaluation and management of patients with severe and difficult asthma.
5 Inhaler devices

Although studies of inhaler devices are more suitable for an evidence based approach than many other aspects of asthma management, a number of methodological issues complicate evidence review in this area. In young (0-5 years) children, little or no evidence is available on which to base recommendations.

5.1 TECHNIQUE AND TRAINING

Studies of technique and the effects of training have used arbitrary non-standardised scores making comparison difficult. Although technique will have some bearing, it does not necessarily relate to clinical effectiveness.

The proportion of patients making no mistakes with an inhaler in one well conducted study was 23-43% for pMDI, 53-59% for dry powder inhaler (DPI) and 55-57% for pMDI + spacer. When technique was assessed as number of steps correct out of the total number of steps, pMDI + spacer was slightly better than DPI.

Teaching technique improved the correct usage score from a mean of 60% to 79%. Figures for no mistakes post-teaching were 63% for pMDI, 65% for DPI, and 75% for breath-actuated MDI (the latter figure based on one study of 2,467 patients).352

Prescribe inhalers only after patients have received training in the use of the device and have demonstrated satisfactory technique.

5.2 β₂ AGONIST DELIVERY

5.2.1 ACUTE ASTHMA

pMDI + spacer is at least as good as a nebuliser at treating mild and moderate exacerbations of asthma in children and adults.353-356

Children and adults with mild and moderate exacerbations of asthma should be treated by pMDI + spacer with doses titrated according to clinical response.

There are no data to make recommendations in severe (life threatening) asthma.

5.2.2 STABLE ASTHMA

For children aged 0-5, there is no evidence comparing nebuliser and other inhalers and the data are insufficiently extensive or robust to draw conclusions for pMDI vs. DPI.

In children aged 5-12 there is no significant difference between pMDI and DPI. In adults there is no significant difference between pMDI + spacer and DPI. The lower pulse rate with pMDI v Turbohaler is the only difference with regard to side effects. Patients have been shown to prefer Turbohaler to pMDI.352,357,358

In children aged 5-12, pMDI + spacer is as effective as any other hand held inhaler.

In adults, pMDI ± spacer is as effective as any other hand held inhaler, but patients may prefer some types of DPI.

There are no data to make recommendations in children under five.

Choice of reliever inhaler for stable asthma should be based on patient preference and assessment of correct use. Many patients will not be prepared to carry a spacer.
5.3 INHALED STEROIDS FOR STABLE ASTHMA

There are no comparative data on inhaled steroids for stable asthma in children under five years. A single study included 4-5 year olds, but the data were not extractable.

For the delivery of inhaled steroids in stable asthma in children aged 5-12 years, pMDI is as effective as Clickhaler,359,360 and Pulvinal is as effective as Diskhaler.361 No significant clinical difference was found between pMDI and Turbohaler at half the dose for the same drug (budesonide).352,362 This comparison cannot necessarily be made against other inhaled steroid/device combinations.

In adults, there is no clinical difference in effectiveness of pMDI ± spacer v DPI. Breath-actuated MDI is as effective as pMDI. More recent DPIs are as effective as older DPIs.305 Nebulisers have not been shown to be superior to pMDI + spacer for delivery of inhaled steroids in chronic asthma. A specialised specific nebuliser may provide improved lung function and reduced rescue therapy use, but at high prescribed doses. Higher doses (>2 mg) are generally only licensed for use from a nebuliser.352,362

<table>
<thead>
<tr>
<th>Age Group</th>
<th>pMDI + spacer</th>
<th>DPI</th>
</tr>
</thead>
<tbody>
<tr>
<td>&gt;12 years</td>
<td>1**</td>
<td>1**</td>
</tr>
<tr>
<td>5-12 years</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;5 years</td>
<td>1**</td>
<td></td>
</tr>
</tbody>
</table>

In children aged 5-12 years, pMDI + spacer is as effective as any DPI.

In adults, a pMDI ± spacer is as effective as any DPI.

No recommendation can be given for nebulised therapy in children aged 5-12 years and there is no evidence relating to children aged <5 years.

5.4 CFC PROPELLANT PMDI VS HFA PROPELLANT PMDI

HFA pMDI salbutamol is as effective as CFC pMDI salbutamol at standard therapeutic doses.359,363-368

It is important to differentiate Qvar from other HFA beclametasone products. Many studies now show Qvar equivalence at half the dose of CFC BDP pMDI, whereas non-Qvar HFA BDP pMDI studies show equivalence at 1:1 dosing.360,369-375

HFA fluticasone is as effective as CFC fluticasone across the standard clinical dose range.376-380

<table>
<thead>
<tr>
<th>Age Group</th>
<th>CFC pMDI</th>
<th>HFA pMDI</th>
</tr>
</thead>
<tbody>
<tr>
<td>&gt;12 years</td>
<td>1**</td>
<td>1**</td>
</tr>
<tr>
<td>5-12 years</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;5 years</td>
<td>1**</td>
<td></td>
</tr>
</tbody>
</table>

Salbutamol HFA can be substituted for salbutamol CFC at 1:1 dosing.

HFA BDP pMDI (Qvar) may be substituted for CFC BDP pMDI at 1:2 dosing. This ratio does not apply to reformulated HFA BDP pMDIs.

Fluticasone HFA can be substituted for fluticasone CFC at 1:1 dosing.
5.5 PRESCRIBING DEVICES

There is no evidence to dictate an order in which devices should be tested for those patients who cannot use pMDI. In the absence of evidence, the most important points to consider are patient preference and local cost.

- The choice of device may be determined by the choice of drug.
- If the patient is unable to use a device satisfactorily an alternative should be found.
- The patient should have their ability to use an inhaler device assessed by a competent healthcare professional (see section 5.1).
- The medication needs to be titrated against clinical response to ensure optimum efficacy.
- Reassess inhaler technique as part of structured clinical review (see section 8.1.2).

In children aged 0-5 years, pMDI and spacer are the preferred method of delivery of β₂ agonists or inhaled steroids. A face mask is required until the child can breathe reproducibly using the spacer mouthpiece. Where this is ineffective a nebuliser may be required.

5.6 USE AND CARE OF SPACERS

- The spacer should be compatible with the pMDI being used.
- The drug should be administered by repeated single actuations of the metered dose inhaler into the spacer, each followed by inhalation.
- There should be minimal delay between pMDI actuation and inhalation.
- Tidal breathing is as effective as single breaths.
- Spacers should be cleaned monthly rather than weekly as per manufacturer’s recommendations or performance is adversely affected. They should be washed in detergent and allowed to dry in air. The mouthpiece should be wiped clean of detergent before use.
- Drug delivery may vary significantly due to static charge. Metal and other antistatic spacers are not affected in this way.
- Plastic spacers should be replaced at least every 12 months but some may need changing at six months.
6 Management of acute asthma

6.1 Lessons from studies of asthma deaths and near-fatal asthma

Confidential enquiries into over 200 asthma deaths in the UK conclude there are factors associated with the disease, the medical management and the patient’s behaviour or psychosocial status which contribute to death. Most deaths occurred before admission to hospital.\textsuperscript{381-385}

6.1.1 Disease factors

Most patients who died of asthma had chronically severe asthma. In a minority the fatal attack occurred suddenly in a patient with mild or moderately severe background disease.\textsuperscript{381-386}

6.1.2 Medical management

Many of the deaths occurred in patients who had received inadequate treatment with inhaled steroid or steroid tablets and/or inadequate objective monitoring of their asthma. Follow up was inadequate in some and others should have been referred earlier for specialist advice. There was widespread under-use of written management plans. Heavy or increasing use of $\beta_2$ agonist therapy was associated with asthma death.\textsuperscript{381-385,387,388}

Deaths have continued to be reported following inappropriate prescription of $\beta$-blocker therapy or heavy sedation (see section 4.7.7).

A small proportion of patients with asthma were sensitive to non-steroidal anti-inflammatory agents; all asthma patients should be asked about past reactions to these agents.

6.1.3 Adverse psychosocial and behavioural factors

Behavioural and adverse psychosocial factors were recorded in the majority of patients who died of asthma.\textsuperscript{381-385} The most important are shown in Table 9.
Table 9: Patients at risk of developing near-fatal or fatal asthma

<table>
<thead>
<tr>
<th>A COMBINATION OF SEVERE ASTHMA recognised by one or more of:</th>
</tr>
</thead>
<tbody>
<tr>
<td>• previous near-fatal asthma, eg previous ventilation or respiratory acidosis</td>
</tr>
<tr>
<td>• previous admission for asthma especially if in the last year</td>
</tr>
<tr>
<td>• requiring three or more classes of asthma medication</td>
</tr>
<tr>
<td>• heavy use of $\beta_2$ agonist</td>
</tr>
<tr>
<td>• repeated attendances at ED for asthma care especially if in the last year</td>
</tr>
<tr>
<td>• “brittle” asthma.</td>
</tr>
<tr>
<td>AND ADVERSE BEHAVIOURAL OR PSYCHOSOCIAL FEATURES recognised by one or more of:</td>
</tr>
<tr>
<td>-------------------------------------------------------------</td>
</tr>
<tr>
<td>• non-compliance with treatment or monitoring</td>
</tr>
<tr>
<td>• failure to attend appointments</td>
</tr>
<tr>
<td>• self discharge from hospital</td>
</tr>
<tr>
<td>• psychosis, depression, other psychiatric illness or deliberate self harm</td>
</tr>
<tr>
<td>• current or recent major tranquilliser use</td>
</tr>
<tr>
<td>• denial</td>
</tr>
<tr>
<td>• alcohol or drug abuse</td>
</tr>
<tr>
<td>• obesity</td>
</tr>
<tr>
<td>• learning difficulties</td>
</tr>
<tr>
<td>• employment problems</td>
</tr>
<tr>
<td>• income problems</td>
</tr>
<tr>
<td>• social isolation</td>
</tr>
<tr>
<td>• childhood abuse</td>
</tr>
<tr>
<td>• severe domestic, marital or legal stress.</td>
</tr>
</tbody>
</table>

Case control studies support most of these observations. Compared with control patients admitted to hospital with asthma, those who died were significantly more likely to have learning difficulties; psychosis or prescribed antipsychotic drugs; financial or employment problems; repeatedly failed to attend appointments or discharged themselves from hospital; drug or alcohol abuse; obesity; or a previous near-fatal attack.

Compared with control patients with asthma in the community, patients who died had more severe disease; more likelihood of a hospital admission or visit to the ED for their asthma in the previous year; more likelihood of a previous near-fatal attack; poor medical management; failure to measure pulmonary function; and non-compliance.

B Healthcare professionals must be aware that patients with severe asthma and one or more adverse psychosocial factors are at risk of death.

Studies comparing near-fatal asthma with deaths from asthma have concluded that patients with near-fatal asthma have identical adverse factors to those described in table 9, and that these contribute to the near-fatal asthma attack. Compared with patients who die, those with near-fatal asthma are significantly younger, are significantly more likely to have had a previous near-fatal asthma attack, are less likely to have concurrent medical conditions, are less likely to experience delay in receiving medical care, and more likely to have ready access to acute medical care.

With near-fatal asthma it is advisable to involve a close relative when discussing future management.
Patients with brittle or difficult asthma should also be identified (see sections 6.2.3 and 7.1.1 and Table 10).

- Keep patients who have had near-fatal asthma or brittle asthma under specialist supervision indefinitely.

6.1.4 SEASONAL FACTORS

In the UK there is a peak of asthma deaths in young people (aged up to 44 years) in July and August and in December and January in older people.\(^{391,394}\)

6.1.5 PREDICTION AND PREVENTION OF A SEVERE ASTHMA ATTACK

Most attacks of asthma severe enough to require hospital admission develop relatively slowly over a period of six hours or more. In one study, over 80% developed over more than 48 hours.\(^{395-400}\) There is therefore time for effective action to reduce the number of attacks requiring hospitalisation. There are many similarities between patients who die from asthma, patients with near-fatal asthma and control patients with asthma who are admitted to hospital.

- A respiratory specialist should follow up patients admitted with severe asthma for at least one year after the admission.

6.2 ACUTE ASTHMA IN ADULTS

Annexes 2-4 contain algorithms summarising the recommended treatment for patients presenting with acute or uncontrolled asthma in primary care (Annex 2), ED (Annex 3), and hospital (Annex 4).

6.2.1 RECOGNITION OF ACUTE ASTHMA

Definitions of increasing levels of severity of acute asthma exacerbations are provided in Table 10.\(^{322,401-405}\) Predicted PEF values\(^{406}\) should be used only if the recent best PEF (within two years) is unknown.

6.2.2 SELF TREATMENT BY PATIENTS DEVELOPING ACUTE OR UNCONTROLLED ASTHMA

Many patients with asthma, and all patients with severe asthma, should have an agreed written action plan and their own peak flow meter, with regular checks of inhaler technique and compliance. They should know when and how to increase their medication and when to seek medical assistance. Asthma action plans can decrease hospitalisation for\(^{407}\) and deaths from\(^{408}\) asthma (see section 9.1).

6.2.3 INITIAL ASSESSMENT

All possible initial contact personnel, eg practice receptionists, ambulance call takers, NHS Direct (England and Wales), NHS 24 (Scotland), should be aware that asthma patients complaining of respiratory symptoms may be at risk and should have immediate access to a doctor or trained asthma nurse. The assessments required to determine whether the patient is suffering from an acute attack of asthma, the severity of the attack and the nature of treatment required are detailed in tables 10 and 11. It may be helpful to use a systematic recording process. Proformas have proved useful in the ED setting.\(^{409}\)
Table 10: Levels of severity of acute asthma exacerbations

<table>
<thead>
<tr>
<th>Category</th>
<th>Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Near-fatal asthma</td>
<td>Raised PaCO\textsubscript{2} and/or requiring mechanical ventilation with raised inflation pressures\textsuperscript{391-393}</td>
</tr>
<tr>
<td>Life threatening asthma</td>
<td>Any one of the following in a patient with severe asthma:</td>
</tr>
<tr>
<td></td>
<td>- PEF &lt;33% best or predicted</td>
</tr>
<tr>
<td></td>
<td>- SpO\textsubscript{2} &lt;92%</td>
</tr>
<tr>
<td></td>
<td>- PaO\textsubscript{2} &lt;8kPa</td>
</tr>
<tr>
<td></td>
<td>- normal PaCO\textsubscript{2} (4.6 – 6.0 kPa)</td>
</tr>
<tr>
<td></td>
<td>- silent chest</td>
</tr>
<tr>
<td></td>
<td>- cyanosis</td>
</tr>
<tr>
<td></td>
<td>- feeble respiratory effort</td>
</tr>
<tr>
<td>Acute severe asthma</td>
<td>Any one of:</td>
</tr>
<tr>
<td></td>
<td>- PEF 33-50% best or predicted</td>
</tr>
<tr>
<td></td>
<td>- respiratory rate $\geq$ 25/min</td>
</tr>
<tr>
<td></td>
<td>- heart rate $\geq$ 110/min</td>
</tr>
<tr>
<td></td>
<td>- inability to complete sentences in one breath</td>
</tr>
<tr>
<td>Moderate asthma exacerbation</td>
<td>- Increasing symptoms</td>
</tr>
<tr>
<td></td>
<td>- PEF $&gt;$ 50-75% best or predicted</td>
</tr>
<tr>
<td></td>
<td>- no features of acute severe asthma</td>
</tr>
<tr>
<td>Brittle asthma</td>
<td>- Type 1: wide PEF variability ($&gt;$ 40% diurnal variation for $&gt;$ 50% of the time over a period $&gt;$ 150 days) despite intense therapy</td>
</tr>
<tr>
<td></td>
<td>- Type 2: sudden severe attacks on a background of apparently well controlled asthma</td>
</tr>
</tbody>
</table>

6.2.4 PREVENTION OF ACUTE DETERIORATION

A register of patients at risk may help primary care health professionals to identify patients who are more likely to die from their asthma. A system should be in place to ensure that these patients are contacted if they fail to attend for follow up.

6.2.5 CRITERIA FOR REFERRAL

D Refer to hospital any patients with features of acute severe or life threatening asthma.

Other factors, such as failure to respond to treatment, social circumstances or concomitant disease, may warrant hospital referral.
### Table 11: Initial assessment - the role of symptoms, signs and measurements

| Clinical features | Clinical features, symptoms and respiratory and cardiovascular signs can identify some patients with severe asthma, eg severe breathlessness (including too breathless to complete sentences in one breath), tachypnea, tachycardia, silent chest, cyanosis or collapse.\textsuperscript{322, 401-405}
| | None of these singly or together is specific and their absence does not exclude a severe attack. |
| PEF or FEV\textsubscript{1} | Measurements of airway calibre improve recognition of the degree of severity, the appropriateness or intensity of therapy, and decisions about management in hospital or at home.\textsuperscript{410, 411} PEF or FEV\textsubscript{1} are both useful and valid measures of airway calibre. PEF is more convenient and cheaper.
| | PEF expressed as a percentage of the patient’s previous best value is most useful clinically. PEF as a percentage of predicted gives a rough guide in the absence of a known previous best value. Different peak flow meters give different readings. Where possible the same or similar type of peak flow meter should be used. The Nunn and Gregg nomogram is recommended for use with peak flow meter, or the European Coal and Steel published normal values for use with FEV\textsubscript{1}.\textsuperscript{412} |
| Pulse oximetry | Measure oxygen saturation (SpO\textsubscript{2}) with a pulse oximeter to determine the adequacy of oxygen therapy and the need for arterial blood gas (ABG) measurement. The aim of oxygen therapy is to maintain SpO\textsubscript{2} $\geq 92\%$ . |
| Blood gases (ABG) | Patients with SpO\textsubscript{2} $<$92\% or other features of life threatening asthma require ABG measurement.\textsuperscript{322, 401-403, 405 413} |
| Chest X-ray | Chest X-ray is not routinely recommended in patients in the absence of:
- suspected pneumomediastinum or pneumothorax
- suspected consolidation
- life threatening asthma
- failure to respond to treatment satisfactorily
- requirement for ventilation. |
| Systolic paradox | Systolic paradox (pulsus paradoxus) is an inadequate indicator of the severity of an attack and should not be used.\textsuperscript{322, 401,402-405, 414} |
6.2.6 CRITERIA FOR ADMISSION

B Admit patients with any feature of a life threatening or near-fatal attack.381-385, 391, 393

B Admit patients with any feature of a severe attack persisting after initial treatment. 381-385, 391, 393

C Patients whose peak flow is greater than 75% best or predicted one hour after initial treatment may be discharged from ED unless they meet any of the following criteria, when admission may be appropriate:
- still have significant symptoms
- concerns about compliance
- living alone/socially isolated
- psychological problems
- physical disability or learning difficulties
- previous near-fatal or brittle asthma
- exacerbation despite adequate dose steroid tablets pre-presentation
- presentation at night
- pregnancy.

Criteria for admission in adults are summarised in annexes 2 and 3.

6.3 TREATMENT OF ACUTE ASTHMA IN ADULTS

6.3.1 OXYGEN

Patients with acute severe asthma are hypoxaemic.415-418 This should be corrected urgently using high concentrations of inspired oxygen (usually 40-60%) and a high flow mask such as a Hudson mask. Unlike patients with COPD there is little danger of precipitating hypercapnea with high flow oxygen. Hypercapnea indicates the development of near-fatal asthma and the need for emergency specialist/anaesthetic intervention. Oxygen saturations of at least 92% should be aimed for.

C Give high flow oxygen to all patients with acute severe asthma.

Oxygen-driven nebulisers are preferred to nebulise β₂ agonist bronchodilators in hospitals, ambulances and primary care because of the theoretical risk of oxygen desaturation while using air driven compressors.322,333,419 (NB: To generate the flow rate of 6 l/min required to drive most nebulisers, a high flow regulator must be fitted to the oxygen cylinder). The absence of supplemental oxygen should not prevent nebulised therapy from being administered when appropriate.420

A
- In hospital, ambulance and primary care, nebulised β₂ agonist bronchodilators should be driven by oxygen.

- Outside hospital, high dose β₂ agonist bronchodilators may be delivered via large volume spacers or nebulisers.

C The absence of supplemental oxygen should not prevent nebulised therapy being given if indicated.
6.3.2 \( \beta_2 \) AGONIST BRONCHODILATORS

In most cases inhaled \( \beta_2 \) agonists given in high doses act quickly to relieve bronchospasm with few side effects.\textsuperscript{421-423} There is no evidence for any difference in efficacy between salbutamol and terbutaline.

In acute asthma without life threatening features, \( \beta_2 \) agonists can be administered by repeated activations of a pMDI via an appropriate large volume spacer or by wet nebulisation driven by oxygen, if available.\textsuperscript{353} Inhaled \( \beta_2 \) agonists are as efficacious and preferable to intravenous \( \beta_2 \) agonists (meta-analysis has excluded subcutaneous trials) in adult acute asthma in the majority of cases.\textsuperscript{424}

A Use high-dose inhaled \( \beta_2 \) agonists as first line agents in acute asthma and administer as early as possible. Reserve intravenous \( \beta_2 \) agonists for those patients in whom inhaled therapy cannot be used reliably.

☐ In acute asthma with life threatening features the nebulised route (oxygen-driven) is recommended.

Parenteral \( \beta_2 \) agonists, in addition to inhaled \( \beta_2 \) agonists, may have a role in ventilated patients or those in extremis; however there is limited evidence to support this.

Continuous nebulisation of \( \beta_2 \) agonists is as efficacious as bolus nebulisation in relieving acute asthma.\textsuperscript{425-427} Most cases of acute asthma will respond adequately to bolus nebulisation of \( \beta_2 \) agonists.

A In severe asthma (PEF or FEV\(_1\) < 50% best or predicted) and asthma that is poorly responsive to an initial bolus dose of \( \beta_2 \) agonist, consider continuous nebulisation.

Repeat doses of \( \beta_2 \) agonists at 15-30 minute intervals or give continuous nebulisation of salbutamol at 5-10 mg/hour (requires appropriate nebuliser) if there is an inadequate response to initial treatment. Higher bolus doses, eg 10 mg of salbutamol, are unlikely to be more effective.

6.3.3 STEROID THERAPY

Steroids reduce mortality, relapses, subsequent hospital admission and requirement for \( \beta_2 \) agonist therapy. The earlier they are given in the acute attack the better the outcome.\textsuperscript{428,429}

A Give steroids in adequate doses in all cases of acute asthma.

Steroid tablets are as effective as injected steroids, provided they can be swallowed and retained.\textsuperscript{428} Prednisolone 40-50 mg daily or parenteral hydrocortisone 400 mg daily (100 mg six-hourly) are as effective as higher doses.\textsuperscript{430} For convenience, steroid tablets may be given as 2 x 25 mg tablets daily rather than 8-12 x 5 mg tablets.

☐ Continue prednisolone 40-50 mg daily for at least five days or until recovery.

Following recovery from the acute exacerbation steroids can be stopped abruptly. Doses do not need tapering provided the patient receives inhaled steroids\textsuperscript{431,432} (apart from patients on maintenance steroid treatment or rare instances where steroids are required for three or more weeks).

There is no evidence that inhaled steroids should be substituted for steroid tablets in treating patients with acute severe, or life threatening asthma. Further randomised controlled trials to determine the role of inhaled steroids in these patients are required.

Inhaled steroids do not provide benefit in addition to the initial treatment,\textsuperscript{433} but should be continued (or started as soon as possible) to start the chronic asthma management plan.
6.3.4 IPRATROPIUM BROMIDE

Combining nebulised ipratropium bromide with a nebulised \( \beta_2 \) agonist produces significantly greater bronchodilation than a \( \beta_2 \) agonist alone, leading to a faster recovery and shorter duration of admission. Anticholinergic treatment is not necessary and may not be beneficial in milder exacerbations of asthma or after stabilisation.\(^{434-436}\)

B Add nebulised ipratropium bromide (0.5 mg 4-6 hourly) to \( \beta_2 \) agonist treatment for patients with acute severe or life threatening asthma or those with a poor initial response to \( \beta_2 \) agonist therapy.

6.3.5 INTRAVENOUS MAGNESIUM SULPHATE

A single dose of IV magnesium sulphate is safe and effective in patients with acute severe asthma.\(^{437}\)

The safety and efficacy of repeated doses have not been assessed. Repeated doses could cause hypermagnesaemia with muscle weakness and respiratory failure.

B Consider giving a single dose of IV magnesium sulphate for patients with:

- acute severe asthma who have not had a good initial response to inhaled bronchodilator therapy.
- life threatening or near fatal asthma.

\[ \text{IV magnesium sulphate (1.2-2 g IV infusion over 20 minutes) should only be used following consultation with senior medical staff.} \]

More studies are needed to determine the optimal frequency and dose of IV magnesium sulphate therapy.

6.3.6 INTRAVENOUS AMINOPHYLLINE

In acute asthma, IV aminophylline is not likely to result in any additional bronchodilation compared to standard care with inhaled bronchodilators and steroids. Side effects such as arrhythmias and vomiting are increased if IV aminophylline is used.\(^{438}\)

\[ \text{Use IV aminophylline only after consultation with senior medical staff.} \]

Some patients with near-fatal asthma or life threatening asthma with a poor response to initial therapy may gain additional benefit from IV aminophylline (5 mg/kg loading dose over 20 minutes unless on maintenance oral therapy, then infusion of 0.5-0.7 mg/kg/hr). Such patients are probably rare and could not be identified in a meta-analysis of trials.\(^{438}\) If IV aminophylline is given to patients on oral aminophylline or theophylline, blood levels should be checked on admission. Levels should be checked daily for all patients on aminophylline infusions.

6.3.7 LEUKOTRIENE RECEPTOR ANTAGONISTS

There is insufficient evidence at present to make a recommendation about the use of leukotriene receptor antagonists in the management of acute asthma.

6.3.8 ANTIBIOTICS

When an infection precipitates an exacerbation of asthma it is likely to be viral. The role of bacterial infection has been overestimated.\(^{439}\)

B Routine prescription of antibiotics is not indicated for acute asthma.

6.3.9 HELIOX

The use of heliox (helium/oxygen mixture in a ratio of 80:20 or 70:30) in acute adult asthma cannot be recommended on the basis of present evidence.\(^{440,441}\)
6.3.10 INTRAVENOUS FLUIDS

There are no controlled trials, observational or cohort studies of differing fluid regimes in acute asthma. Some patients with acute asthma require rehydration and correction of electrolyte imbalance. Hypokalaemia can be caused or exacerbated by β₂ agonist and/or steroid treatment and must be corrected.

6.3.11 REFERRAL TO INTENSIVE CARE

Indications for admission to intensive care or high-dependency units include patients requiring ventilatory support and those with severe acute or life threatening asthma who are failing to respond to therapy, as evidenced by:

- deteriorating PEF
- persisting or worsening hypoxia
- hypercapnea
- arterial blood gas analysis showing fall in pH or rising H⁺ concentration
- exhaustion, feeble respiration
- drowsiness, confusion
- coma or respiratory arrest.322,401

Not all patients admitted to the Intensive Care Unit (ICU) need ventilation, but those with worsening hypoxia or hypercapnea, drowsiness or unconsciousness and those who have had a respiratory arrest require intermittent positive pressure ventilation. Intubation in such patients is very difficult and should ideally be performed by an anaesthetist or ICU consultant.

All patients transferred to intensive care units should be accompanied by a doctor suitably equipped and skilled to intubate if necessary.

6.3.12 NON-INVASIVE VENTILATION

Non-invasive ventilation (NIV) is well established in the management of ventilatory failure caused by extrapulmonary restrictive conditions and exacerbations of COPD. Hypercapneic respiratory failure developing during an acute asthmatic episode is an indication for urgent ICU admission. It is unlikely that NIV would replace intubation in these very unstable patients but it has been suggested that this treatment can be used safely and effectively.442

Future studies might usefully examine its role in the gradually tiring patient, but at present this treatment cannot be recommended outside randomised controlled trials.

6.4 FURTHER INVESTIGATION AND MONITORING

- Measure and record PEF 15-30 minutes after starting treatment, and thereafter according to the response. Measure and record PEF before and after nebulised or inhaled β₂ agonist bronchodilator (at least four times daily) throughout the hospital stay and until controlled after discharge.
- Record oxygen saturation by oximetry and maintain arterial SaO₂ > 92%.
- Repeat measurements of blood gas tensions within two hours of starting treatment if:
  - the initial PaO₂ is <8 kPa unless SaO₂ is > 92%; or
  - the initial PaCO₂ is normal or raised; or
  - the patient’s condition deteriorates.

- Measure them again if the patient’s condition has not improved by 4-6 hours.
- Measure and record the heart rate.
- Measure serum potassium and blood glucose concentrations.
- Measure the serum theophylline concentration if aminophylline is continued for more than 24 hours (aim at a concentration of 55-110 mcg/moll).
6.5 ASTHMA MANAGEMENT PROTOCOLS AND PROFORMAS

The use of structured proformas facilitates improvements in the process of care in emergency departments and hospital wards and improves patient outcomes. The use of this type of documentation can assist data collection aimed at determining quality of care and outcomes.409,443,445

6.6 HOSPITAL DISCHARGE AND FOLLOW UP (see annex 4)

6.6.1 TIMING OF DISCHARGE

No single physiological parameter defines absolutely the timing of discharge from an admission with acute asthma. Patients should have clinical signs compatible with home management, be on reducing amounts of β_2_ agonist (preferably no more than four hourly) and be on medical therapy they can continue safely at home.

Although diurnal variability of PEF is not always present during an exacerbation, evidence suggests that patients discharged with PEF < 75% best or predicted and with diurnal variability > 25% are at greater risk of early relapse and readmission.446,447

6.6.2 PATIENT EDUCATION

Following discharge from hospital or emergency departments, a proportion of patients re-attend with more than 15% re-attending within two weeks. Some repeat attenders need emergency care, but many delay seeking help, and are under-treated and/or under-monitored.448

Prior to discharge, trained staff should give asthma education. This should include education on inhaler technique and PEF record keeping, with a written PEF and symptom-based action plan being provided allowing the patient to adjust their therapy within recommendations. These measures have been shown to reduce morbidity after the exacerbation and reduce relapse rates.449

There is some experience of a discrete population of patients who use emergency departments rather than primary care services for their asthma care.90

For the above groups there is a role for a trained asthma liaison nurse based in, or associated with, the emergency department.

6.6.3 FOLLOW UP

A careful history should elicit the reasons for the exacerbation and explore possible actions the patient should take to prevent future emergency presentations.

Medication should be altered depending upon the assessment and the patient provided with an asthma action plan aimed at preventing relapse, optimising treatment and preventing delay in seeking assistance in the future.

Follow up should be arranged prior to discharge with the patient’s general practitioner or asthma nurse within two working days; and with a hospital specialist asthma nurse or respiratory physician at about one month after admission.

It is essential that the patient’s primary care practice is informed within 24 hours of discharge from the emergency department or hospital following an asthma exacerbation. Ideally this communication should be directly with a named individual responsible for asthma care within the practice, by means of fax or email.
6.7 ACUTE ASTHMA IN CHILDREN AGED OVER 2 YEARS

6.7.1 INITIAL ASSESSMENT

Table 12 details criteria for assessment of severity of acute asthma attacks in children. See also annexes 5-7.

Table 12: Clinical features for assessment of severity

<table>
<thead>
<tr>
<th>Acute severe</th>
<th>Life threatening</th>
</tr>
</thead>
<tbody>
<tr>
<td>Can’t complete sentences in one breath or too</td>
<td>Silent chest</td>
</tr>
<tr>
<td>breathless to talk or feed</td>
<td>Cyanosis</td>
</tr>
<tr>
<td>Pulse</td>
<td>Poor respiratory effort</td>
</tr>
<tr>
<td>&gt;120 in children aged &gt; 5 years</td>
<td>Hypotension</td>
</tr>
<tr>
<td>&gt;130 in children aged 2-5 years</td>
<td>Exhaustion</td>
</tr>
<tr>
<td>Respiration</td>
<td>Confusion</td>
</tr>
<tr>
<td>&gt;30 breaths/min aged &gt; 5 years</td>
<td>Coma</td>
</tr>
<tr>
<td>&gt;50 breaths/min aged 2-5 years</td>
<td></td>
</tr>
</tbody>
</table>

Before children can receive appropriate treatment for acute asthma in any setting, it is essential to assess accurately the severity of their symptoms. The following clinical signs should be recorded:

- Pulse rate
  *(increasing tachycardia generally denotes worsening asthma; a fall in heart rate in life threatening asthma is a pre-terminal event)*

- Respiratory rate and degree of breathlessness
  *(ie too breathless to complete sentences in one breath or to feed)*

- Use of accessory muscles of respiration
  *(best noted by palpation of neck muscles)*

- Amount of wheezing
  *(which might become biphasic or less apparent with increasing airways obstruction)*

- Degree of agitation and conscious level
  *(always give calm reassurance)*

Clinical signs correlate poorly with the severity of airways obstruction. Some children with acute severe asthma do not appear distressed.

Objective measurements of PEF and SpO₂ are essential. Suitable equipment should be available for use by all health professionals assessing acute asthma in both primary and secondary care settings.

Low oxygen saturations after initial bronchodilator treatment selects a more severe group of patients. Consider intensive inpatient treatment for children with SpO₂ < 92% on air after initial bronchodilator treatment.

Decisions about admission should be made by trained physicians after repeated assessment of the response to further bronchodilator treatment. A measurement of <50% predicted PEF or FEV₁ with poor improvement after initial bronchodilator treatment is predictive of a more prolonged asthma attack. Attempt to measure PEF or FEV₁ in all children aged > 5 years, taking the best of three measurements, ideally expressed as percentage of personal best for PEF (as detailed in a written action plan) or alternatively as percentage of predicted for PEF or FEV₁.

Chest X-rays and ABG measurements rarely provide additional useful information and are not routinely indicated.
6.8 TREATMENT OF ACUTE ASTHMA IN CHILDREN AGED OVER 2 YEARS

Emergency units attending to children with acute asthma should have a registered sick children’s nurse available on duty at all times and staff familiar with the specific needs of children. The use of proformas can increase the accuracy of severity assessment.

An assessment-driven algorithm has been shown to reduce treatment costs and hospital stay.456

D The use of structured care protocols detailing bronchodilator usage, clinical assessment, and specific criteria for safe discharge is recommended.

6.8.1 OXYGEN

Children with life threatening asthma or SpO₂ < 92% should receive high flow oxygen via a tight fitting face mask or nasal cannula at sufficient flow rates to achieve normal saturations.

6.8.2 β₂ AGONIST BRONCHODILATORS

A Inhaled β₂ agonists are the first line treatment for acute asthma.457-460

pMDI + spacer is an effective alternative to nebulisers for bronchodilator inhalation to treat mild to moderate asthma.353,461 Children receiving β₂ agonists via pMDI + spacer are less likely to have tachycardia and hypoxia than when the same drug is given via a nebuliser.353

A pMDI + spacer is the preferred option in mild to moderate asthma.

Information about implementing evidence based guidelines using such devices has been published.462 Children aged < 3 years are likely to require a face mask connected to the mouthpiece of a spacer for successful drug delivery. Inhalers should be actuated into the spacer in individual puffs and inhaled immediately by tidal breathing.

Frequent doses of β₂ agonists are safe for the treatment of acute asthma,457-459 although children with mild symptoms benefit from lower doses.460

B Individualise drug dosing according to severity and adjust according to the patient’s response.

Two to four puffs repeated every 20-30 minutes according to clinical response might be sufficient for mild attacks although up to 10 puffs might be needed for more severe asthma.

Children with acute asthma in primary care who have not improved after receiving up to 10 puffs of β₂ agonist should be referred to hospital. Further doses of bronchodilator should be given as necessary whilst awaiting transfer.

Treat children transported to hospital by ambulance with oxygen and nebulised β₂ agonists during the journey.

Transfer children with severe or life threatening asthma urgently to hospital to receive frequent doses of nebulised β₂ agonists (2.5-5 mg salbutamol or 5-10 mg terbutaline).

Doses can be repeated every 20-30 minutes. Continuous nebulised β₂ agonists are of no greater benefit than the use of frequent intermittent doses in the same total hourly dosage.463,464
6.8.3 IV SALBUTAMOL

The role of intravenous $\beta_2$ agonists in addition to nebulised treatment remains unclear. One study has shown that an IV bolus of salbutamol given in addition to near-maximal doses of nebulised salbutamol results in clinically significant benefits. The early addition of a bolus dose of intravenous salbutamol (15 mcg/kg) can be an effective adjunct to treatment in severe cases.

Continuous intravenous infusion should be considered when there is uncertainty about reliable inhalation or for severe refractory asthma. Doses above 1-2 mcg/kg/min (200 mcg/ml solution) should be given in a paediatric intensive care unit (PICU) setting (up to 5 mcg/kg/min) with regular monitoring of electrolytes.

6.8.4 STEROID THERAPY

Steroid tablets

The early use of steroids for acute asthma can reduce the need for hospital admission and prevent a relapse in symptoms after initial presentation. Benefits can be apparent within three to four hours.

A Give prednisolone early in the treatment of acute asthma attacks.

A soluble preparation dissolved in a spoonful of water is preferable in those unable to swallow tablets. Use a dose of 20 mg for children 2-5 years old and 30-40 mg for children >5 years.

Oral and intravenous steroids are of similar efficacy. Intravenous hydrocortisone (4 mg/kg repeated four hourly) should be reserved for severely affected children who are unable to retain oral medication.

Larger doses do not appear to offer a therapeutic advantage for the majority of children. There is no need to taper the dose of steroid tablets at the end of treatment.

- Use a dose of 20 mg prednisolone for children aged 2-5 years and a dose of 30-40 mg for children > 5 years. Those already receiving maintenance steroid tablets should receive 2 mg/kg prednisolone up to a maximum dose of 60 mg.
- Repeat the dose of prednisolone in children who vomit and consider intravenous steroids in those who are unable to retain orally ingested medication.
- Treatment for up to three days is usually sufficient, but the length of course should be tailored to the number of days necessary to bring about recovery.

Inhaled steroids

There is insufficient evidence to support the use of inhaled steroids as alternative or additional treatment to steroid tablets for acute asthma.

Do not initiate inhaled steroids in preference to steroid tablets to treat acute childhood asthma.

Children with chronic asthma not receiving regular preventative treatment will benefit from initiating inhaled steroids as part of their long term management. There is no evidence that increasing the dose of inhaled steroids is effective in treating acute symptoms, but it is good practice for children already receiving inhaled steroids to continue with their usual maintenance doses.
6.8.5 IPRATROPIUM BROMIDE

There is good evidence for the safety and efficacy of frequent doses of ipratropium bromide used in addition to $\beta_2$ agonists for the first two hours of a severe asthma attack. Benefits are more apparent in the most severe patients. 471

A If symptoms are refractory to initial $\beta_2$ agonist treatment, add ipratropium bromide (250 mcg/dose mixed with the nebulised $\beta_2$ agonist solution).

Frequent doses up to every 20-30 minutes (250 mcg/dose mixed with the $\beta_2$ agonist solution in the same nebuliser) should be used early. The dose frequency should be reduced as clinical improvement occurs.

☑ Repeated doses of ipratropium bromide should be given early to treat children poorly responsive to $\beta_2$ agonists.

Children with continuing severe asthma despite frequent nebulised $\beta_2$ agonists and ipratropium bromide and those with life threatening features need urgent review by a specialist with a view to transfer to a high dependency unit (HDU) or PICU.

6.8.6 IV AMINOPHYLLINE

There is no evidence that aminophylline is of benefit for mild to moderate asthma and side effects are common and troublesome. 438, 472 However, one well conducted study has shown evidence for benefit in severe acute asthma unresponsive to multiple doses of $\beta_2$ agonists and steroids. 473

A Aminophylline is not recommended in children with mild to moderate acute asthma.

C Consider aminophylline in a HDU or PICU setting for children with severe or life threatening bronchospasm unresponsive to maximal doses of bronchodilators and steroid tablets.

A 5 mg/kg loading dose should be given over 20 minutes with ECG monitoring (omit in those receiving maintenance oral theophyllines) followed by a continuous infusion at 1 mg/kg/hour. Estimate serum theophylline levels in patients already receiving oral treatment and in those receiving prolonged treatment.

6.8.7 OTHER THERAPIES

There is no evidence to support the use of heliox or leukotriene receptor antagonists for the treatment of acute asthma in childhood.

There is insufficient evidence to support or refute the role of antibiotics in acute asthma, 474 but the majority of acute asthma attacks are triggered by viral infection.

☑ Do not give antibiotics routinely in the management of acute childhood asthma.

6.8.8 INTRAVENOUS FLUIDS

Children with prolonged severe asthma not tolerating oral fluids will require intravenous hydration. Two thirds of the child’s maintenance requirement should be given because of the possibility of inappropriate antidiuretic hormone secretion. Serum electrolytes should be measured and hypokalaemia corrected if detected.

☑ ECG monitoring is mandatory for all intravenous treatments.

6.8.9 IV MAGNESIUM SULPHATE

Intravenous magnesium sulphate is a safe treatment for acute asthma although its place in management is not yet established. 437, 475 Doses of up to 40 mg/kg/day (maximum 2 g) by slow infusion have been used. Studies of efficacy for severe childhood asthma unresponsive to more conventional therapies have been inconsistent in providing evidence of benefit.
6.8.10 FURTHER INVESTIGATION AND MONITORING

Children can be discharged when stable on 3-4 hourly inhaled bronchodilators that can be continued at home. PEF and/or FEV₁ should be >75% of best or predicted and SpO₂ >94%.

Adult studies show that “optimal care” comprising self monitoring, regular review and a written asthma action plan can improve outcomes. Acute asthma attacks should be considered a failure of preventive therapy and thought should be given about how to help families avoid further severe episodes. Discharge plans should address the following:

- Check inhaler technique
- Consider the need for regular inhaled steroids
- Provide a written asthma action plan for subsequent asthma with clear instructions about the use of bronchodilators, seeking urgent medical attention in the event of worsening symptoms and, if appropriate, starting a course of oral steroids
- Arrange follow up by a GP within one week
- Arrange follow up in a paediatric asthma clinic within one to two months.

6.9 ASSESSMENT OF ACUTE ASTHMA IN CHILDREN AGED LESS THAN 2 YEARS

The assessment of acute asthma in early childhood can be difficult (see annex 8). Intermittent wheezing attacks are usually due to viral infection and the response to asthma medication is inconsistent. Prematurity and low birth weight are risk factors for recurrent wheezing. The differential diagnosis of symptoms includes aspiration pneumonitis, pneumonia, bronchiolitis, tracheomalacia, and complications of underlying conditions such as congenital anomalies and cystic fibrosis. These guidelines are intended for those who are thought to have asthma causing acute wheeze. They should not be used as a guide for treating acute bronchiolitis.

6.10 TREATMENT OF ACUTE ASTHMA IN CHILDREN AGED LESS THAN 2 YEARS

6.10.1 β₂ AGONIST BRONCHODILATORS

A trial of bronchodilator therapy should be considered when symptoms are of concern. If inhalers have been successfully administered but there is no response, review the diagnosis and consider the use of other treatment options.

Oral β₂ agonists have not been shown to affect symptom score or length of hospital stay for acute asthma in infancy when compared to placebo.477

B Oral β₂ agonists are not recommended for acute asthma in infants.

Inhaled β₂ agonists are the initial treatment of choice for acute asthma. Close fitting face masks are essential for optimal drug delivery. The dose received is increased if the child is breathing appropriately and not taking large gasps because of distress and screaming.

There is good evidence that pMDI + spacer is as effective as, if not better than, nebulisers for treating mild to moderate asthma in children aged ≤2 years.355-478,479

A For mild to moderate acute asthma, a pMDI + spacer is the optimal drug delivery device.

Whilst β₂ agonists offer marginal benefits to children aged <2 years with acute wheeze, there is little evidence for an impact on the need for hospital admission or length of hospital stay.480-482
6.10.2 STEROID THERAPY
Steroid tablets in conjunction with $\beta_2$ agonists have been shown to reduce hospital admission rates when used in the emergency department.\textsuperscript{483} Steroid tablets have also been shown to reduce the length of hospital stay.\textsuperscript{477,480,483}

**B** Consider steroid tablets in infants early in the management of moderate to severe episodes of acute asthma in the hospital setting.

One study has shown similar benefits when comparing oral and nebulised steroids for acute asthma.\textsuperscript{480}

☑️ Steroid tablet therapy (10 mg of soluble prednisolone for up to three days) is the preferred steroid preparation for use in this age group.

6.10.3 IPRATROPIUM BROMIDE
The addition of ipratropium bromide to $\beta_2$ agonists for acute severe asthma may lead to some improvement in clinical symptoms and reduce the need for more intensive treatment. It does not reduce the length of hospital stay either in combination with $\beta_2$ agonists or in comparison with placebo.\textsuperscript{484}

**B** Consider inhaled ipratropium bromide in combination with an inhaled $\beta_2$ agonist for more severe symptoms.

6.10.4 FURTHER INVESTIGATION AND MONITORING
Many children with recurrent episodes of viral-induced wheezing in infancy do not go on to have chronic atopic asthma. The majority do not require treatment with regular inhaled steroids. Parents should be advised about the relationship between cigarette smoke exposure and wheezy illnesses (see sections 3.1.9 and 3.3.1). Referral to suitable agencies should be offered to those who wish to give up smoking.

Parents of wheezy infants should receive appropriate discharge plans along similar lines to those given for older children (see section 6.8.10).
7 Special situations

7.1 DIFFICULT ASTHMA

7.1.1 DEFINING AND ASSESSING DIFFICULT ASTHMA

The term difficult asthma generally refers to a clinical situation where a prior diagnosis of asthma exists, and asthma-like symptoms and exacerbations persist, despite prescription of high-dose asthma therapy. There is no universally agreed definition of difficult asthma in children or adults, and specifically at what level of treatment prescription or exacerbation frequency, the term difficult asthma should apply. Consequently there are no precise data on the prevalence of this clinical problem. Previous consensus studies have suggested failure to achieve symptom control despite prescribed high-dose inhaled steroid as a minimum requirement, whilst more recent consensus work has stipulated a treatment level equivalent to at least step 4 (see section 4.4 and Figures 4, 5 and 6), before labelling as “difficult”.485,486

In this guideline difficult asthma is defined as persistent symptoms and/or frequent exacerbations despite treatment at step 4 or step 5.

Observational uncontrolled studies in subjects with difficult asthma, using multidisciplinary assessment models have identified high rates of alternative or coexistent diagnoses and psychological comorbidity.29,487-489 These uncontrolled studies, using systematic multidisciplinary assessment and management, have suggested improved outcomes in adults and children, but controlled clinical trials are required. Within this broadly defined group of subjects with difficult asthma, a proportion will have refractory disease, which is relatively resistant to currently available therapies. This group can only be identified after detailed evaluation, including exclusion of alternative causes of persistent symptoms, management of other comorbidities and confirmation of adherence with therapy.

Patients with difficult asthma should be systematically evaluated, including:
- confirmation of the diagnosis of asthma and
- identification of the mechanism of persisting symptoms and assessment of adherence with therapy.

This assessment should be facilitated through a dedicated multidisciplinary difficult asthma service, by a team experienced in the assessment and management of difficult asthma.

7.2 FACTORS CONTRIBUTING TO DIFFICULT ASTHMA

7.2.1 POOR ADHERENCE

Poor adherence with asthma medication is associated with poor asthma outcome in adults and children (see section 9.2). Few studies have addressed this issue in subjects defined as having difficult asthma. In a case control series, poor adherence based on prescription records was identified in 22% of children with difficult to control asthma, though adherence was not reported in the stable controls.490 In a descriptive study of 100 adult subjects, with a physician diagnosis of ‘severe asthma’ 28 patients were on > 15 mg prednisolone and of these nine (32%) were found to be non-adherent with prednisolone.488 There is no published evidence that poor adherence, if identified, can be successfully addressed in this population.

Poor adherence with maintenance therapy should be considered as a possible mechanism in difficult asthma.
7.2.2 PSYCHOSOCIAL FACTORS

Fatal and near-fatal asthma have been associated with psychosocial dysfunction (see section 6.7.3). Most observational studies,\textsuperscript{29, 488, 491–494} and a case control study,\textsuperscript{495} in subjects with difficult asthma have also suggested a high level of psychological morbidity, though this observation has not been universal.\textsuperscript{496, 497} A meta-analysis of behavioural adjustment in children suggested increasing ‘asthma severity’, defined on the basis of treatment requirements was associated with greater behavioural difficulties.\textsuperscript{498} The core issue of ‘cause and effect’ remains unclear; specifically the extent to which persistent asthma symptoms despite aggressive treatment results in psychological morbidity or whether pre-existing psychological morbidity makes asthma difficult to control.

There is a lack of evidence that interventions specifically targeting psychological morbidity in difficult asthma are of benefit. A small proof of concept study targeting depression demonstrated a reduction in oral steroid use\textsuperscript{499} and an observational study in ‘high-risk’ children with asthma suggested potential benefit from joint consultation with a child psychiatrist with an improvement in symptom scores and adherence with therapy.\textsuperscript{500} However, a non-blinded randomised intervention study in adults with difficult asthma showed no benefit from a six month nurse-delivered psychoeducational programme.\textsuperscript{501} A meta-analysis of psychoeducational interventions in difficult asthma concluded that many of the studies were of poor quality, though there was some evidence of positive effect of psychosocial educational interventions on hospital admissions in adults and children and on symptoms in children. There was not enough evidence to warrant significant changes in clinical practice and little information available on cost effectiveness.\textsuperscript{502}

\textbf{C} Healthcare professionals should be aware that difficult asthma is commonly associated with coexistent psychological morbidity.

\textbf{D} Assessment of coexistent psychological morbidity should be performed as part of a difficult asthma assessment. In children this may include a psychosocial assessment of the family.

7.2.3 DYSFUNCTIONAL BREATHING

Observational uncontrolled studies in subjects with difficult asthma have identified high rates of dysfunctional breathing as an alternative or concomitant diagnosis to asthma causing symptoms.\textsuperscript{29, 488} It remains unclear what is the best mechanism of identifying and managing this problem.

\textbf{D} Dysfunctional breathing should be considered as part of a difficult asthma assessment.

7.2.4 ALLERGY

Acute asthma has been associated with IgE dependent sensitisation to indoor allergens.\textsuperscript{503} In case control studies, mould sensitisation has been associated with recurrent admission to hospital and oral steroid use\textsuperscript{504, 505} and with intensive care unit admissions and respiratory arrest.\textsuperscript{506, 507} There is no published evidence of any intervention study in this group. Research in this area is required.

\textbf{C} In patients with difficult asthma and recurrent hospital admission, allergen testing to moulds should be performed.
7.2.5 MONITORING AIRWAY RESPONSE

Two randomised blinded controlled trials and one open randomised study have supported the use of titrating steroid treatment against sputum eosinophilia in adults with moderate to severe asthma, with greatest benefit seen in patients receiving higher doses of inhaled steroid therapy. In the study with the largest numbers of patients receiving high dose inhaled steroid treatment, patients who were considered to be poorly adherent with treatment, or had inadequately controlled aggravating factors, such as rhinitis or gastro-oesophageal reflux were specifically excluded. Case series have suggested that sputum induction is safe in patients with difficult to control asthma.

Controlled studies using FENO to target treatment have not specifically targeted adults or children with difficult asthma.

| B In patients with difficult asthma, consider monitoring induced sputum eosinophil counts to guide steroid treatment. | 1* 1* 3 |
7.3 ASTHMA IN PREGNANCY

7.3.1 NATURAL HISTORY

Several physiological changes occur during pregnancy that could worsen or improve asthma, but it is not clear which, if any, are important in determining the course of asthma during pregnancy. Pregnancy can affect the course of asthma and asthma can affect pregnancy outcomes.

The natural history of asthma during pregnancy is extremely variable. In a prospective cohort study of 366 pregnancies in 330 asthmatic women, asthma worsened during pregnancy in 35%. Studies suggest that 11-18% of pregnant women with asthma will have at least one emergency department visit for acute asthma and of these 62% will require hospitalisation. There is also some evidence that the course of asthma is similar in successive pregnancies. Severe asthma is more likely to worsen during pregnancy than mild asthma, but some patients with very severe asthma may experience improvement, while symptoms may deteriorate in some patients with mild asthma.

D Offer pre-pregnancy counselling to women with asthma regarding the importance and safety of continuing their asthma medications during pregnancy to ensure good asthma control.

The conclusions of a meta-analysis of 14 studies is in agreement with the commonly quoted generalisation that during pregnancy about one third of asthma patients experience an improvement in their asthma, one third experience a worsening of symptoms, and one third remain the same.

In a large cohort study, the most severe symptoms were experienced by patients between the 24th and 36th week of pregnancy. Thereafter symptoms decreased significantly in the last four weeks and 90% had no asthma symptoms during labour or delivery. Of those who did, only two patients required anything more than inhaled bronchodilators. A further study has confirmed the observation that the last month of pregnancy is the one in which patients are least likely to have an asthma exacerbation.

A cohort study comparing 198 pregnant women with asthma to 198 women without asthma reported that non-atopic patients with asthma tend to have more severe asthma. Pre-eclampsia was also more common in this group. However with adequate surveillance and treatment, pregnancy and delivery complications can be avoided. A systematic review has shown that baseline asthma severity does determine what happens to the course of asthma in pregnancy and asthma may affect the risk of adverse outcomes.

C Monitor pregnant women with asthma closely so that any change in course can be matched with an appropriate change in treatment.

Uncontrolled asthma is associated with many maternal and fetal complications, including hyperemesis, hypertension, pre-eclampsia, vaginal haemorrhage, complicated labour, intrauterine growth restriction, preterm birth, increased perinatal mortality, and neonatal hypoxia. A large Swedish population-based study using record linkage data demonstrated increased risks for pre-term birth, low birth weight, perinatal mortality and pre-eclampsia in women with asthma. The risks for prematurity and low birth weight were higher in women with more severe asthma necessitating admission.

In contrast, if asthma is well controlled throughout pregnancy there is little or no increased risk of adverse maternal or fetal complications. Pregnancy should therefore be an indication to optimise therapy and maximise lung function in order to reduce the risk of acute exacerbation.

☐ Advise women who smoke about the dangers for themselves and their babies and give appropriate support to stop smoking.
7.4 MANAGEMENT OF ACUTE ASTHMA IN PREGNANCY

The management of acute asthma in pregnancy may be affected by concerns about harmful effects of medication on the fetus. In a prospective controlled study of 51 pregnant women and 500 non-pregnant women presenting with acute asthma to an emergency department in Boston, USA, pregnant patients with asthma were less likely to receive appropriate treatment with steroids and, as a result, were more likely to experience ongoing exacerbation at two weeks. Available studies give little cause for concern regarding treatment side effects (see section 7.3) and the maternal and fetal risks of uncontrolled asthma are much greater than the risks from using conventional asthma medications for management of acute asthma. In the last two confidential enquiries into maternal deaths in the UK (covering 1994-1999) there were eight deaths from asthma.

Oxygen should be delivered to maintain saturation above 95% in order to prevent maternal and fetal hypoxia. Drug therapy should be given as for a non-pregnant patient with acute asthma, including repeated doses of inhaled $\beta_2$ agonists and early administration of steroid tablets. In severe cases, intravenous aminophylline or intravenous $\beta_2$ agonists can be used as indicated. Continuous fetal monitoring should be performed when asthma is uncontrolled or severe, or when fetal assessment on admission is not reassuring.

C Give drug therapy for acute asthma as for the non-pregnant patient.

D Deliver oxygen immediately to maintain saturation above 95%.

D Acute severe asthma in pregnancy is an emergency and should be treated vigorously in hospital.

Continuous fetal monitoring is recommended for severe acute asthma.

For women with poorly controlled asthma during pregnancy there should be close liaison between the respiratory physician and obstetrician.

7.5 DRUG THERAPY IN PREGNANCY

In general, the medicines used to treat asthma are safe in pregnancy. The risk of harm to the fetus from severe or chronically under-treated asthma outweighs any small risk from the medications used to control asthma.

7.5.1 $\beta_2$ AGONISTS

No significant association has been demonstrated between major congenital malformations or adverse perinatal outcome and exposure to $\beta_2$ agonists. A prospective study of 259 pregnant patients with asthma who were using bronchodilators compared with 101 pregnant patients with asthma who were not, and 295 control patients, found no differences in perinatal mortality, congenital abnormalities, prematurity, mean birth weight, Apgar scores or labour/delivery complications. Evidence from prescription event monitoring suggests that salmeterol is also safe in pregnancy.

C Use $\beta_2$ agonists as normal during pregnancy.

7.5.2 INHALED STEROIDS

No significant association has been demonstrated between major congenital malformations or adverse perinatal outcome and exposure to inhaled steroids. Inhaled anti-inflammatory treatment has been shown to decrease the risk of an acute attack of asthma in pregnancy and the risk of readmission following asthma exacerbation.

C Use inhaled steroids as normal during pregnancy.
7.5.3 THEOPHYLLINES

No significant association has been demonstrated between major congenital malformations or adverse perinatal outcome and exposure to methylxanthines.530,538

For women requiring therapeutic levels of theophylline to maintain asthma control, measurement of theophylline levels is recommended. Since protein binding decreases in pregnancy, resulting in increased free drug levels, a lower therapeutic range is probably appropriate.539

C Use oral and intravenous theophyllines as normal during pregnancy.

D Check blood levels of theophylline in acute severe asthma and in those critically dependent on therapeutic theophylline levels.

7.5.4 STEROID TABLETS

The balance of evidence suggests that steroid tablets are not teratogenic.522, 530, 540 Data from many studies have failed to demonstrate an association between first trimester exposure to steroid tablets and oral clefts.540 Although one meta-analysis found an increased risk,541 a prospective study by the same group found no difference in the rate of major birth defects in prednisolone-exposed and control babies.541 One case control study that may have influenced the findings of the meta-analysis found a significant association between exposure to steroids in the first trimester and an increased risk of cleft lip,542 although this increase is not significant if only paired controls are considered.

Even if the association is real, the benefit to the mother and the fetus of steroids for treating a life threatening disease justify their use in pregnancy.524 Pregnant women with acute asthma exacerbation are less likely to be treated with steroid tablets than non-pregnant women.527 This failure to administer steroid tablets when indicated increases the risk of ongoing exacerbation and therefore the risks to the mother and her fetus.

Some studies have found an association between steroid tablet use and pregnancy-induced hypertension or pre-eclampsia and pre-term labour,520 but severe asthma may be a confounding variable.

C Use steroid tablets as normal when indicated during pregnancy for severe asthma. Steroid tablets should never be withheld because of pregnancy.

7.5.5 LEUKOTRIENE RECEPTOR ANTAGONISTS

Data regarding the safety of leukotriene antagonists in pregnancy are extremely limited. Animal studies and post-marketing surveillance for zafirlukast and montelukast are reassuring. There are animal data of concern for zileuton.543

D Do not commence leukotriene antagonists during pregnancy. They may be continued in women who have demonstrated significant improvement in asthma control with these agents prior to pregnancy not achievable with other medications.

7.5.6 CHROMONES

No significant association has been demonstrated between major congenital malformations or adverse perinatal outcome and exposure to chromones.529,530

C Use chromones as normal during pregnancy.
7.6 MANAGEMENT DURING LABOUR

Acute attacks of asthma are very rare in labour due to endogenous steroid production. In women receiving steroid tablets there is a theoretical risk of maternal hypothalamic-pituitary-adrenal axis suppression. Women with asthma may safely use all forms of pain relief in labour.

In some studies there is an association between asthma and an increased caesarean section rate, but this may be due to planned caesarean sections or inductions of labour rather than due to any direct effect of asthma on intrapartum indications.

Data suggest that the risk of postpartum exacerbation of asthma is increased in women having caesarean sections. This may relate to the severity of their asthma rather than to the caesarean section, or to factors such as postoperative pain with diaphragmatic splinting, hypoventilation and atelectasis. Prostaglandin E2 may safely be used for labour inductions. Prostaglandin F2α (carboprost/hemobate) used to treat postpartum haemorrhage due to uterine atony may cause bronchospasm. Although ergometrine may cause bronchospasm particularly in association with general anaesthesia, this is not a problem encountered when syntometrine (syntocinon/ergometrine) is used for postpartum haemorrhage prophylaxis.

Although suppression of the fetal hypothalamic-pituitary-adrenal axis is a theoretical possibility with maternal systemic steroid therapy, there is no evidence from clinical practice or the literature to support this.546

☐ Advise women that acute asthma is rare in labour.

☐ Advise women to continue their usual asthma medications in labour.

☐ In the absence of acute severe asthma, reserve caesarean section for the usual obstetric indications.

C If anaesthesia is required, regional blockade is preferable to general anaesthesia in women with asthma.

☐ Women receiving steroid tablets at a dose exceeding prednisolone 7.5 mg per day for more than two weeks prior to delivery should receive parenteral hydrocortisone 100 mg 6-8 hourly during labour.

D Use prostaglandin F2α with extreme caution in women with asthma because of the risk of inducing bronchoconstriction.

7.7 DRUG THERAPY IN BREASTFEEDING MOTHERS

The medicines used to treat asthma, including steroid tablets, have been shown in early studies to be safe to use in nursing mothers. There is less experience with newer agents. Less than 1% of the maternal dose of theophylline is excreted into breast milk.547

Prednisolone is secreted in breast milk, but milk concentrations of prednisolone are only 5-25% of those in serum. The proportion of an oral or intravenous dose of prednisolone recovered in breast milk is less than 0.1%. For maternal doses of at least 20 mg once or twice daily the nursing infant is exposed to minimal amounts of steroid with no clinically significant risk.

C Encourage women with asthma to breast feed.

C Use asthma medications as normal during lactation, in line with manufacturers’ recommendations.
7.8 OCCUPATIONAL ASTHMA

7.8.1 INCIDENCE
The true frequency of occupational asthma is not known, but under-reporting is likely. Published reports, which come from surveillance schemes, compensation registries or epidemiological studies, estimate that occupational asthma may account for about 9-15% of adult onset asthma. It is now the commonest industrial lung disease in the developed world with over 400 reported causes.

The diagnosis should be suspected in all adults with symptoms of airflow limitation, and positively searched for in those with high-risk occupations or exposures. Patients with pre-existing asthma aggravated non-specifically by dust and fumes at work (work-aggravated asthma) should be distinguished from those with pre-existing asthma who become additionally sensitised to an occupational agent.

In patients with adult onset, or reappearance of childhood asthma, clinicians should be suspicious that there may be an occupational cause.

7.8.2 AT-RISK POPULATIONS
Several hundred agents have been reported to cause occupational asthma and new causes are reported regularly in the medical literature.

The most frequently reported causative agents include isocyanates, flour and grain dust, colophony and fluxes, latex, animals, aldehydes and wood dust.

The workers most commonly reported to occupational asthma surveillance schemes include paint sprayers, bakers and pastry makers, nurses, chemical workers, animal handlers, welders, food processing workers and timber workers.

Workers reported to be at increased risk of developing asthma include bakers, food processors, forestry workers, chemical workers, plastics and rubber workers, metal workers, welders, textile workers, electrical and electronic production workers, storage workers, farm workers, waiters, cleaners, painters, dental workers and laboratory technicians.

7.8.3 DIAGNOSIS
Occupational asthma should be considered in all workers with symptoms of airflow limitation. The best screening question to ask is whether symptoms improve on days away from work. This is more sensitive than asking whether symptoms are worse at work, as many symptoms deteriorate in the hours after work or during sleep.

Adults with airflow obstruction should be asked:
- Are you better on days away from work?
- Are you better on holiday?

Those with positive answers should be investigated for occupational asthma.

These questions are not specific for occupational asthma and also identify those with asthma due to agents at home (who may improve on holidays), and those who do much less physical exertion away from work.

Occupational asthma can be present when tests of lung function are normal, limiting their use as a screening tool. Asthmatic symptoms improving away from work can produce false negative diagnoses, so further validation is needed.

Serial measurement of peak respiratory flow is the most readily available initial investigation, and the sensitivity and specificity of serial peak flow measurement in the diagnosis of occupational asthma are high.
Although skin prick tests or blood tests for specific IgE are available, there are few standardized allergens commercially available which limits their use. A positive test denotes sensitisation, which can occur with or without disease. The diagnosis of occupational asthma can usually be made without specific bronchial provocation testing, considered to be the gold standard diagnostic test. The availability of centres with expertise and facilities for specific provocation testing is very limited in the UK and the test itself is time consuming.

As a general observation, the history is more useful in excluding occupational asthma than in confirming it. A significant proportion of workers with symptoms that improve on days away from work or on holiday have been shown by objective tests not to have occupational asthma. Expert histories have poor specificity compared with specific challenge testing. Free histories taken by experts have high sensitivity but their specificity is lower.

In suspected work-related asthma, the diagnosis of asthma should be confirmed using standard objective criteria.

7.8.4 SENSITIVITY AND SPECIFICITY OF SERIAL PEAK FLOW MEASUREMENTS

Direct and blinded comparisons of serial peak flow measurement with either specific bronchial provocation testing, or an expert diagnosis based on a combination of other types of evidence, reported consistently high sensitivities and specificities, averaging 80% and 90% respectively.

Just one computed method of analysis has been reported, with a sensitivity of 75% and a specificity of 94%.

Computed analysis of peak flow records has good diagnostic performance, but statistical analysis of serial peak flow measurements appears to be of limited diagnostic value compared to expert interpretation.

Serial measurements of peak expiratory flow

Measurements should be made every two hours from waking to sleeping for four weeks, keeping treatment constant and documenting times at work.

Minimum standards for diagnostic sensitivity >70% and specificity >85% are:

- At least three days in each consecutive work period
- At least three series of consecutive days at work with three periods away from work (usually about three weeks)
- At least four evenly spaced readings per day

The analysis is best done with the aid of a criterion-based expert system. Suitable record forms and support are available from www.occupationalasthma.com

Objective diagnosis of occupational asthma should be made using serial peak flow measurements, with at least four readings per day.

7.8.5 NON-SPECIFIC REACTIVITY

Studies of non-specific reactivity are confounded by different methods used, different cut-offs for normality and the interval between last occupational exposure and the performance of the test (increasing time may allow recovery of initial hyper-reactors). Such studies show that non-specific bronchial hyper-reactivity may be normal in 5-40% of specific challenge positive workers. Testing with higher concentrations of methacholine or histamine, at which some people without asthma would react, reduces the number of non-reacting people with occupational asthma, but still leaves some non-reactors. One study showed no additional benefit of non-specific bronchial reactivity measurement over and above a history and specific IgE to inhaled antigens. A normal test of non-specific reactivity is not sufficiently specific to exclude occupational asthma in clinical practice.
Changes in non-specific reactivity at and away from work alone have been found to have only moderate sensitivity and specificity for diagnosis. Three studies were identified where at and away from work exposure measurements were attempted. One did not investigate workers further when at work reactivity was normal, limiting its interpretation. Using a 3.2 fold change in reactivity, one study found a sensitivity of 48% and a specificity of 64%. Reducing the required change to twofold increased the sensitivity to 67%, reducing specificity to 54%. A smaller study with 14 workers with occupational asthma showed a sensitivity of 62% and specificity of 78%.  

7.8.6 SPECIFIC BRONCHIAL PROVOCATION TESTING

Specific provocation challenges are usually used as the gold standard for occupational asthma diagnosis making assessments of their diagnostic validity difficult. In addition, there are no standardised methods for many occupational agents. There is also evidence that the threshold exposure increases with time since last exposure, making the tests less sensitive after prolonged absence from work. There are reports of people having non-specific reactions to specific challenges at concentrations likely to be found in the workplace or of negative reactions to specific challenges in workers with otherwise good evidence of occupational asthma when challenge concentrations are confined to levels below occupational exposure standards.

D A negative specific bronchial challenge in a worker with otherwise good evidence of occupational asthma is not sufficient to exclude the diagnosis.

7.9 MANAGEMENT OF OCCUPATIONAL ASTHMA

The aim of management is to identify the cause, remove the worker from exposure, and for the worker to have worthwhile employment.

Complete avoidance of exposure may or may not improve symptoms and bronchial hyper-responsiveness. Both the duration of continued exposure following the onset of symptoms and the severity of asthma at diagnosis may be important determinants of outcome. Early diagnosis and early avoidance of further exposure, either by relocation of the worker or substitution of the hazard offer the best chance of complete recovery. Workers who remain in the same job and continue to be exposed to the same causative agent after diagnosis are unlikely to improve and symptoms may worsen. The likelihood of improvement or resolution of symptoms or of preventing deterioration is greater in workers who have no further exposure to the causative agent.

Several studies have shown that the prognosis for workers with occupational asthma is worse for those who remain exposed for more than one year after symptoms develop, compared with those removed earlier.

D Relocation away from exposure should occur as soon as diagnosis is confirmed, and ideally within 12 months of the first work-related symptoms of asthma.

There is consistent evidence from clinical and workforce case series that about one third of workers with occupational asthma are unemployed after diagnosis. It is unclear whether this risk is higher than that for other adults with asthma. The risk of unemployment may fall with increasing time after diagnosis. There is consistent evidence that loss of employment following a diagnosis of occupational asthma is associated with loss of income. Adults with occupational asthma may find employment more difficult than adults with non-occupational asthma. Approximately one third of workers with occupational asthma have been shown to be unemployed up to six years after diagnosis.
8 Organisation and delivery of care, and audit

8.1 ROUTINE PRIMARY CARE

8.1.1 ACCESS TO ROUTINE PRIMARY CARE

Primary care services delivered by doctors and nurses trained in asthma management improves diagnosis, prescribing, education, monitoring, and continuity of care. Successful training programmes typically include outreach educational visits to practices or practitioners using interactive educational methods focused around clinical guidelines, occasionally including audit and feedback of care.

A All people with asthma should have access to primary care services delivered by doctors and nurses with appropriate training in asthma management.

Audit the percentage of clinicians who have taken part in a suitable asthma educational update within last two years.

8.1.2 STRUCTURED REVIEW

Proactive clinical review of people with asthma improves clinical outcomes. Evidence for benefit is strongest when reviews include discussion and use of a written action plan. Benefits include reduced school or work absence, reduced exacerbation rate, improved symptom control and reduced attendance at the emergency department. Proactive structured review, as opposed to opportunistic or unscheduled review, is associated with reduced exacerbation rate and days lost from normal activity. It is difficult to be prescriptive about the frequency of review as need will vary with the severity of the disease. Outcome is probably similar whether a practice nurse (PN), or a general practitioner (GP) conducts the review. Clinicians trained in asthma management achieve better outcomes for their patients.

A In primary care, people with asthma should be reviewed regularly by a nurse or doctor with appropriate training in asthma management. Review should incorporate a written action plan.

Audit the percentage of patients reviewed annually. Consider focusing on particular groups such as those overusing bronchodilators, patients on higher treatment steps, those with exacerbations or from groups with more complex needs.

Audit the percentage of patients receiving action plans. Consider focusing on subgroups listed above.

READ coding of patients who are newly diagnosed or register at a practice will ensure a meaningful database for audit and review purposes. Specifically identifying patients with high risk asthma (eg those with frequent admissions) in an effort to target more detailed input is logical but supported by limited evidence. Not all patients want regular review, or are willing to attend a pre-arranged appointment. Reviews carried out by telephone may be as effective as those using face-to-face consultations, but face-to-face review will be appropriate for some patients, such as those with poor asthma control or inhaler-related problems.

B Consider carrying out routine reviews by telephone for people with asthma.
Asthma clinics in primary care may be a convenient way of delivering care, but there is limited evidence that they themselves improve outcome. Most practices will provide asthma reviews as part of routine appointment sessions. It is what happens during the review consultation that matters. Audit that feeds back guidelines recommendations on the management of individual patients may improve outcomes.

**C** General practices should maintain a register of people with asthma.

**C** Clinical review should be structured and utilise a standard recording system.

**B** Feedback of audit data to clinicians should link guidelines recommendations to management of individual patients.

The ideal content of an asthma review consultation is uncertain. Discussion and provision of a written action plan leads to improved outcomes. Other activities likely to be important are reviewing understanding of medication role and use, checking inhaler technique, recording lung function. Structured review systems such as the Royal College of Physicians ‘Three Key Questions’, the Tayside Asthma Stamp, and the modified Jones Morbidity Index improve the recording of relevant data and may prompt a search for causes of suboptimal asthma control, such as under-treatment, poor adherence or poor inhaler technique. However, such tools can lead to a more physician-centred or template-directed consultation. Reviewing patients using a patient-centred style of consultation can lead to improved outcomes.

### 8.1.3 SHARED CARE

Shared care schemes have been shown to be effective in some healthcare environments. There are no UK studies directly comparing primary and secondary care management, but international work suggests there may be little difference: what is done would appear to be more important than who by or where. Integrated care schemes such as Grampian Asthma Study in Integrated Care (GRASSIC) suggest that place of care is not directly linked to clinical outcome. Shared care had a similar outcome to outpatient care. Outreach support for primary care by asthma specialist nurses may reduce unscheduled asthma care but only if targeted around follow-up of patients recently attending secondary care with exacerbations.

Community pharmacists trained in asthma care and teaching self management skills may improve asthma control, although evidence is sparse and inconsistent.

### 8.1.4 PATIENT SUBGROUPS

Ethnic subgroups have adverse clinical outcomes, including higher hospital admission and exacerbation rates. In some countries ethnic minority groups have higher death rates due to asthma than do their contemporaries. Minority groups describe poorer access to primary care and acute medical care, and compared with majority groups, have a higher use of emergency facilities for routine care. Educating primary care clinicians improves diagnosis, prescribing, education, and continuity of care for minority group children. There is an established link between poor socioeconomic status and adverse asthma outcome. Adolescents and the elderly are particularly vulnerable to the adverse effects of asthma. Adolescents and young adults make more frequent use of emergency asthma healthcare services, make less use of structured clinical review services than other age groups, and have high reliance on bronchodilators. Asthma in the elderly is a neglected area of research, despite high mortality and morbidity.

**D** Healthcare professionals who provide asthma care should have heightened awareness of the complex needs of ethnic minorities, socially disadvantaged groups, adolescents, the elderly and those with communication difficulties.

- Audit asthma outcomes in relevant subgroups of the population.
8.2 ACUTE EXACERBATIONS

People with asthma who experience deterioration in symptom control leading to an acute exacerbation can access a wide variety of sources of care. Few studies have looked at the relative merits of one type of service compared to another. Exceptions include a UK study showing a better outcome for patients managed by a specialist respiratory ward compared to a general medical ward, and a US study showing more favourable outcome in patients managed by specialist allergists compared to generalists.669,670

C Manage hospital inpatients with asthma in specialist rather than general units.

All services involved in the care of acute asthma should be staffed by appropriately trained personnel and have access to all the equipment needed to manage acute asthma.

Audit the percentage of inpatients receiving care from specialist asthma nurse or chest physician.

Models of care addressing access such as NHS Direct/NHS 24 produce similar outcomes to routine general practice, but have high referral rates and are unlikely to promote the continuity of care required for longer term management.671

A structured clinical assessment and a standardised recording system are associated with favourable outcome in acute exacerbations.672 Audit of the management of patients with acute asthma attacks is associated with improved concordance with recommended guidelines and in turn improved clinical outcome and reduced exacerbation rate.673-675

There is no evidence that the publication of guidelines per se improves care: clinicians need to link best practice to the management of individual patients. This effect is apparent in hospital and general practice care.447 Certain actions, for example early prescription of oral corticosteroids for acute exacerbations of asthma, reduce hospitalisation and relapse rates. Clinicians should refer to relevant chapters in this guideline for advice.

B Clinicians in primary and secondary care should treat asthma according to recommended guidelines.

Audit the percentage of patients treated according to key guideline recommendations.

Using acute asthma management protocols and clinical pathways can be beneficial and cost effective. Sub-optimal control of asthma leading to exacerbation is more expensive to manage than well controlled asthma.630 Early discharge schemes from hospital and emergency departments may be cost effective.445,676

The safety of telephone help lines has not been established. ‘Direct dial’ emergency admission schemes may be of benefit to a small group of patients with severe or ‘brittle’ asthma but there is insufficient evidence to justify their widespread introduction.677 Admission criteria are discussed elsewhere (see section 6.2.6).

Criteria for and timing of discharge from hospital and emergency departments has been studied. The key event in recovery appears to be improved symptoms and peak flow rather than a complete return to normality. Discharge when improvement is apparent may be as safe as discharge when full stability is achieved. Asthma specialist nurse education of adults and school-age (but not pre-school) children at or shortly after hospital attendance improves symptom control, self management and re-attendance rates.678-683

Making an appointment for review in primary care prior to discharge improves follow-up rates (but not outcomes).684 Review within 30 days after hospital attendance with acute asthma is associated with reduced risk of further acute episodes.685 There is most evidence of benefit when follow up is provided by specialist nurses. Various types of follow up after an acute exacerbation have been evaluated including GP care, hospital outpatient, and telephone follow up.680,686 There would appear to be little difference in outcome depending on place or personnel involved in follow up (see section 6.6).676
Discharge from hospital or the emergency department should be a planned, supervised event which includes self management planning. It may safely take place as soon as clinical improvement is apparent.

All people attending hospital with acute exacerbations of asthma should be reviewed by a clinician with particular expertise in asthma management, preferably within 30 days.

- Audit the percentage of people receiving specialist nurse advice including self management planning before discharge.
- Audit the percentage of people reviewed within 30 days after hospital attendance with acute exacerbation of asthma.

8.3 AUDIT

Audit is a moderately effective way to improve the process and probably outcome of care. Its impact is increased if combined with other strategies to change clinician behaviour, for example outreach education programmes. Whilst trials of audit in asthma care are few, those showing benefits have tended to incorporate feedback data to clinicians on the process of care such as frequency of review, checking of inhaler technique or lung function measurement. Passive feedback of aggregated data, for instance on prescribing patterns, does not change practice.

8.3.1 TYPES OF AUDIT IN ASTHMA CARE

National or regional audits of asthma deaths have focused attention on delivery of care for severe asthma. Some primary care trusts have PCT-wide programmes of audit which extract practice data electronically and feedback comparative data on process of care, promoting a benchmarking approach to quality improvement. The GMS Quality and Outcomes Framework (QOF) links audit of asthma care to financial incentives. Critical event audit focuses on an adverse event such as an asthma death, or failure of delivery care. How effective these activities are in improving outcomes of asthma care is uncertain.

Common sense suggests that auditing activities shown to improve patient outcomes is worthwhile. This chapter links suggestions for audit to guideline recommendations. Audit datasets are available at www.brit-thoracic.org.uk.

8.3.2 SUMMARY OF RECOMMENDED AUDITS

**Diagnosis**

Audit the percentage of adults with an Asthma Control Questionnaire score recorded and an Asthma Control Questionnaire of > 0.75.

**Non-pharmacological management**

Audit the percentage of patients and parents-to-be with smoking status recorded and the percentage who have received smoking cessation advice.

**Pharmacological management**

Audit:

- the percentage of patients with potential adverse effects of treatment, for example, the percentage of children prescribed or using > 800 micrograms/day of inhaled beclametasone who are not under the care of a specialist respiratory physician
- the percentage of patients in whom there has been documented consideration of downward dose titration for inhaled corticosteroid
- the percentage of patients using > 800 micrograms/day of inhaled beclametasone without documented consideration of add-on therapy
- the percentage of patients in whom there has been documented consideration of downward dose titration for inhaled corticosteroid.
Inhaler devices
Audit the percentage of patients in whom there is a record of satisfactory inhaler technique.
Audit the percentage of patients using a spacer device for mild to moderately severe exacerbations.

Management of acute asthma
Audit the percentage of patients in whom key steps in the management of acute asthma have been followed, for example, the percentage with a PEF measurement, the percentage with a justified X-ray on admission to hospital, or the percentage receiving corticosteroid tablets in adequate dosage and duration.

Asthma in pregnancy
Audit:
- the percentage of pregnant women with documented discussion of the need to continue β₂ agonists and inhaled corticosteroid medication in pregnancy
- the percentage of pregnant women and partners who smoke with documented advice on smoking cessation.

Occupational asthma
Audit the number of adults with adult-onset asthma for whom an occupational cause has been considered.

Organisation and delivery of care
Audit:
- the percentage of clinicians who have taken part in suitable asthma educational update within last two years
- the percentage of patients reviewed annually. Consider focusing on particular groups such as those overusing bronchodilators, patients on higher treatment steps, those with exacerbations or from groups with more complex needs
- asthma outcomes in relevant subgroups of the population
- the percentage of inpatients receiving care from specialist asthma nurse or chest physician
- the percentage of patients treated according to key guideline recommendations
- the percentage of people receiving specialist nurse advice including self management planning before discharge
- the percentage of people reviewed within 30 days after hospital attendance with acute exacerbation of asthma.

Patient education and self management
Audit the percentage of patients receiving written action plans.

Concordance and compliance
Audit prescription requests to determine compliance.
9 Patient education and self management

9.1 SELF-MANAGEMENT EDUCATION AND PERSONALISED ASTHMA ACTION PLANS

Written personalised action plans as part of self management education have been shown to improve health outcomes for people with asthma. The evidence is particularly good for those in secondary care with moderate to severe disease, and those who have had recent exacerbations where successful interventions have reduced hospitalisations and emergency department attendances in people with severe asthma. A consistent finding in many studies has been improvement in patient outcomes such as self-efficacy, knowledge and confidence.

A Patients with asthma should be offered self-management education that focuses on individual needs, and be reinforced by a written personalised action plan.

A Prior to discharge, in-patients should receive written personalised action plans, given by clinicians with expertise in asthma management.

9.1.1 COMPONENTS OF A SELF MANAGEMENT PROGRAMME

Self management education is a multi-faceted intervention with wide variation in the construction of programmes. One systematic review has identified key components associated with beneficial outcome (see Table 13). While self management programmes are effective, individual components are not effective in isolation reinforcing the need to support the provision of personalised action plans with patient education.

Successful programmes vary considerably, but encompass:

- Structured education, reinforced with written personal action plans, though the duration, intensity and format for delivery may vary.
- Specific advice about recognising loss of asthma control, though this may be assessed by symptoms or peak flows or both.
- Actions, summarised as two or three action points, to take if asthma deteriorates, including seeking emergency help, commencing oral steroids (which may include provision of an emergency course of steroid tablets) recommencing or temporarily increasing inhaled steroids, as appropriate to clinical severity.

Some published studies report long, intensive programmes. However, there is evidence that short programmes are as effective, and that usual care can be raised to a standard that incorporates many of the core elements of the successful extensive programmes.

A Introduce personalised action plans as part of a structured educational discussion.
Checklist 1. Suggested content for an educational programme/discussion

This checklist is intended as an example, which health professionals should adapt to meet the needs of individual patients and/or carers. The purpose of education is to empower patients and/or carers to undertake self management more appropriately and effectively. Information given should be tailored to individual patient’s social, emotional and disease status, and age. Different approaches are needed for different ages.

- Nature of the disease
- Nature of the treatment
- Identify areas where patient most wants treatment to have effect
- How to use the treatment
- Development of self monitoring/self assessment skills
- Negotiation of the personalised action plan in light of identified patient goals
- Recognition and management of acute exacerbations
- Appropriate allergen or trigger avoidance.

9.1.2 SELF MANAGEMENT PROGRAMMES IN SPECIFIC PATIENT GROUPS

A range of different patient populations are included in the trials. It cannot be assumed that a successful intervention in one setting will be feasible or appropriate in another. The greatest benefits are shown in those managed in secondary care. Primary care studies have also shown benefit though effects are weaker, perhaps because clinical benefit is harder to demonstrate in people with mild asthma. Innovative approaches to self management education in teenagers (web-based, peer delivered within schools) appear to have more success than more traditional programmes. A different approach may be needed for pre-school children, many of whom have viral induced wheeze. There are no studies which specifically address the provision of self-management education to the elderly. Sub group analyses from UK trials have suggested that existing self-management programmes may be of less benefit in ethnic minority groups, but there is a lack of studies evaluating more appropriate interventions.

Self management programmes will only achieve better health outcomes if the prescribed asthma treatment is appropriate and within guideline recommendations. There is some evidence that ownership of a self management plan may attract better treatment (ie increased steroid provision from attending physicians).

9.2 COMPLIANCE AND CONCORDANCE

The term compliance embodies a traditional model of prescriptive care which refers to the objectively measured usage of prescribed medication, or frequency of monitoring. Non-compliance may be intentional or unintentional. The term ‘concordance’ signifies a negotiated agreement between the professional and the patient. Non-concordance describes an inability of both parties to come to an understanding, not merely a failure of the patient to follow the health professional’s instructions. Studies which assess whether or not the patient believes that their behaviour is appropriate find correlations between beliefs about illness and medicine and concordance. Achieving concordance is likely to improve (though not guarantee) compliance.
9.2.1 COMPLIANCE WITH MONITORING AND TREATMENT

Compliance with regular monitoring with peak flow meters, even in clinical drug trials is poor, with recorded daily use as low as 6%.750,751 The lack of evidence supporting long term peak flow monitoring,647,735,752,753 however, does not negate the use of home charting at critical times: for example, at diagnosis and initial assessment, when assessing response to changes in treatment, as part of a personalised action plan during exacerbations.735 Comparison should be with the patients’ best peak flow (not predicted).730

Patients are more likely to under-use than over-use treatment754-756 and under-use should be considered when there is a failure to control asthma symptoms. Patient self reporting and healthcare professional assessment both overestimate regular use of prophylactic medication.754,755,757 Computer repeat-prescribing systems, widely available in general practice, provide a good indication of adherence with prescribed asthma regimens. Electronic monitoring, whilst the most accurate method, is only practical in clinical drug trials.754

- Computer repeat-prescribing systems provide a useful index of compliance.
- Where the patient agrees with the health professional that the action is appropriate compliance is more likely.

9.2.2 INTERVENTIONS TO IMPROVE COMPLIANCE AND CONCORDANCE

Compliance can be improved by simple written instructions and reminders of when to use medication.758 There is a suggestion in the literature that interventions designed to improve communication between patients and health professionals achieve better programme adherence.625,737,759 Presenting important information first and repeating it can improve patient recall.760 Computer,761 and innovative web-based self management programmes may increase use of regular medication.762 Within managed care programmes, nurse-led telephone-based self management education supported by written information can increase the use of inhaled steroids.763,764

- Provide simple, verbal and written instructions and information on drug treatment for patients and carers.

There is insufficient evidence to make clear recommendations on how the broader issues of concordance may be improved. Some practical tips for improving compliance are given in checklist 2.

Checklist 2: Practical tips for improving concordance

Open-ended questions like “If we could make one thing better for your asthma what would it be?” may help to elicit a more patient-centred agenda.

Make it clear you are listening and responding to the patient’s concerns and goals.

Reinforce practical information and negotiated treatment plans with written instruction.

Consider reminder strategies.

Recall patients who miss appointments.
9.3 IMPLEMENTATION IN PRACTICE

Successful interventions have been delivered by trained asthma healthcare professionals, in the UK usually doctors and nurses, though a quality improvement programme which trained professionals in asthma self management showed no impact on clinical outcomes.678,679,690,692,694,765

Three primary care studies explicitly link the provision of self management education with the facilitation of regular, structured review, consistent with the concept of ‘guided self management’. All three increased ownership of personalised action plans and one showed a reduction in episodes of ‘speech limiting wheeze’.631,741,766

B Initiatives which encourage regular, structured review explicitly incorporating self management education should be used to increase ownership of personalised action plans.

9.4 PRACTICAL ADVICE

9.4.1 AVAILABLE RESOURCES

A number of resources are available to support health professionals, including the ‘Be in Control’ materials produced by Asthma UK. Annex 11 reproduces the Asthma UK personalised action plan available from their website www.asthma.org.uk/control. Additional support and information for patients and carers is also available from the Asthma UK website (www.asthma.org.uk) and their Adviceline run by asthma specialist nurses: 08457 01 02 03 which includes an interpreting service covering 22 languages and Typetalk.

9.4.2 GOOD PRACTICE POINTS

Every asthma consultation is an opportunity to review, reinforce and extend both knowledge and skills. This is true whether the patient is seen in primary care, the accident and emergency department or the outpatient clinic. It is important to recognise that education is a process and not a single event.

A hospital admission represents a window of opportunity to review self management skills. No patient should leave hospital without a written personalised action plan and the benefit may be greatest at first admission.

An acute consultation offers the opportunity to determine what action the patient has already taken to deal with the exacerbation. Their self management strategy may be reinforced or refined and the need for consolidation at a routine follow up considered.

A consultation for an upper respiratory tract infection or other known trigger is an opportunity to rehearse with the patient their self management in the event of their asthma deteriorating.

Brief simple education linked to patient goals is most likely to be acceptable to patients.
Table 13. Summary of the key components of a personalised action plan (adapted from Gibson et al)\textsuperscript{730}

<table>
<thead>
<tr>
<th>Component of an action plan</th>
<th>Result</th>
<th>Practical considerations</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Format of action points:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Symptom vs peak flow triggered</td>
<td>Similar effect</td>
<td>Asthma UK action plans include both symptom triggers and peak flow levels at which action should be taken.</td>
</tr>
<tr>
<td>Standard written instructions</td>
<td>Consistently beneficial</td>
<td></td>
</tr>
<tr>
<td>Traffic light configuration</td>
<td>Not clearly better than standard instructions</td>
<td></td>
</tr>
<tr>
<td><strong>Number of action points</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2-3 action points</td>
<td>Consistently beneficial</td>
<td>Usual action points are:</td>
</tr>
<tr>
<td>4 action points</td>
<td>Not clearly better than 2-3 points</td>
<td>PEF &lt;80% best: increase inhaled steroids</td>
</tr>
<tr>
<td><strong>Peak expiratory flow (PEF) levels</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Based on percentage personal best PEF</td>
<td>Consistently beneficial</td>
<td>PEF &lt;60% best: commence oral steroids</td>
</tr>
<tr>
<td>Based on percentage predicted PEF</td>
<td>Not consistently better than usual care</td>
<td>PEF &lt;40% best: seek urgent medical advice</td>
</tr>
<tr>
<td><strong>Treatment instructions</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Individualised using inhaled and oral steroids</td>
<td>Consistently beneficial</td>
<td>Personal best should be assessed once treatment has been optimised and peak flows are stable.</td>
</tr>
<tr>
<td>Individualised using oral steroids only</td>
<td>Insufficient data to evaluate</td>
<td>Best peak flow should be updated every few years in adults, and more frequently in growing children.</td>
</tr>
<tr>
<td>Individualised using inhaled steroids</td>
<td>Insufficient data to evaluate</td>
<td></td>
</tr>
</tbody>
</table>

Patients may safely hold an emergency supply of prednisolone tablets for use if their symptoms continue to deteriorate and/or if their peak flow falls to 60% of their best. Increasing inhaled steroids is ineffective if patients are already taking moderate or high doses (\( \geq 400 \) mcg daily) and these patients should be advised to move straight to the oral steroid step. Those on low doses (eg 200 mcg) of inhaled steroids may be advised to increase the dose substantially (eg to 1,200 mcg daily) at the onset of a deterioration.\textsuperscript{631} Any patients who have stopped medication should be reminded to recommence their inhaled steroids.
Development of the guideline

10.1 INTRODUCTION

The guideline has been developed by multidisciplinary groups of practising clinicians using a standard methodology based on a systematic review of the evidence. Further details about SIGN and the guideline development methodology are contained in “SIGN 50: A Guideline Developer’s Handbook”, available at www.sign.ac.uk.

Development involved the work of ten different multidisciplinary evidence review groups, a steering group and an executive group, chaired jointly by Dr Bernard Higgins on behalf of the BTS and Dr Graham Douglas on behalf of SIGN.

All members of the guideline development group made declarations of interest and further details of these are available on request from the SIGN Executive. Guideline development and literature review expertise, support and facilitation were provided by the SIGN Executive.

10.2 EXECUTIVE AND STEERING GROUPS

Dr Graham Douglas* Consultant Respiratory Physician, Aberdeen Royal Infirmary (Co-chair)
Dr Bernard Higgins* Consultant Respiratory Physician, Freeman Hospital, Newcastle upon Tyne (Co-chair)
Professor Neil Barnes Consultant Respiratory Physician, Barts and The London NHS Trust
Dr Anne Boyter Senior Lecturer, Strathclyde Institute of Pharmacy and Biomedical Sciences, Glasgow
Professor Sherwood Burge Consultant Respiratory Physician, Birmingham Heartlands Hospital
Dr Chris Cates* Senior Research Fellow, St George’s, University of London
Dr Gary Connett Consultant Paediatrician, Southampton General Hospital
Dr Jon Couriel* Consultant in Paediatric Respiratory Medicine, Alder Hey Children’s Hospital, Liverpool
Dr Paul Cullinan Consultant Physician/Reader, Imperial College, London
Mrs Sheila Edwards* Chief Executive, British Thoracic Society, London
Ms Erica Evans Asthma Care Development Manager, Asthma UK, London
Ms Monica Fletcher Chief Executive, Education for Health, Warwick
Professor Chris Griffiths Professor of Primary Care, Institute of Health Science Education, London
Dr Liam Heaney Senior Lecturer in Respiratory Medicine, Queen’s University, Belfast
Ms Michele Hilton Boon* Information Officer, SIGN Executive
Dr Steve Holmes General Practitioner and Chair, General Practice Airways Group, Somerset
Mrs Ruth McArthur Practice Nurse/National Training Co-ordinator, Education for Health, East Kilbride
Dr Cathy Nelson-Piercy Consultant Obstetric Physician, St Thomas’ Hospital, London
Professor Martyn Partridge* Professor of Respiratory Medicine, Imperial College, London and Chief Medical Adviser, Asthma UK
Dr James Paton* Reader and Honorary Consultant Paediatrician, Royal Hospital for Sick Children, Glasgow
10.3 EVIDENCE REVIEW GROUPS

DIAGNOSIS

Dr Jon Couriel  
(Chair)  
Consultant in Paediatric Respiratory Medicine,  
Royal Liverpool Children’s Hospital

Dr James Paton  
(Chair)  
Reader and Honorary Consultant Paediatrician,  
Royal Hospital for Sick Children, Glasgow

Professor Ian Pavord  
(Chair)  
Consultant Physician/Honorary Professor of Medicine,  
Glenfield Hospital, Leicester

Professor Justin Beilby  
Head of the Department of General Practice,  
University of Adelaide, Australia

Professor Anne Chang  
Head of Child Health Division, Menzies School of Health Research, Darwin and Royal Children’s Hospital,  
Brisbane, Australia

Dr Peter Gibson  
Adult Respiratory Physician, John Hunter Chest Institute,  
Brisbane, Australia

Professor Peter Helms  
Professor of Child Health, University of Aberdeen

Dr Bernard Higgins  
Consultant Respiratory Physician, Freeman Hospital,  
Newcastle upon Tyne

Mrs Ruth McArthur  
Practice Nurse/National Training Co-ordinator,  
Education for Health, East Kilbride

Dr Sarah Mayell  
Specialist Registrar, Alder Hey Hospital, Liverpool

Dr Dominick Shaw  
Specialist Registrar, City Hospital Campus, Nottingham

Dr Mike Thomas  
Asthma UK Senior Research Fellow, University of Aberdeen/  
General Practitioner, Gloucestershire

NON-PHARMACOLOGICAL MANAGEMENT

Dr Paul Cullinan  
(Chair)  
Reader in Occupational and Environmental Lung Disease,  
Royal Brompton Hospital, London

Professor John Warner  
(Chair)  
Professor of Paediatrics and Head of Department,  
Imperial College, London

Dr David Bellamy  
General Practitioner, Bournemouth and Poole Primary Care Trust

Dr Graham Devereux  
Consultant in Thoracic Medicine, Aberdeen Royal Infirmary

Dr David Reilly  
Lead Consultant Physician,  
Glasgow Homoeopathic Hospital
PHARMACOLOGICAL MANAGEMENT

Professor Neil Barnes  
(Chair)  
Professor Mike Shields  
(Co-chair)  
Dr Anne Boyter  
Dr Steve Cunningham  
Dr Graeme Currie  
Ms Grainne d’Ancona  
Dr Mike McKeen  
Ms Linda Pearce  
Dr Savitha Pushparajah  
Dr Mike Smith  
Dr David Spencer  
Dr Alison Whittaker

INHALER DEVICES

Dr John White (Chair)  
Dr Chris Cates  
Sr Karen Heslop  
Dr Alex Horsley

MANAGEMENT OF ACUTE ASTHMA

Dr Gary Connett  
(Chair)  
Professor Colin Robertson  
(Chair)  
Dr Richard Chavasse  
Dr Mike Greenstone  
Dr Nick Innes  
Dr Mark Levy  
Dr Rob Niven
Dr Ronan O’Driscoll  
Respiratory Physician, Hope Hospital, Salford

Dr Peter Weller  
Consultant Paediatrician (Respiratory Medicine),  
Birmingham Children’s Hospital

DELIVERY/ ORGANISATION OF CARE

Professor Chris Griffiths  
Professor of Primary Care, Institute of Health Science  
Education, London

Ms Monica Fletcher  
Chief Executive, Education for Health, Warwick

Professor David Price  
GPIAG Professor of Primary Care Respiratory Medicine,  
Foresterhill Health Centre, Aberdeen

Dr Richard Russell  
Consultant Physician, Heatherwood and Wexham Park Hospitals, Berkshire

PATIENT EDUCATION, SELF MANAGEMENT AND COMPLIANCE

Dr Hilary Pinnock (Chair)  
General Practitioner, Whitstable Medical Practice, Kent

Dr Graham Douglas  
Consultant Respiratory Physician, Aberdeen Royal Infirmary

Mrs Erica Evans  
Care Development Manager, Asthma UK, London

Dr Liesl Osman  
Senior Research Fellow, Aberdeen Royal Infirmary

SPECIAL SITUATIONS

**Difficult asthma**

Dr Liam Heaney (Chair)  
Senior Lecturer in Respiratory Medicine,  
Queens University, Belfast

Dr Chris Brightling  
Senior Clinical Research Fellow,  
Glenfield Hospital, Leicester

Dr Andrew Menzies-Gow  
Consultant Respiratory Physician, Royal Brompton Hospital, London

Dr Brian Smith  
South Australian State President of the Thoracic Society of Australia

Dr Nicola Wilson  
Honorary Consultant Paediatrician,  
Royal Brompton Hospital, London

**Asthma in pregnancy**

Dr Cathy Nelson-Piercy (Chair)  
Consultant Obstetric Physician,  
St Thomas’ Hospital, London

Dr Graham Douglas  
Consultant Respiratory Physician, Aberdeen Royal Infirmary

Dr Bernard Higgins  
Consultant Respiratory Physician, Freeman Hospital,  
Newcastle upon Tyne

Mrs Ruth McArthur  
Practice Nurse/National Training Co-ordinator Education for Health, East Kilbride

**Occupational asthma**

Dr Sherwood Burge (Chair)  
Consultant Respiratory Physician, Birmingham  
Heartlands Hospital

Professor Anthony Frew  
Professor of Allergy and Respiratory Medicine,  
Brighton General Hospital
10.4 DISSEMINATION GROUP

Professor Martyn Partridge  
(Chair)  
Professor of Respiratory Medicine, Imperial College, London  
and Chief Medical Adviser, Asthma UK

Mrs Sheila Edwards  
Chief Executive, British Thoracic Society, London

Ms Monica Fletcher  
Chief Executive, Education for Health, Warwick

Dr Bernard Higgins  
Consultant Respiratory Physician, Freeman Hospital, Newcastle upon Tyne

Dr Steve Holmes  
General Practitioner and Chair, General Practice Airways Group, Somerset

Dr James Paton  
Reader and Honorary Consultant Paediatrician, Royal Hospital for Sick Children, Glasgow

Dr Hilary Pinnock  
General Practitioner, Whitstable Medical Practice, Kent

Dr Safia Qureshi  
Programme Director, SIGN

Mrs Sally Welham  
Deputy Chief Executive, British Thoracic Society, London

10.5 SYSTEMATIC LITERATURE REVIEW

The evidence base for this guideline built on the reviews carried out for the original (2003) version of the guideline and subsequent updates. The specific areas updated in this version of the guideline were:

- Non-pharmacological management
- Paediatric diagnosis
- Pharmacological management
- Difficult asthma.

All searches covered the Cochrane Library, Embase, and Medline. The time period covered depended on the topic, but all were brought up to date for the beginning of 2007. A copy of the search narrative, including listings of strategies, is available on the SIGN website as part of the supporting material for this guideline.

10.6 CONSULTATION AND PEER REVIEW

10.6.1 CONSULTATION

The most recent changes to this guideline were presented for discussion in draft form at the Winter Meeting of the British Thoracic Society in December 2007. The draft guideline was also available on the SIGN and BTS websites for a limited period at this stage to allow those unable to attend the meeting to contribute to the development of the guideline.
10.6.2 SPECIALIST REVIEWERS

The guideline was also reviewed in draft form by the following independent expert referees, who were asked to comment primarily on the comprehensiveness and accuracy of interpretation of the evidence base supporting the recommendations in the guideline. SIGN and the BTS are very grateful to all of these experts for their contribution to the guideline.

Dr Sandra Anderson  
Principal Hospital Scientist, Royal Prince Alfred Hospital, Sydney, Australia

Professor Richard Beasley  
Professor of Medicine, Medical Research Institute of New Zealand, Wellington

Mr Michael Dennis  
Deputy Head of Prescribing, Great Yarmouth and Waveney (Teaching) PCT, Suffolk

Dr Kevin Gruffydd-Jones  
Education Member, General Practice Airways Group and General Practitioner, Box Surgery, Wiltshire

Dr John Haughney  
General Practitioner, Alison Lea Medical Centre, East Kilbride

Miss Tracy Horner  
Medicines Management Technician, Bexhill Hospital, East Sussex

Dr Norman Johnson  
Chairman of the BTS Standards of Care Committee, British Thoracic Society, London

Dr Duncan Keely  
General Practitioner, Thame Health Centre, Oxon

Professor Helen Redell  
Clinical Associate Professor, University of Sydney, Australia

Dr Robert Scott-Jupp  
Consultant Paediatrician, Salisbury District Hospital, Salisbury

Professor Anne Tattersfield  
Head of Respiratory Medicine, University of Nottingham

Professor Neil C Thomson  
Professor of Respiratory Medicine, Gartnavel General Hospital, Glasgow

Dr Mark Woodhead  
Consultant in General and Respiratory Medicine, Central Manchester and Manchester Children’s University Hospitals
Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABG</td>
<td>arterial blood gas</td>
</tr>
<tr>
<td>ABPA</td>
<td>allergic bronchopulmonary aspergillosis</td>
</tr>
<tr>
<td>ACT</td>
<td>Asthma Control Test</td>
</tr>
<tr>
<td>ACTH</td>
<td>adrenocorticotropic hormone</td>
</tr>
<tr>
<td>AQLQ</td>
<td>Asthma Quality of Life Questionnaire</td>
</tr>
<tr>
<td>BDP</td>
<td>beclometasone</td>
</tr>
<tr>
<td>BTS</td>
<td>British Thoracic Society</td>
</tr>
<tr>
<td>COPD</td>
<td>chronic obstructive pulmonary disease</td>
</tr>
<tr>
<td>CXR</td>
<td>chest X-ray</td>
</tr>
<tr>
<td>DPI</td>
<td>dry powder inhaler</td>
</tr>
<tr>
<td>ED</td>
<td>emergency department</td>
</tr>
<tr>
<td>ETS</td>
<td>environmental tobacco smoke</td>
</tr>
<tr>
<td>FENO</td>
<td>exhaled nitric oxide concentration</td>
</tr>
<tr>
<td>FEV₁</td>
<td>forced expiratory volume in one second</td>
</tr>
<tr>
<td>FVC</td>
<td>forced vital capacity</td>
</tr>
<tr>
<td>GMS</td>
<td>General Medical Services</td>
</tr>
<tr>
<td>GP</td>
<td>general practitioner</td>
</tr>
<tr>
<td>GRASSIC</td>
<td>Grampian Asthma Study in Integrated Care</td>
</tr>
<tr>
<td>HDU</td>
<td>high dependency unit</td>
</tr>
<tr>
<td>ICU</td>
<td>intensive care unit</td>
</tr>
<tr>
<td>IM</td>
<td>intramuscular</td>
</tr>
<tr>
<td>IOS</td>
<td>impulse oscillometry</td>
</tr>
<tr>
<td>LABA</td>
<td>long-acting $\beta_2$ agonist</td>
</tr>
<tr>
<td>MDI</td>
<td>metered dose inhaler</td>
</tr>
<tr>
<td>MHRA</td>
<td>Medicines and Healthcare products Regulatory Agency</td>
</tr>
<tr>
<td>n-3PUFA</td>
<td>omega-3 polyunsaturated fatty acid</td>
</tr>
<tr>
<td>NIV</td>
<td>non-invasive ventilation</td>
</tr>
<tr>
<td>PaCO₂</td>
<td>partial pressure of carbon dioxide in arterial blood</td>
</tr>
<tr>
<td>PaO₂</td>
<td>partial pressure of oxygen in arterial blood</td>
</tr>
<tr>
<td>PC₂₀</td>
<td>the provocative concentration of bronchoconstrictor (eg methacholine) required to cause a 20% fall in FEV₁</td>
</tr>
<tr>
<td>PD₂₀</td>
<td>the provocative dose of bronchoconstrictor (eg methacholine) required to cause a 20% fall in FEV₁</td>
</tr>
<tr>
<td>PEF</td>
<td>peak expiratory flow</td>
</tr>
<tr>
<td>PEF A%H</td>
<td>peak expiratory flow amplitude percent highest</td>
</tr>
<tr>
<td>PICU</td>
<td>paediatric intensive care unit</td>
</tr>
<tr>
<td>PN</td>
<td>practice nurse</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Description</td>
</tr>
<tr>
<td>--------------</td>
<td>-------------</td>
</tr>
<tr>
<td>ppb</td>
<td>parts per billion</td>
</tr>
<tr>
<td>QOF</td>
<td>Quality and Outcomes Framework</td>
</tr>
<tr>
<td>RCP</td>
<td>Royal College of Physicians</td>
</tr>
<tr>
<td>RCT</td>
<td>randomised controlled trial</td>
</tr>
<tr>
<td>RV</td>
<td>residual volume</td>
</tr>
<tr>
<td>SIGN</td>
<td>Scottish Intercollegiate Guidelines Network</td>
</tr>
<tr>
<td>SpO(_2)</td>
<td>saturation of peripheral oxygen</td>
</tr>
<tr>
<td>sRaw</td>
<td>specific airways resistance</td>
</tr>
<tr>
<td>VEmax</td>
<td>ventilation at maximal exercise capacity</td>
</tr>
</tbody>
</table>
Annex 1

Summary of search histories by section

Literature searches to support the various sections of this guideline are conducted on a rolling basis. This summary indicates the currency of the searches supporting each section. Searches in all databases began with the earliest year available at that time, which varied from database to database; for example, searches in Embase extended back to 1980 and in CINAHL to 1982. Specific date coverage is provided for Medline. Detailed search strategies are available on the SIGN website in the supplementary material section. Sections that have not been updated since 2006 will be the subject of renewed searches in 2008-09, after which the guideline will be updated on line.

Section 2 Diagnosis

Diagnosis in children
The search was last updated in April 2007. Coverage in Medline extends from 2003-2006. This search supplemented the broader search on diagnosis conducted for the original 2003 diagnosis section.

Diagnosis in adults; monitoring
The search was last updated in February 2006. Coverage in Medline extends from 1966-2005.

Section 3 Non-pharmacological management
The search was last updated in February 2006. Coverage in Medline extends from 1966-2005.

Section 4 Pharmacological management

Section 5 Inhaler devices

Section 6 Management of acute asthma

Section 7 Special situations

Difficult asthma
The search was conducted in July 2007 and covered 1996-June 2007.

Asthma in pregnancy

Occupational asthma
The search was last updated by SIGN in March 2003. In 2005, a systematic review by the British Occupational Health Research Foundation was used as the basis for updating this section.

Section 8 Organisation and delivery of care, and audit
The search was last updated in March 2003. Coverage in Medline extends from 1966-2003.

Section 9 Patient education and self management
The search was last updated in February 2006. Coverage in Medline extends from 1966-2005.
**Annex 2**

### Management of acute severe asthma in adults in general practice

Many deaths from asthma are preventable. Delay can be fatal. Factors leading to poor outcome include:
- Clinical staff. Failing to assess severity by objective measurement
- Patients or relatives failing to appreciate severity
- Under-use of corticosteroids

Regard each emergency asthma consultation as for acute severe asthma until shown otherwise.

#### Moderate asthma
- PEF >50% best or predicted
- Speech normal
- Respiration <25 breaths/min
- Pulse <110 beats/min

#### Acute severe asthma
- PEF 33-50% best or predicted
- Can’t complete sentences
- Respiration ≥25 breaths/min
- Pulse ≥110 beats/min
- SpO2 <92%
- Silent chest, cyanosis or feeble respiratory effort
- Bradycardia, dysrhythmia or hypotension
- Exhaustion, confusion or coma

#### Life threatening asthma
- PEF <33% best or predicted
- SpO2 <92%

### Assess and record:
- Peak expiratory flow (PEF)
- Symptoms and response to self treatment
- Heart and respiratory rates
- Oxygen saturation (by pulse oximetry, if available)

**Caution:** Patients with severe or life-threatening attacks may not be distressed and may not have all the abnormalities listed below. The presence of any should alert the doctor.

### INITIAL ASSESSMENT

<table>
<thead>
<tr>
<th>Moderate asthma</th>
<th>Acute severe asthma</th>
<th>Life threatening asthma</th>
</tr>
</thead>
<tbody>
<tr>
<td>PEF &gt;50% best or predicted</td>
<td>PEF 33-50% best or predicted</td>
<td>PEF &lt;33% best or predicted</td>
</tr>
</tbody>
</table>

### FURTHER ASSESSMENT

#### Treat at home or in surgery and ASSESS RESPONSE TO TREATMENT
- High-dose \(\beta_2\) bronchodilator:
  - Via oxygen-driven nebuliser (salbutamol 5 mg or terbutaline 10 mg)
  - Or via spacer (4-10 puffs [given one at a time single puffs, tidal breathing and inhaled separately] repeated at intervals of 10-20 minutes) or air-driven nebuliser
  - If PEF >50-75% predicted/best:
  - Give prednisolone 40-50 mg
  - Continue or step up usual treatment

#### Consider admission
- Oxygen 40-60% if available
- High-dose \(\beta_2\) bronchodilator:
  - Via oxygen-driven nebuliser (salbutamol 5 mg or terbutaline 10 mg)
  - Or via spacer (4-10 puffs [given one at a time single puffs, tidal breathing and inhaled separately] repeated at intervals of 10-20 minutes)
  - Prednisolone 40-50 mg or IV hydrocortisone 100 mg
  - If no response in acute severe asthma: ADMIT

#### Arrange immediate ADMISSION
- Oxygen 40-60%
- Prednisolone 40-50 mg or IV hydrocortisone 100 mg immediately
- High dose \(\beta_2\) bronchodilator and ipratropium:
  - Via oxygen-driven nebuliser (salbutamol 5 mg or terbutaline 10 mg) and ipratropium 0.5mg
  - Or via spacer (4-10 puffs [given one at a time single puffs, tidal breathing and inhaled separately] repeated at intervals of 10-20 minutes)

### MANAGEMENT

#### TREATMENT
- Admit to hospital if any:
  - life threatening features
  - features of acute severe asthma present after initial treatment
  - previous near-fatal asthma
  - Lower threshold for admission if afternoon or evening attack, recent nocturnal symptoms or hospital admission, previous severe attacks, patient unable to assess own condition, or concern over social circumstances.

- If admitting the patient to hospital:
  - Stay with patient until ambulance arrives
  - Send written assessment and referral details to hospital
  - Give high-dose \(\beta_2\) bronchodilator via oxygen-driven nebuliser in ambulance

- Follow up after treatment or discharge from hospital:
  - GP review within 48 hours
  - Monitor symptoms and PEF
  - Check inhaler technique
  - Written asthma action plan
  - Modify treatment according to guidelines for chronic persistent asthma
  - Address potentially preventable contributors to admission
Annex 3

Management of severe acute asthma in adults in Emergency Department

<table>
<thead>
<tr>
<th>Time</th>
<th>PEF &gt; 75% best or predicted</th>
<th>PEF 33-75% best or predicted</th>
<th>PEF &lt; 33% best or predicted</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>mild</td>
<td>moderate - severe</td>
<td>OR any life threatening features:</td>
</tr>
<tr>
<td>5 mins</td>
<td>Give usual bronchodilator</td>
<td>features of severe asthma</td>
<td>• SpO₂ &lt; 92%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• PEF &lt; 50% best or predicted</td>
<td>• Silent chest, cyanosis, poor</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Respiration ≥ 25/min</td>
<td>respiratory effort</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Pulse ≥ 110 breaths/min</td>
<td>• Bradycardia, arrhythmia,</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Cannot complete sentence</td>
<td>hypotension</td>
</tr>
<tr>
<td></td>
<td></td>
<td>in one breath</td>
<td>• Exhaustion, confusion, coma</td>
</tr>
<tr>
<td>15-20 mins</td>
<td>Clinically stable</td>
<td>No life threatening features AND PEF &gt; 50%</td>
<td>Obtain senior/ICU help now if any life threatening features are present</td>
</tr>
<tr>
<td></td>
<td>AND PEF &gt; 75%</td>
<td></td>
<td>IMMEDIATE MANAGEMENT</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• High concentration oxygen</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>(&gt;80% if possible)</td>
</tr>
<tr>
<td></td>
<td>Repeat salbutamol 5 mg nebuliser</td>
<td></td>
<td>• Give salbutamol 5 mg plus</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>ipratropium 0.5 mg via oxygen-driven nebuliser</td>
</tr>
<tr>
<td></td>
<td>Give prednisolone 40-50 mg orally</td>
<td></td>
<td>• AND prednisolone 40-50 mg</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>orally or IV hydrocortisone</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>100 mg</td>
</tr>
<tr>
<td>60 mins</td>
<td>Patient recovering AND PEF &gt; 75%</td>
<td>Signs of severe asthma</td>
<td>Measure arterial blood gases</td>
</tr>
<tr>
<td></td>
<td></td>
<td>OR PEF &lt; 50%</td>
<td>Markers of severity:</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Normal or raised PaCO₂</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>(PaCO₂ &gt; 4.6 kPa; 35 mmHg)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Severe hypoxia</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>(PaO₂ &lt; 8 kPa; 60 mmHg)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Low pH (or high H+ )</td>
</tr>
<tr>
<td>120 mins</td>
<td>Patient stable AND PEF &gt; 50 %</td>
<td>Signs of severe asthma</td>
<td>• Give/repeat salbutamol 5 mg</td>
</tr>
<tr>
<td></td>
<td></td>
<td>OR PEF &lt; 50%</td>
<td>with ipratropium 0.5 mg via</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>oxygen-driven nebuliser</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>after 15 minutes</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Consider continuous salbutamol</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>nebuliser 5-10 mg/hr</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Consider IV magnesium sulphate</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>1.2-2 g over 20 minutes</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Correct fluid/electrolytes, especially K⁺ disturbances</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Chest X-ray</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>ADMIT</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Patient accompanied by a nurse or doctor at all times</td>
</tr>
</tbody>
</table>

POTENTIAL DISCHARGE
- In all patients who received nebulised β₂ agonists prior to presentation, consider an extended observation period prior to discharge.
- If PEF < 50% on presentation, give prednisolone 40-50 mg/day for 5 days.
- In all patients ensure treatment supply of inhaled steroid and β₂ agonist and check inhaler technique.
- Arrange GP follow up 2 days post-discharge.
- Fax discharge letter to GP.
- Refer to asthma liaison nurse/chest clinic.

Peak expiratory flow in normal adults
Annex 4

Management of acute severe asthma in adults in hospital

**Features of acute severe asthma**

- Peak expiratory flow (PEF) 33-50% of best (use % predicted if recent best unknown)
- Can’t complete sentences in one breath
- Respirations ≥ 25 breaths/min
- Pulse ≥ 110 beats/min

**Life threatening features**

- PEF < 33% of best or predicted
- SpO₂ < 92%
- Silent chest, cyanosis, or feeble respiratory effort
- Bradycardia, dysrhythmia, or hypotension
- Exhaustion, confusion, or coma

**If a patient has any life threatening feature, measure arterial blood gases. No other investigations are needed for immediate management.**

**Blood gas markers of a life threatening attack:**

- Normal (4.6-6 kPa, 35-45 mmHg) PaCO₂
- Severe hypoxia: PaCO₂ < 8 kPa (60 mmHg) irrespective of treatment with oxygen
- A low pH (or high H⁺)

**Caution:** Patients with severe or life threatening attacks may not be distressed and may not have all these abnormalities. The presence of any should alert the doctor.

**Near fatal asthma**

- Raised PaCO₂
- Requiring mechanical ventilation with raised inflation pressures

**Peak expiratory flow in normal adults**

<table>
<thead>
<tr>
<th>Age in Years</th>
<th>WOMEN</th>
<th>MEN</th>
</tr>
</thead>
<tbody>
<tr>
<td>5-6</td>
<td>57</td>
<td>60</td>
</tr>
<tr>
<td>7-8</td>
<td>57</td>
<td>63</td>
</tr>
<tr>
<td>9-10</td>
<td>57</td>
<td>66</td>
</tr>
<tr>
<td>11-12</td>
<td>57</td>
<td>69</td>
</tr>
<tr>
<td>13-14</td>
<td>57</td>
<td>75</td>
</tr>
<tr>
<td>15-16</td>
<td>57</td>
<td>152</td>
</tr>
</tbody>
</table>

**IMMEDIATE TREATMENT**

- Oxygen 40-60% (CO₂ retention is not usually aggravated by oxygen therapy in asthma)
- Salbutamol 5 mg or terbutaline 10 mg via an oxygen-driven nebuliser
- Ipratropium bromide 0.5 mg via an oxygen-driven nebuliser
- Prednisolone tablets: 40-50 mg or IV hydrocortisone 100 mg or both if very ill
- No sedatives of any kind
- Chest X ray if pneumothorax or consolidation are suspected or patient requires mechanical ventilation

**IF LIFE THREATENING FEATURES ARE PRESENT:**

- Discuss with senior clinician and ICU team
- Add IV magnesium sulphate 1.2-2 g infusion over 20 minutes (unless already given)
- Give nebulised β₂ agonist more frequently e.g. salbutamol 5 mg up to every 15-30 minutes or 10 mg continuously hourly

**SUBSEQUENT MANAGEMENT**

**IF PATIENT IS IMPROVING continue:**

- 40-60% oxygen
- Prednisolone 40-50mg daily or IV hydrocortisone 100 mg 6 hourly
- Nebulised β₂ agonist and ipratropium 4-6 hourly

**IF PATIENT NOT IMPROVING AFTER 15-30 MINUTES:**

- Give nebulised β₂ agonist more frequently e.g. salbutamol 5 mg up to every 15-30 minutes or 10 mg continuously hourly
- Continue ipratropium 0.5 mg 4-6 hourly until patient is improving

**IF PATIENT IS STILL NOT IMPROVING:**

- Discuss patient with senior clinician and ICU team
- IV magnesium sulphate 1.2-2 g over 20 minutes (unless already given)
- Senior clinician may consider use of IV β₂ agonist or IV aminophylline or progression to mechanical ventilation

**MONITORING**

- Repeat measurement of PEF 15-30 minutes after starting treatment
- Oximetry: maintain SpO₂ > 92%
- Repeat blood gas measurements within 2 hours of starting treatment if:
  - initial PaO₂ < 8 kPa (60 mmHg) unless subsequent SpO₂ > 92%
  - PaCO₂ normal or raised
  - patient deteriorates
- Chart PEF before and after giving β₂ agonists and at least 4 times daily throughout hospital stay

**DISCHARGE**

**When discharged from hospital, patients should have:**

- Been on discharge medication for 24 hours and have had inhaler technique checked and recorded
- PEF > 75% of best or predicted and PEF diurnal variability < 25% unless discharge is agreed with respiratory physician
- Treatment with oral and inhaled steroids in addition to bronchodilators
- Own PEF meter and written asthma action plan
- GP follow up arranged within 2 working days
- Follow up appointment in respiratory clinic within 4 weeks

Patients with severe asthma (indicated by need for admission) and adverse behavioural or psychosocial features are at risk of further severe or fatal attacks

- Determine reason(s) for exacerbation and admission
- Send details of admission, discharge and potential best PEF to GP
### Management of acute asthma in children in general practice

#### Age 2-5 years

<table>
<thead>
<tr>
<th>ASSESS ASTHMA SEVERITY</th>
<th>Life-threatening asthma</th>
</tr>
</thead>
<tbody>
<tr>
<td>Moderate exacerbation</td>
<td>- SpO₂ &lt; 92%</td>
</tr>
<tr>
<td></td>
<td>- Too breathless to talk</td>
</tr>
<tr>
<td></td>
<td>- Heart rate &gt; 130/min</td>
</tr>
<tr>
<td></td>
<td>- Respiratory rate &gt; 50/min</td>
</tr>
<tr>
<td></td>
<td>- Cyanosis</td>
</tr>
</tbody>
</table>

#### Age > 5 years

<table>
<thead>
<tr>
<th>ASSESS ASTHMA SEVERITY</th>
<th>Life-threatening asthma</th>
</tr>
</thead>
<tbody>
<tr>
<td>Moderate exacerbation</td>
<td>- PEF &lt; 50% best or predicted</td>
</tr>
<tr>
<td></td>
<td>- Too breathless to talk</td>
</tr>
<tr>
<td></td>
<td>- Heart rate &gt; 120/min</td>
</tr>
<tr>
<td></td>
<td>- Respiratory rate &gt; 30/min</td>
</tr>
<tr>
<td></td>
<td>- Cyanosis</td>
</tr>
</tbody>
</table>

#### ASSESS ASTHMA SEVERITY

- **Moderate exacerbation**
  - SpO₂ ≥ 92%
  - Able to talk
  - Heart rate ≤ 130/min
  - Respiratory rate ≤ 30/min
- **Severe exacerbation**
  - SpO₂ < 92%
  - Too breathless to talk
  - Heart rate > 130/min
  - Respiratory rate > 50/min
  - Use of accessory neck muscles
- **Life-threatening asthma**
  - SpO₂ < 92% plus any of:
    - Silent chest
    - Poor respiratory effort
    - Agitation
    - Altered consciousness
    - Cyanosis

#### IF POOR RESPONSE

**ARRANGE ADMISSION**

<table>
<thead>
<tr>
<th>GOOD RESPONSE</th>
<th>POOR RESPONSE</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>IF POOR RESPONSE</strong></td>
<td><strong>ARRANGE ADMISSION</strong></td>
</tr>
<tr>
<td><strong>β₂ agonist 4-6 puffs via spacer or nebuliser</strong></td>
<td><strong>β₂ agonist 4-6 puffs via spacer or nebuliser</strong></td>
</tr>
<tr>
<td><strong>β₂ agonist and arrange admission</strong></td>
<td><strong>β₂ agonist and arrange admission</strong></td>
</tr>
<tr>
<td><strong>Reteat β₂ agonist via oxygen-driven nebuliser whilst arranging immediate hospital admission</strong></td>
<td><strong>Reteat β₂ agonist via oxygen-driven nebuliser whilst arranging immediate hospital admission</strong></td>
</tr>
</tbody>
</table>

#### IF POOR RESPONSE REPEAT

**β₂ agonist via oxygen-driven nebuliser whilst arranging immediate hospital admission**

**IF POOR RESPONSE ARRANGE ADMISSION**

- **Good response**
  - Continue β₂ agonist via spacer or nebuliser, as needed but not exceeding 4-hourly
  - If symptoms are not controlled, repeat β₂ agonist and refer to hospital
  - Arrange follow-up clinic visit
- **Poor response**
  - Stop patient until ambulance arrives
  - Send written assessment and referral details
  - Repeat β₂ agonist via oxygen-driven nebuliser in ambulance

#### LOWER THRESHOLD FOR ADMISSION IF:

- Attack in late afternoon or at night
- Recent hospital admission or previous severe attack
- Concern over social circumstances or ability to cope at home

**NB:** If a patient has signs and symptoms across categories, always treat according to their most severe features
Annex 6

Management of acute asthma in children in Emergency Department

ASSIST ANASTHMA SEVERITY
Age ≤ 5 years
Oxygen via
Severe exacerbation
≥
P  prednisolone 20 mg/kg
magnesium sulphate Bolus IV in
review inhaler technique

Continuous (Suppl IV): iv
Tamol infusion
R 5 mg/kg loading dose over
20 minutes (omit in the
case of inhaled steroid
failure)

Assess response to treatment
Reassess repeat bronchodilators
up to every 0-30 minutes according to
symptoms across categories,
respiratory rate >30/min
irritable
EF%
<92% plus any of:
PEF
<92% per attack
FEV1 <50% for age
Moderate exacerbation
Severe exacerbation
Asthma attack
Asthma Life threatening
**Management of acute asthma in infants aged <2 years in hospital**

**ASSESS ASTHMA SEVERITY**

**NB:** If a patient has signs and symptoms across categories, always treat according to their most severe features

<table>
<thead>
<tr>
<th>Severe</th>
<th>Moderate</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>SpO₂</em> &lt; 92%</td>
<td><em>SpO₂</em> ≥ 92%</td>
</tr>
<tr>
<td>Cyanosis</td>
<td>Audible wheezing</td>
</tr>
<tr>
<td>Marked respiratory distress</td>
<td>Using accessory muscles</td>
</tr>
<tr>
<td>Too breathless to feed</td>
<td>Still feeding</td>
</tr>
</tbody>
</table>

Most infants are audibly wheezy with intercostal recession but not distressed

Life threatening features include apnoea, bradycardia and poor respiratory effort

**Immediate management**

Oxygen via close fitting face mask or nasal prongs to achieve normal saturations

Give trial of β₂ agonist: salbutamol up to 10 puffs via spacer and face mask or nebulised salbutamol 2.5 mg or nebulised terbutaline 5 mg

Repeat β₂ agonist every 1-4 hours if responding

If poor response:

Add nebulised ipratropium bromide 0.25 mg

Consider: soluble prednisolone 10 mg daily for up to 3 days

Continuous close monitoring

- Heart rate
- Pulse rate
- Pulse oximetry
- Supportive nursing care with adequate hydration
- Consider the need for a chest X-ray

If not responding or any life threatening features discuss with senior paediatrician or PICU team
1. At least 1 in 10 cases of new or reappearance of childhood asthma in adult life are attributable to occupation.

2. Enquire of adult patients with rhinitis or asthma about their job and the materials with which they work.

3. Rhino-conjunctivitis may precede IgE-associated occupational asthma; the risk of developing asthma being highest in the year after the onset of rhinitis.

4. The prognosis of occupational asthma is improved by early identification and early avoidance of further exposure to its cause.

5. Confirm a diagnosis supported by objective criteria and not on the basis of a compatible history alone because of the potential implications for employment.

6. Arrange for workers whom you suspect of having work-related asthma to perform serial peak flow measurements at least four times a day.

Annex 9
Annex 10

Peak expiratory flow in normal adults

Annex 11
Annex 11 (contd)


65. Prasad A, Langford B, Stradling JR, Ho LP. Exhaled nitric oxide
64. Barreto M, Villa MP, Monti F, Bohmerova Z, Martella S, Montesano M, 
62. Covar RA, Spahn JD, Martin RJ, Silkoff PE, Sundstrom DA, Murphy J, 
60. Prasad A, Langford JR, Hop WC, de Jongste JC. Daily ambulatory
56. Prasad A, Langford JR, Hop WC, de Jongste JC. Daily ambulatory
52. Prasad A, Langford JR, Hop WC, de Jongste JC. Daily ambulatory
REFERENCES


REFERENCES


262. Men-Dong-Tang for treatment of allergic asthma. Pediatric Allergy & Immunology 2005;16(1):76-81.


REFERENCES


BRITISH GUIDELINE ON THE MANAGEMENT OF ASTHMA


426. Rudnitsky GS, Eberlein RS, Schoffstall JM, Mazur JE, Spivey WH.
424. Travers A, Jones AP, Kelly K, Barker SJ, Camargo CA, Rowe BH.
404. Brenner B, Kohn MS. The acute asthmatic patient in the ED: to admit
401. Scottish Intercollegiate Guidelines Network. Emergency management
399. Turner MO, Noertjojo K, Vedal S, Bai T, Crump S, Fitzgerald JM. Risk
419. Gleeson JG, Green S, Price JF. Air or oxygen as driving gas for nebulised
416. Rebuck AS, Read J. Assessment and management of severe asthma. Am
415. McFadden ER Jr, Lyons HA. Arterial-blood gas tension in asthma. N
414. Pearson MG, Spence DP, Ryland I, Harrison BD. Value of pulsus
411. Emerman CL, Cydulka RK. Effect of pulmonary function testing on the
408. Abramson MJ, Bailey MJ, Couper FJ, Driver JS, Drummer OH, Forbes
422. Rossing TH, Fanta CH, Goldstein DH, Snapper JR, McFadden ER
449. Graham VA, Milton AF, Knowles GK, Davies RJ. Routine antibiotics in
437. Manser R, Reid D, Abramson M. Corticosteroids for acute severe asthma
436. Rodrigo G, Rodrigo C, Burschlin O. A meta-analysis of the effects of
435. Manser R, Reid D, Abramson M. Corticosteroids for acute severe asthma
434. Kass JE, Terregino CA. The effect of heliox in acute severe asthma: a
433. Cowie RI, Revitt SG, Underwood MF, Field SK. The effect of a peak
432. Rodrigo G, Rodrigo C, Burschlin O. A meta-analysis of the effects of
431. Udwadia ZF, Harrison BD. An attempt to determine the optimal duration
430. Manser R, Reid D, Abrams M. Corticosteroids for acute severe asthma
428. Manser R, Reid D, Abramson M. Corticosteroids for acute severe asthma
426. Wright RO, Santucci KA, Jay GD, Steele DW. Evaluation of pre- and
How many times per day should peak expiratory flow rate be assessed in the diagnosis of occupational asthma due to isocyanates? Thorax 1997;52(1):75-6.


Aims and Scope: Thorax enjoys an enviable and longstanding reputation for publishing clinical and experimental research articles covering many disciplines, including pathology, immunology and surgery.

International Advisory Board

N Ambrosio (Italy)
N J Barnanik (USA)
P J Barnes (UK)
C R W Beasley (New Zealand)
J R Britton (UK)
A S Buist (USA)
E R Chilvers (UK)
S-H Cho (Korea)
S-E Dahlen (Sweden)
G C Donaldson (UK)
M W Elliott (UK)
Y Fukuchi (Japan)
D M Geddes (UK)
G Goldstraw (UK)
R Goldstein (Canada)
C Griffiths (UK)
J C Hogg (Canada)
S T Holgate (UK)
P Hopewell (USA)
M Ichinose (Japan)
A Kendrick (UK)
N G Papadopoulous (Greece)
M R Partridge (UK)
I D Pavord (UK)
M G Pearson (UK)
T A E Platts Mills (USA)
L Restrick (UK)
D S Robinson (UK)
R M Rudd (UK)
T A R Seemungal (Trinidad & Tobago)
S Sethi (USA)
A K Simonds (UK)
P Slivinski (Poland)
R A Stockley (UK)
J K Stoller (USA)
M J Tobin (USA)
A Torres (Spain)
J Vestbo (Denmark)
E H Walters (Australia)
S T Weiss (USA)
A Wells (UK)
JW Wilson (Australia)
A A Woodcock (UK)
M Woodhead (UK)
R Ziuvaillance (USA)

J Moore-Gillon (UK)
A Morice (UK)
R Panettieri (USA)
Papi (Italy)
J M FitzGerald (Canada)
J W Wilson (Australia)
A Wells (USA)
S T Weiss (USA)
A A Woodcock (UK)
M Woodhead (UK)
R Ziuvaillance (USA)

Contact Details

Editorial Office
BMJ Publishing Group Ltd, BMA House, Tavistock Square, London WC1H 9JR, UK
T: +44 (0)20 7383 6147
F: +44 (0)20 7383 6668
E: thorax@bmjgroup.com

Permissions
See http://journals.bmj.com/misc/permissions.dtl

Supplement Enquiries
T: +44 (0)20 7383 6057
F: +44 (0)20 7554 6795
E: journals@bmjgroup.com

Subscriptions [except USA]
Subcription Manager, BMJ Journals, BMJ Publishing Group Ltd, PO BOX 299, London WC1H 9TD, UK
T: +44 (0)20 7383 6270
F: +44 (0)20 7383 6402
E: subscriptions@bmjgroup.com
http://group.bmj.com/group/subs-sales/subscriptions

US Subscriptions
PP&B PO Box 361, Birmingham, AL 35201-0361
T: +1 800 348 6473 (toll free in the USA)
F: +1 205 995 1588
E: bmj-clinicalevidence@ebsco.com

Advertising
T: +44 (0)20 7383 6181
F: +44 (0)20 7383 6556
E: ecวรรณ@bmjgroup.com
http://group.bmj.com/group/advertising

Author Reprints
T: +44 (0)20 7383 6305
F: +44 (0)20 7383 6699
E: swilliams@bmjgroup.com

Commercial Reprints [except USA & Canada]
Nadia Gurney-Randall
T: +44 (0)20 8465 5852
M: +44 (0)7866 262344
F: +44 (0)20 8465 5870
E: ngurneyrandall@bmjgroup.com

Commercial Reprints (USA & Canada)
Marsha Fogler
T: +1 800 482 1450 (toll free in the USA)
T: +1 856 489 4446 (outside the USA)
F: +1 856 489 4449
E: mfogler@medicalreprints.com

British Thoracic Society
17 Doughty Street
London WC1N 2PL, UK
T: 44 (0)20 7381 8778
F: 44 (0)20 7381 8766
E: bts@brit-thoracic.org.uk
http://www.brit-thoracic.org.uk/index.html

Subscription Information

Thorax is published monthly (subscribers receive all supplements)

Institutional Rates 2008
Print
£437; US$830; €647

Online
Site licences are priced on FTE basis and allow access by the whole institution. Print is available at deeply discounted rates for online subscribers; details available online at http://group.bmj.com/group/subs-sales/subscriptions or contact the Subscription Manager in the UK (see above right)

Personal Rates 2008
Print (includes online access at no additional cost)
£185; US$352; €274

Online only
£99; US$188; €147
ISSN 0040-6376 (print)
ISSN 1468-3296 (online)

Supplementary rate:
£437; US$830; €647

Print
£185; US$352; €274

Online
£99; US$188; €147
ISSN 0040-6376 (print)
ISSN 1468-3296 (online)

Residents of some EC countries must pay VAT, for details call us or visit http://group.bmj.com/group/subs-sales/subscriptions/sub-var

Guidelines for Authors and Reviewers
Full instructions are available online at http://thorax.bmj.com for authors. Articles must be submitted electronically http://submit-thorax.bmj.com. Authors retain copyright but are required to grant Thorax an exclusive licence to publish http://thorax.bmj.com/fora/licence.dtl

Impact Factor: 6.064